[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 268
1. Tsakalozou E, Horn J, Leggas M: An HPLC assay for the lipophilic camptothecin analog AR-67 carboxylate and lactone in human whole blood. Biomed Chromatogr; 2010 Oct;24(10):1045-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin, DB-67) is a camptothecin analog currently in early stage clinical trials.
  • However the lactone form of third-generation lipophilic congeners, such as AR-67, is more stable, possibly due to partitioning into red cell membranes.
  • Samples were prepared by red cell lysis, protein precipitation with methanol and centrifugation to remove denatured materials.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 John Wiley & Sons, Ltd.
  • [Cites] Anticancer Drugs. 1999 Sep;10(8):705-10 [10573202.001]
  • [Cites] Clin Cancer Res. 2010 Jan 15;16(2):673-80 [20068096.001]
  • [Cites] Ann N Y Acad Sci. 2000;922:27-35 [11193902.001]
  • [Cites] Cancer Chemother Pharmacol. 2001 Jul;48(1):83-7 [11488529.001]
  • [Cites] J Control Release. 2001 Jul 6;74(1-3):325-33 [11489514.001]
  • [Cites] J Chromatogr B Biomed Sci Appl. 2001 Nov 25;764(1-2):49-58 [11817043.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):405-12 [11839656.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2202-9 [12114421.001]
  • [Cites] Anticancer Drugs. 2003 Mar;14(3):227-32 [12634617.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Oct 5;795(2):383-8 [14522044.001]
  • [Cites] J Med Chem. 1989 Mar;32(3):715-20 [2537428.001]
  • [Cites] Cancer Res. 1989 Mar 15;49(6):1465-9 [2538227.001]
  • [Cites] Cancer Res. 1989 Aug 15;49(16):4385-9 [2545341.001]
  • [Cites] Pharm Res. 1992 Jun;9(6):826-33 [1409369.001]
  • [Cites] Anal Biochem. 1993 Jul;212(1):285-7 [8368506.001]
  • [Cites] J Med Chem. 1994 Jan 7;37(1):40-6 [8289200.001]
  • [Cites] Biochemistry. 1994 Aug 30;33(34):10325-36 [8068669.001]
  • [Cites] Biochemistry. 1995 Oct 24;34(42):13722-8 [7577964.001]
  • [Cites] Oncology (Williston Park). 1998 Aug;12(8 Suppl 6):68-71 [9726095.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;43(6):454-60 [10321504.001]
  • [Cites] J Med Chem. 1999 Aug 12;42(16):3018-22 [10447944.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7357-64 [15534112.001]
  • [Cites] Curr Med Chem. 2006;13(17):2021-39 [16842195.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Nov 21;844(1):15-22 [16860004.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):561-8 [17150998.001]
  • [Cites] Biomed Chromatogr. 2009 Jul;23(7):707-13 [19277971.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(12):2459-67 [10856106.001]
  • (PMID = 20853460.001).
  • [ISSN] 1099-0801
  • [Journal-full-title] Biomedical chromatography : BMC
  • [ISO-abbreviation] Biomed. Chromatogr.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA123867; United States / NCI NIH HHS / CA / R21-CA123867
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carboxylic Acids; 0 / Lactones; 0 / Organosilicon Compounds; 3YEA04NV6H / 7-tert-butyldimethylsilyl-10-hydroxycamptothecin; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ NIHMS170384; NLM/ PMC2943862
  •  go-up   go-down


2. Lupattelli M, Mascioni F, Bellavita R, Draghini L, Tarducci R, Castagnoli P, Russo G, Aristei C: Long-term anorectal function after postoperative chemoradiotherapy in high-risk rectal cancer patients. Tumori; 2010 Jan-Feb;96(1):34-41
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term anorectal function after postoperative chemoradiotherapy in high-risk rectal cancer patients.
  • AIMS AND BACKGROUND: After sphincter-preserving surgery for rectal cancer and postoperative radiochemotherapy, many patients have unsatisfactory anorectal functional results which are not considered by the most common toxicity scales.
  • The aim of the present study was to retrospectively assess the long-term incidence of impaired anorectal function in rectal cancer patients who underwent anterior resection and postoperative radiochemotherapy.
  • METHODS: Ninety-nine patients who underwent sphincter-saving surgery and postoperative radiochemotherapy for stage II-III rectal cancer from July 1991 to January 2002 were given a questionnaire on anorectal function.
  • [MeSH-major] Anal Canal / physiopathology. Rectal Neoplasms / therapy. Rectum / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20437855.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


3. Krengli M, Milia ME, Turri L, Mones E, Bassi MC, Cannillo B, Deantonio L, Sacchetti G, Brambilla M, Inglese E: FDG-PET/CT imaging for staging and target volume delineation in conformal radiotherapy of anal carcinoma. Radiat Oncol; 2010;5:10
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-PET/CT imaging for staging and target volume delineation in conformal radiotherapy of anal carcinoma.
  • BACKGROUND: FDG-PET/CT imaging has an emerging role in staging and treatment planning of various tumor locations and a number of literature studies show that also the carcinoma of the anal canal may benefit from this diagnostic approach.
  • We analyzed the potential impact of FDG-PET/CT in stage definition and target volume delineation of patients affected by carcinoma of the anal canal and candidates for curative radiotherapy.
  • METHODS: Twenty seven patients with biopsy proven anal carcinoma were enrolled.
  • Pathology was squamous cell carcinoma in 20 cases, cloacogenic carcinoma in 3, adenocarcinoma in 2, and basal cell carcinoma in 2.
  • RESULTS: PET/CT fused images led to change the stage in 5/27 cases (18.5%): 3 cases from N0 to N2 and 2 from M0 to M1 leading to change the treatment intent from curative to palliative in a case.Based on PET/CT imaging, GTV and CTV contours changed in 15/27 (55.6%) and in 10/27 cases (37.0%) respectively.
  • CONCLUSIONS: FDG-PET/CT has a potential relevant impact in staging and target volume delineation of the carcinoma of the anal canal.
  • Clinical stage variation occurred in 18.5% of cases with change of treatment intent in 3.7%.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma / pathology. Neoplasm Staging / methods. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Conformal

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiother Oncol. 2001 Oct;61(1):15-22 [11578724.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):824-30 [19117696.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):893-900 [15936575.001]
  • [Cites] Mol Imaging Biol. 2005 Jul-Aug;7(4):309-13 [16028002.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):720-5 [16626889.001]
  • [Cites] Technol Cancer Res Treat. 2007 Feb;6(1):31-6 [17241098.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):155-62 [17707268.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1423-6 [17931795.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):180-6 [17996387.001]
  • [Cites] Med Phys. 2008 Apr;35(4):1207-13 [18491512.001]
  • [Cites] Radiother Oncol. 2008 Jun;87(3):376-82 [18453023.001]
  • [Cites] Br J Cancer. 2009 Mar 10;100(5):693-700 [19259091.001]
  • [Cites] Strahlenther Onkol. 2009 Apr;185(4):254-9 [19370429.001]
  • [Cites] Br J Radiol. 2009 Jun;82(978):509-13 [19153180.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • (PMID = 20137093.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ PMC2851594
  •  go-up   go-down


Advertisement
4. Siarheyeva A, Liu R, Sharom FJ: Characterization of an asymmetric occluded state of P-glycoprotein with two bound nucleotides: implications for catalysis. J Biol Chem; 2010 Mar 5;285(10):7575-86
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ATPgammaS also interacts with P-glycoprotein with high affinity as assessed by inhibition of ATP hydrolysis and protection from covalent labeling of a Walker A Cys residue, whereas other non-hydrolyzable ATP analogues do not.
  • Asymmetric ATPgammaS-bound P-glycoprotein does not display reduced binding affinity for drugs, implying that transport is not driven by ATP binding and likely takes place at a later stage of the catalytic cycle.

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEMS Microbiol Lett. 1999 Oct 15;179(2):187-202 [10518715.001]
  • [Cites] Biochemistry. 1999 May 25;38(21):6887-96 [10346910.001]
  • [Cites] J Biol Chem. 2006 Sep 8;281(36):26501-11 [16844693.001]
  • [Cites] J Biol Chem. 2006 Sep 22;281(38):28397-407 [16877382.001]
  • [Cites] Biochem J. 2006 Oct 15;399(2):315-23 [16803457.001]
  • [Cites] Biochemistry. 2006 Dec 19;45(50):15056-67 [17154543.001]
  • [Cites] Mol Cancer Ther. 2007 Jan;6(1):13-23 [17237262.001]
  • [Cites] FEBS Lett. 2007 Mar 6;581(5):935-8 [17303126.001]
  • [Cites] Physiology (Bethesda). 2007 Apr;22:122-30 [17420303.001]
  • [Cites] Nature. 2007 Nov 22;450(7169):515-21 [18033289.001]
  • [Cites] Biochemistry. 2007 Dec 4;46(48):13787-99 [17988154.001]
  • [Cites] Microbiol Mol Biol Rev. 2008 Jun;72(2):317-64, table of contents [18535149.001]
  • [Cites] Xenobiotica. 2008 Jul;38(7-8):802-32 [18668431.001]
  • [Cites] Science. 2009 Mar 27;323(5922):1718-22 [19325113.001]
  • [Cites] Chem Rev. 2009 Jul;109(7):2989-3011 [19583429.001]
  • [Cites] Arch Biochem Biophys. 2009 Dec;492(1-2):17-28 [19818729.001]
  • [Cites] Mol Pharmacol. 2005 Jun;67(6):1944-53 [15755910.001]
  • [Cites] EMBO J. 2005 Jun 1;24(11):1901-10 [15889153.001]
  • [Cites] Biochemistry. 2005 Sep 27;44(38):12879-86 [16171403.001]
  • [Cites] Biochemistry. 2005 Oct 25;44(42):14010-9 [16229490.001]
  • [Cites] Biochem Soc Trans. 2005 Nov;33(Pt 5):990-5 [16246029.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):17969-74 [16326809.001]
  • [Cites] FEBS Lett. 2006 Feb 13;580(4):1056-63 [16380120.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 2006 Mar;372(6):385-99 [16541253.001]
  • [Cites] J Bioenerg Biomembr. 2005 Dec;37(6):497-500 [16691489.001]
  • [Cites] Biochim Biophys Acta. 1999 Dec 6;1461(2):327-45 [10581365.001]
  • [Cites] Cell. 2000 Jun 23;101(7):789-800 [10892749.001]
  • [Cites] Biochemistry. 2000 Oct 3;39(39):11901-6 [11009602.001]
  • [Cites] Biochemistry. 2000 Dec 5;39(48):14927-38 [11101309.001]
  • [Cites] Res Microbiol. 2001 Apr-May;152(3-4):211-29 [11421270.001]
  • [Cites] Genome Res. 2001 Jul;11(7):1156-66 [11435397.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):5110-9 [11741902.001]
  • [Cites] Mol Cell. 2002 Jul;10(1):139-49 [12150914.001]
  • [Cites] Biochemistry. 2002 Nov 26;41(47):13989-4000 [12437356.001]
  • [Cites] J Mol Biol. 2002 Dec 13;324(5):965-73 [12470952.001]
  • [Cites] Biochemistry. 2003 Feb 4;42(4):1170-7 [12549939.001]
  • [Cites] Biochemistry. 2003 Feb 11;42(5):1345-53 [12564938.001]
  • [Cites] J Biol Chem. 2003 Jul 18;278(29):26862-9 [12746444.001]
  • [Cites] J Biol Chem. 2003 Aug 8;278(32):29686-92 [12777379.001]
  • [Cites] J Mol Biol. 2003 Nov 21;334(2):255-67 [14607117.001]
  • [Cites] J Biol Chem. 2004 Jul 23;279(30):31212-20 [15159388.001]
  • [Cites] Nat Struct Mol Biol. 2004 Oct;11(10):918-26 [15452563.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Anal Biochem. 1977 Dec;83(2):346-56 [603028.001]
  • [Cites] J Biochem. 1982 May;91(5):1629-37 [6124538.001]
  • [Cites] Anal Biochem. 1983 May;131(1):69-74 [6311050.001]
  • [Cites] Biochim Biophys Acta. 1984 Jul 25;774(2):277-87 [6331507.001]
  • [Cites] J Biol Chem. 1985 Dec 5;260(28):15055-8 [3905789.001]
  • [Cites] J Biol Chem. 1993 Feb 25;268(6):4197-206 [8095047.001]
  • [Cites] J Biol Chem. 1994 Mar 25;269(12):8986-92 [7907596.001]
  • [Cites] Biochemistry. 1994 Jun 14;33(23):7069-76 [7911680.001]
  • [Cites] Biochem J. 1995 Jun 1;308 ( Pt 2):381-90 [7772017.001]
  • [Cites] J Biol Chem. 1995 Aug 18;270(33):19383-90 [7642618.001]
  • [Cites] J Biol Chem. 1995 Sep 29;270(39):22957-61 [7559432.001]
  • [Cites] J Biol Chem. 1995 Nov 10;270(45):26956-61 [7592942.001]
  • [Cites] FEBS Lett. 1995 Dec 27;377(3):285-9 [8549739.001]
  • [Cites] Biochemistry. 1996 Sep 10;35(36):11865-73 [8794769.001]
  • [Cites] Biochemistry. 1998 Apr 7;37(14):5010-9 [9538020.001]
  • [Cites] Arch Pharm (Weinheim). 1998 Jul-Aug;331(7-8):233-40 [9747179.001]
  • [Cites] Acta Physiol Scand Suppl. 1998 Aug;643:213-8 [9789563.001]
  • [Cites] EMBO J. 2006 Jul 26;25(14):3432-43 [16858415.001]
  • (PMID = 20061384.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Affinity Labels; 0 / Anilino Naphthalenesulfonates; 0 / Antibiotics, Antineoplastic; 0 / Nucleotides; 0 / P-Glycoprotein; 0 / Tubulin Modulators; 25612-73-1 / Adenylyl Imidodiphosphate; 3469-78-1 / 5'-adenylyl (beta,gamma-methylene)diphosphonate; 35094-46-3 / adenosine 5'-O-(3-thiotriphosphate); 3WHH0066W5 / Vanadates; 5V9KLZ54CY / Vinblastine; 71936-81-7 / 2-(4'-maleimidylanilino)naphthalene-6-sulfonic acid; 8L70Q75FXE / Adenosine Triphosphate; ZS7284E0ZP / Daunorubicin
  • [Other-IDs] NLM/ PMC2844205
  •  go-up   go-down


5. Compérat E, Egevad L, Camparo P, Roupret M, Vaessen C, Valdman A, Jonmarker S, Capron F, Cussenot O, Charlotte F: Clinical significance of intratumoral CD8+ regulatory T cells in prostate carcinoma. Anal Quant Cytol Histol; 2010 Feb;32(1):39-44
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of intratumoral CD8+ regulatory T cells in prostate carcinoma.
  • OBJECTIVE: To explore Foxp3, a member of the forkhead box family of transcription factors, which is a major gene for regulatory T (Treg) cell development of CD4+CD25+ or CD8+CD25+ phenotype.
  • Serum prostate-specific antigen levels before and after RP, Gleason score (GS), surgical margin status and pathologic stage were available.
  • CONCLUSION: Treg cells were more common in cancer than in benign prostatic tissue.
  • Patients with prostate cancer show an immunosuppressive regulatory profile, including nonresponsive Tregs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20701086.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


6. Mazzucchelli R, Barbisan F, Tagliabracci A, Lopez-Beltran A, Cheng L, Scarpelli M, Montironi R: Search for residual prostate cancer on pT0 radical prostatectomy after positive biopsy. Virchows Arch; 2007 Apr;450(4):371-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Search for residual prostate cancer on pT0 radical prostatectomy after positive biopsy.
  • Reported incidence of no residual prostate cancer (i.e. pathological stage pT0) on radical prostatectomy ranges from 0.07 to 4.2%.
  • The aim of this study was to search for residual cancer on radical prostatectomy (RP) specimens when an initial sampling failed to find the cancer in patients with positive biopsy.
  • 0.3 and 0.8%, respectively, of the total number of RPs included in the study) with positive biopsy and with no residual cancer in the initial routine histological examination of the RP.
  • There were no cases with a false positive biopsy diagnosis, and cancer was not overlooked or missed in the initial routine histological examination of any of the 8 pT0 RPs.
  • A minute focus of cancer (the diameter was always below 2.0 mm) was found on the additional sections in five.
  • In particular, cancer was found after block-flipping in one of them.
  • In an additional case, cancer was eventually discovered after immunostaining tissue sections for cytokeratin CAM 5.2, for p63 and PSA.
  • In the remaining two cases (one untreated and the other hormonally treated), cancer was not found (0.15% of the 1,328 RPs included in the study); the review of the description of the macroscopic appearance of the RP and of its slides revealed that part of the peripheral zone corresponding to the site of the positive biopsy was missing, i.e. not removed from the patient at the time of the operation at least in one of the two.
  • An extensive search for residual cancer reduces the number of pT0 RPs after a positive biopsy from 0.6 to 0.15%.
  • In addition, atypical foci should be stained for basal cell markers and often AMACR, especially in hormone-treated cases.
  • DNA analysis for tissue identity should be performed when the other steps have been taken without finding cancer.
  • [MeSH-major] Neoplasm, Residual / diagnosis. Prostatectomy. Prostatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1991 Feb;15(2):111-20 [1989458.001]
  • [Cites] Cancer. 1991 Aug 15;68(4):821-8 [1906775.001]
  • [Cites] Am J Clin Pathol. 1993 Dec;100(6):666-70 [8249915.001]
  • [Cites] Eur Urol. 1993;24(4):461-5 [8287886.001]
  • [Cites] Cancer. 1994 Mar 1;73(5):1472-7 [8111715.001]
  • [Cites] Arch Pathol Lab Med. 1994 Mar;118(3):293-7 [8135635.001]
  • [Cites] J Urol. 1994 Jun;151(6):1565-70 [7514689.001]
  • [Cites] Am J Surg Pathol. 1995 Sep;19(9):1002-9 [7661273.001]
  • [Cites] Mod Pathol. 1995 May;8(4):456-7 [7567949.001]
  • [Cites] Diagn Mol Pathol. 1995 Dec;4(4):286-91 [8634786.001]
  • [Cites] Semin Urol Oncol. 1996 May;14(2 Suppl 2):39-45; discussion 46-7 [8725890.001]
  • [Cites] Am J Surg Pathol. 1997 Feb;21(2):174-8 [9042283.001]
  • [Cites] Urology. 1997 May;49(5):721-5 [9145977.001]
  • [Cites] BJU Int. 2004 Nov;94(7):1145-6 [15541149.001]
  • [Cites] Am J Surg Pathol. 2005 Apr;29(4):467-73 [15767799.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jun;130(6):811-6 [16740032.001]
  • [Cites] Eur Urol. 2006 Dec;50(6):1248-52; discussion 1253 [16828964.001]
  • [Cites] Anal Quant Cytol Histol. 2007 Apr;29(2):79-86 [17484271.001]
  • [Cites] J Mol Diagn. 2001 Feb;3(1):11-5 [11227066.001]
  • [Cites] Eur Urol. 2000 Dec;38(6):714-20 [11111189.001]
  • [Cites] J Clin Pathol. 2000 Mar;53(3):238-40 [10823148.001]
  • [Cites] Virchows Arch. 2003 Mar;442(3):211-7 [12647209.001]
  • [Cites] Urology. 2003 Sep;62(3):476-80 [12946750.001]
  • [Cites] Eur Urol. 2003 Dec;44(6):626-36 [14644113.001]
  • [Cites] Eur Urol. 2004 Jan;45(1):35 [14667512.001]
  • [Cites] Eur Urol. 2004 Jan;45(1):36-41 [14667513.001]
  • [Cites] Eur Urol. 2004 Jan;45(1):42-5 [14667514.001]
  • [Cites] BJU Int. 2004 Jul;94(1):57-8 [15217431.001]
  • [Cites] Urology. 2004 Oct;64(4):733-7 [15491711.001]
  • (PMID = 17285325.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CAM 5.2 antigen; 68238-35-7 / Keratins; EC 3.4.21.77 / Prostate-Specific Antigen; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  • [Other-IDs] NLM/ PMC1888722
  •  go-up   go-down


7. Garrett K, Kalady MF: Anal neoplasms. Surg Clin North Am; 2010 Feb;90(1):147-61, Table of Contents
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal neoplasms.
  • A variety of lesions comprise tumors of the anal canal, with carcinoma in situ and epidermoid cancers being the most common.
  • Less common anal neoplasms include adenocarcinoma, melanoma, gastrointestinal stromal cell tumors, neuroendocrine tumors, and Buschke-Lowenstein tumors.
  • In this article different tumors and management of each, including a brief review of local excision for rectal cancer, are discussed in turn.
  • [MeSH-major] Anus Neoplasms / surgery
  • [MeSH-minor] Carcinoma in Situ / pathology. Carcinoma, Squamous Cell / pathology. Carcinoma, Verrucous / diagnosis. Carcinoma, Verrucous / pathology. Humans. Intestinal Mucosa / pathology. Neoplasm Recurrence, Local / surgery. Prognosis. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20109639.001).
  • [ISSN] 1558-3171
  • [Journal-full-title] The Surgical clinics of North America
  • [ISO-abbreviation] Surg. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 105
  •  go-up   go-down


8. Urquhart BL, Freeman DJ, Cutler MJ, Mainra R, Spence JD, House AA: Mesna for treatment of hyperhomocysteinemia in hemodialysis patients: a placebo-controlled, double-blind, randomized trial. Clin J Am Soc Nephrol; 2008 Jul;3(4):1041-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • More than 90% of patients with end-stage renal disease have hyperhomocysteinemia despite vitamin supplementation.
  • DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Patients with end-stage renal disease were randomly assigned to receive either intravenous mesna 5 mg/kg or placebo thrice weekly before dialysis.

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1995 Nov 25;346(8987):1395-8 [7475822.001]
  • [Cites] J Pharm Sci. 2006 Aug;95(8):1742-50 [16795014.001]
  • [Cites] Metabolism. 2000 Feb;49(2):215-9 [10690947.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1314-21 [10778956.001]
  • [Cites] Circulation. 2000 Jun 20;101(24):2829-32 [10859289.001]
  • [Cites] Nephrol Dial Transplant. 2000 Jul;15(7):1029-34 [10862642.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2000 Jul;20(7):1704-6 [10894806.001]
  • [Cites] Clin Invest Med. 2001 Feb;24(1):5-11 [11266032.001]
  • [Cites] J Biol Chem. 2001 Aug 10;276(32):30111-7 [11371573.001]
  • [Cites] J Am Soc Nephrol. 2002 Jan;13(1):265-8 [11752047.001]
  • [Cites] Kidney Int. 2002 Feb;61(2):609-14 [11849403.001]
  • [Cites] Nephrol Dial Transplant. 2002 May;17(5):865-70 [11981075.001]
  • [Cites] Am J Kidney Dis. 2007 Jan;49(1):109-17 [17185151.001]
  • [Cites] Lancet. 2007 Jan 20;369(9557):208-16 [17240287.001]
  • [Cites] Lancet. 2007 Jun 2;369(9576):1876-82 [17544768.001]
  • [Cites] JAMA. 2007 Sep 12;298(10):1163-70 [17848650.001]
  • [Cites] Metabolism. 2002 Jul;51(7):881-6 [12077735.001]
  • [Cites] JAMA. 2002 Oct 23-30;288(16):2015-22 [12387654.001]
  • [Cites] J Nephrol. 2002 Nov-Dec;15(6):671-5 [12495282.001]
  • [Cites] Am J Kidney Dis. 2003 Feb;41(2):442-6 [12552508.001]
  • [Cites] Arch Intern Med. 2003 Sep 8;163(16):1933-7 [12963566.001]
  • [Cites] Nephrol Dial Transplant. 2003 Dec;18(12):2596-600 [14605283.001]
  • [Cites] J Clin Pharmacol. 2003 Dec;43(12):1324-8 [14615468.001]
  • [Cites] Circulation. 2004 Jan 27;109(3):369-74 [14732754.001]
  • [Cites] J Am Soc Nephrol. 2004 Feb;15(2):420-6 [14747389.001]
  • [Cites] JAMA. 2004 Feb 4;291(5):565-75 [14762035.001]
  • [Cites] Clin Invest Med. 2004 Feb;27(1):10-3 [15061579.001]
  • [Cites] Eur J Cardiovasc Prev Rehabil. 2004 Jun;11(3):250-3 [15179109.001]
  • [Cites] Am J Kidney Dis. 2004 Oct;44(4):689-94 [15384020.001]
  • [Cites] Anal Biochem. 1992 Feb 1;200(2):218-29 [1632485.001]
  • [Cites] J Am Soc Nephrol. 1992 Jul;3(1):1-11 [1391700.001]
  • [Cites] Br J Cancer. 1993 Sep;68(3):590-3 [8353049.001]
  • [Cites] Clin Chem. 1994 Jun;40(6):873-81 [8087981.001]
  • [Cites] J Nutr. 1994 Oct;124(10):1927-33 [7931701.001]
  • [Cites] Cancer Chemother Pharmacol. 1994;35(2):132-6 [7987989.001]
  • [Cites] Atherosclerosis. 1995 Feb;113(1):129-32 [7755649.001]
  • [Cites] Atherosclerosis. 1995 Apr 7;114(1):93-103 [7605381.001]
  • [Cites] Adv Ren Replace Ther. 1995 Oct;2(4):295-304 [8591121.001]
  • [Cites] Kidney Int. 1996 Jan;49(1):147-52 [8770960.001]
  • [Cites] J Am Soc Nephrol. 1996 Nov;7(11):2414-8 [8959634.001]
  • [Cites] Kidney Int. 1997 Jul;52(1):10-20 [9211341.001]
  • [Cites] Circulation. 1998 Jan 20;97(2):138-41 [9445164.001]
  • [Cites] ASAIO J. 1999 Jan-Feb;45(1):94-7 [9952016.001]
  • [Cites] J Am Soc Nephrol. 1999 May;10(5):1095-9 [10232697.001]
  • [Cites] Am J Nephrol. 1999;19(3):405-10 [10393379.001]
  • [Cites] Clin Chem. 2005 Jan;51(1):196-201 [15528294.001]
  • [Cites] Am J Kidney Dis. 2005 Apr;45(4):702-7 [15806473.001]
  • [Cites] Stroke. 2005 Nov;36(11):2404-9 [16239629.001]
  • [Cites] N Engl J Med. 2006 Apr 13;354(15):1567-77 [16531613.001]
  • [Cites] N Engl J Med. 2006 Apr 13;354(15):1578-88 [16531614.001]
  • [Cites] N Engl J Med. 2006 Apr 13;354(15):1629-32 [16531615.001]
  • [Cites] Atherosclerosis. 1999 Dec;147(2):379-86 [10559524.001]
  • (PMID = 18337551.001).
  • [ISSN] 1555-905X
  • [Journal-full-title] Clinical journal of the American Society of Nephrology : CJASN
  • [ISO-abbreviation] Clin J Am Soc Nephrol
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0LVT1QZ0BA / Homocysteine; NR7O1405Q9 / Mesna
  • [Other-IDs] NLM/ PMC2440266
  •  go-up   go-down


9. Fu S, Arráez-Roman D, Segura-Carretero A, Menéndez JA, Menéndez-Gutiérrez MP, Micol V, Fernández-Gutiérrez A: Qualitative screening of phenolic compounds in olive leaf extracts by hyphenated liquid chromatography and preliminary evaluation of cytotoxic activity against human breast cancer cells. Anal Bioanal Chem; 2010 May;397(2):643-54
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Qualitative screening of phenolic compounds in olive leaf extracts by hyphenated liquid chromatography and preliminary evaluation of cytotoxic activity against human breast cancer cells.
  • In this work, high-performance liquid chromatography (HPLC) coupled to electrospray time-of-flight mass spectrometry (ESI-TOF-MS) and electrospray ion trap multiple-stage tandem mass spectrometry (ESI-IT-MS(2)) has been applied to screen phenolic compounds in olive leaf extracts.
  • Importantly, olive leaf extracts exhibited dose-dependent inhibitory effects on the metabolic status (cell viability) of three breast cancer models in vitro.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / analysis. Antineoplastic Agents, Phytogenic / pharmacology. Breast Neoplasms / drug therapy. Carcinoma / drug therapy. Chromatography, High Pressure Liquid / methods. Olea / chemistry. Phenols / analysis. Phenols / pharmacology
  • [MeSH-minor] Cell Survival / drug effects. Cinnamates / analysis. Cinnamates / isolation & purification. Cinnamates / pharmacology. Female. Flavonoids / analysis. Flavonoids / isolation & purification. Flavonoids / pharmacology. Humans. Iridoids / analysis. Iridoids / isolation & purification. Iridoids / pharmacology. Plant Leaves / chemistry. Pyrans / analysis. Pyrans / isolation & purification. Pyrans / pharmacology. Spectrometry, Mass, Electrospray Ionization / methods. Tandem Mass Spectrometry / methods

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20238105.001).
  • [ISSN] 1618-2650
  • [Journal-full-title] Analytical and bioanalytical chemistry
  • [ISO-abbreviation] Anal Bioanal Chem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Cinnamates; 0 / Flavonoids; 0 / Iridoids; 0 / Phenols; 0 / Pyrans; 2O4553545L / oleuropein; 34422-12-3 / elenolic acid; U14A832J8D / cinnamic acid
  •  go-up   go-down


10. Kruijt B, van der Snoek EM, Sterenborg HJ, Amelink A, Robinson DJ: A dedicated applicator for light delivery and monitoring of PDT of intra-anal intraepithelial neoplasia. Photodiagnosis Photodyn Ther; 2010 Mar;7(1):3-9
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A dedicated applicator for light delivery and monitoring of PDT of intra-anal intraepithelial neoplasia.
  • The objective of this study was to develop an applicator for delivery of light and monitoring of photodynamic therapy (PDT) in the anal cavity for treatment of anal intraepithelial neoplasia grade III (AIN III), which can progress to invasive anal cancer.
  • For light delivery and monitoring of PDT, an applicator based on standard anoscopy equipment was developed which facilitates, in addition to a light treatment fiber, fiber optic probes to monitor blood saturation, blood volume, fluorescence and fluence (rate) at two different locations in situ.
  • Patients were given a light dose of 10-17 J cm(-2) at a fluence rate of 45-50 mW cm(-2) based on in situ measured light treatment parameters.
  • [MeSH-major] Anus Neoplasms / diagnosis. Anus Neoplasms / drug therapy. Carcinoma in Situ / diagnosis. Carcinoma in Situ / drug therapy. Lighting / instrumentation. Photochemotherapy / instrumentation. Photosensitizing Agents / administration & dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20230986.001).
  • [ISSN] 1873-1597
  • [Journal-full-title] Photodiagnosis and photodynamic therapy
  • [ISO-abbreviation] Photodiagnosis Photodyn Ther
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Photosensitizing Agents
  •  go-up   go-down


11. Kim CW, Kim JH, Yu CS, Shin US, Park JS, Jung KY, Kim TW, Yoon SN, Lim SB, Kim JC: Complications after sphincter-saving resection in rectal cancer patients according to whether chemoradiotherapy is performed before or after surgery. Int J Radiat Oncol Biol Phys; 2010 Sep 1;78(1):156-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complications after sphincter-saving resection in rectal cancer patients according to whether chemoradiotherapy is performed before or after surgery.
  • PURPOSE: The aim of the present study was to compare the influence of preoperative chemoradiotherapy (CRT) with postoperative CRT on the incidence and types of postoperative complications in rectal cancer patients who underwent sphincter-saving resection.
  • RESULTS: There was no between-group difference in age, gender, or cancer stage.
  • In the pre-CRT group, the mean level of anastomosis from the anal verge was lower (3.5 +/- 1.4 cm vs. 4.3 +/- 1.7 cm, p < 0.001) and the rate of T4 lesion and temporary diverting ileostomy was higher than in the post-CRT group.
  • [MeSH-major] Adenocarcinoma. Anal Canal / surgery. Neoadjuvant Therapy / methods. Postoperative Complications / etiology. Rectal Neoplasms

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20106604.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


12. Matthiessen P, Hansson L, Sjödahl R, Rutegård J: Anastomotic-vaginal fistula (AVF) after anterior resection of the rectum for cancer--occurrence and risk factors. Colorectal Dis; 2010 Apr;12(4):351-7
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anastomotic-vaginal fistula (AVF) after anterior resection of the rectum for cancer--occurrence and risk factors.
  • OBJECTIVE: The aim of the study was to assess recto-vaginal fistula (RVF) after anterior resection of the rectum for cancer with regard to occurrence and risk factors.
  • METHOD: All female patients [median age 69.5 years, Union Internationale centre le Cancer (UICC) cancer stage IV in 10%] who developed a symptomatic RVF (n = 20) after anterior resection of the rectum for cancer from three separate cohorts of patients were identified and compared with those who developed conventional symptomatic leakage (n = 32), and those who did not leak (n = 338).
  • Risk factors for AVF in multivariate analysis were anastomosis < 5 cm above the anal verge (P = 0.001), preoperative radiotherapy (P = 0.004), and UICC cancer stage IV (P = 0.005).
  • CONCLUSION: Anastomotic-vaginal fistula forms a significant part of all symptomatic leakages after low anterior resection for cancer in women.
  • Risk factors for AVF included low anastomosis, preoperative radiotherapy and UICC cancer stage IV.

  • Genetic Alliance. consumer health - Vaginal cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19220383.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  •  go-up   go-down


13. Swampillai A, Williams M, Osborne M, Mawdsley S, Hughes R, Harrison M, Glynne-Jones R: A single-center study of the utility of squamous cell carcinoma antigen (SCCAg) levels in epidermoid carcinoma of the anal canal and margin (ECACM) treated with chemoradiation (CRT). J Clin Oncol; 2009 May 20;27(15_suppl):4117

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A single-center study of the utility of squamous cell carcinoma antigen (SCCAg) levels in epidermoid carcinoma of the anal canal and margin (ECACM) treated with chemoradiation (CRT).
  • Radiotherapy comprised the schedule of the UK Anal cancer Trial (ACT II).
  • Clinical stage at diagnosis- Tx (6) T1 (28), T2 (80), T3 (65), T4 (16), N0 (126), N+ (66) Nx (3).
  • RESULTS: Mean baseline SCCAg by cT and cN stage were: T1 93 (ng/dl), T2 300, T3 607, T4 882, N0 376, N+ 529 (correlation coeff: T: 0.47, N: 0.33, both p< 0.001).
  • The mean baseline SCCAg for pts achieving CR was 408 and non CR was 513 (p = 0.13).
  • CONCLUSIONS: There is a correlation between T and N stage and baseline SCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961219.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Velenik V, Ocvirk J, Oblak I, Anderluh F: Neoadjuvant cetuximab, capecitabine, and radiotherapy (RT) in locally advanced resectable rectal cancer: results of a phase II trial. J Clin Oncol; 2009 May 20;27(15_suppl):e15029

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant cetuximab, capecitabine, and radiotherapy (RT) in locally advanced resectable rectal cancer: results of a phase II trial.
  • : e15029 Background: Preoperative chemoradiotherapy (CRT) with capecitabine is a treatment of choice for locally advanced rectal cancer.
  • The aim of this prospective, nonrandomized, open-label phase II study was to establish the efficacy and safety profile of cetuximab combined with capecitabine and concurrent RT for locally advanced resectable rectal cancer.
  • METHODS: Patients (pts) with stage II or III rectal cancer confirmed by MRI were treated with capecitabine 1250 mg/m<sup>2</sup> twice daily for 2 weeks.
  • The median tumor distance from anal verge was 6 (range: 1-11) cm.
  • Dose reduction/treatment interruption was necessary for 9/37 (24.3%) pts owing to hypersensitivity reaction (n=4), hepatotoxicity grade 3 (n=1) or diarrhea grade 3 (n=4).
  • Other grade 3 toxicities included dermatitis (n=6, 16.2%), anorexia (n=1, 2.7%) and infection (n=1, 2.7%).
  • The total sphincter preservation rate was 75.7%; in 17 pts whose tumors were located ≤5 cm of the anal verge, the rate was 53%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964401.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Avallone A, Delrio P, Di Gennaro E, Pecori B, Aloi L, Tatangelo F, Petrillo A, Budillon A, Caracò C, Sandomenico C, Comella P: Evaluation of two different schedules of bevacizumab (BEV) with oxaliplatin (OXA), raltitrexed (TOM), levo-folinic acid (LFA), and 5-fluorouracil (5-FU) during preoperative (preop) pelvic RT in high-risk locally advanced rectal cancer (HR-LARC) patients (pts). J Clin Oncol; 2009 May 20;27(15_suppl):e14546

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of two different schedules of bevacizumab (BEV) with oxaliplatin (OXA), raltitrexed (TOM), levo-folinic acid (LFA), and 5-fluorouracil (5-FU) during preoperative (preop) pelvic RT in high-risk locally advanced rectal cancer (HR-LARC) patients (pts).
  • According to the Simon's two-stage design, assuming a hypothesis of a 50% TRG1 (α=0.05, β=0.20), at least 6/16 TRG1 should be obtained to continue pts accrual in every schedule.
  • METHODS: Inclusion criteria were: cT4, cN+, cT3(<5 cm from the anal verge and/or +ve CRM), resectable M1.
  • BEV (5 mg/kg) was given biweekly from day -14 for 4 c in schedule A, and from day -4 for 2 c in schedule B.
  • Changes of circulating endothelial cells (CECs)assessed by flow cytometry in 17 (7 A; 10 B) pts, and glucose metabolism evaluated by FDG-PET in 27 (15 A; 12 B) pts after 1st c of CT were used as surrogate markers of tumor response.
  • Grade 3/4 neutropenia was the most common toxicity with schedule A (7 pts, 44%), while it never occurred with schedule B.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963622.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Hammad N, Philip PA, Shields AF, Heilbrun LK, Venkatramanamoorthy R, El-Rayes BF: A retrospective review of squamous cell carcinoma of the anal canal in HIV-positive and HIV-negative patients. J Clin Oncol; 2009 May 20;27(15_suppl):e15586

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective review of squamous cell carcinoma of the anal canal in HIV-positive and HIV-negative patients.
  • : e15586 Background: Human immunodeficiency virus (HIV) infected patients (pts) are at increased risk for squamous cell carcinoma of the anal canal (SCCAC) and the incidence of SCCAC has increased in the era of HAART (highly active antiretroviral therapy).
  • The aim of this study is to describe the outcome, tolerability, and overall survival (OS) in pts with and without HIV infection treated at Karmanos Cancer Institute, at Wayne State University from 1991 to 2007.
  • We collected data regarding HIV status, demographics (age, gender, race), stage at diagnosis, treatment, response to treatment, toxicity, and survival.
  • HIV (+) pts had significantly better stage (p = 0.011) and less frequent reduced chemotherapy dose (p = 0.001).
  • The major toxicities observed in HIV (+) and (-) pts were diarrhea (36% vs. 64%), neutropenia (27% vs. 21%), and skin toxicity secondary to radiotherapy (XRT: 82% vs. 100%; p = 0.034).
  • CONCLUSIONS: HIV (+) pts had better stage, received standard chemotherapy dose more often, and had more frequent XRT dermatitis than HIV (-) pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962344.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Lobato LF, Stocchi L, da Luz Moreira A, Kalady M, Dietz D, Geisler D, Lavery I, Fazio V: Effect of downstaging without complete pathologic response after neoadjuvant treatment on cancer outcomes for cIII and cII rectal cancers. J Clin Oncol; 2009 May 20;27(15_suppl):4108

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of downstaging without complete pathologic response after neoadjuvant treatment on cancer outcomes for cIII and cII rectal cancers.
  • : 4108 Background: Neoadjuvant chemoradiation followed by surgery is standard of care for locally advanced rectal cancer.
  • The aim of this study was to evaluate whether downstaging impacts prognosis in patients with cII vs. cIII rectal cancer.
  • METHODS: We identified from our colorectal cancer database 233 patients with primary cII and cIII rectal cancer staged by CT and ERUS/MRI who received 5FU-based chemoradiation followed by R0 surgery after a median interval of 7 weeks during 1997-2007.
  • Compared among the remaining 175 patients pathologic downstaging (cII to ypI, cIII to ypII or ypI) vs. No pathologic downstaging (c stage ≤ yp stage).
  • Patients with cII vs. cIII stage were statistically comparable regarding demographics, chemoradiation regimen, interval to surgery after neoadjuvant treatment, tumor distance from anal verge, operations performed and follow-up.
  • The incidence of downstaging was increased in stage cIII vs. cII patients (68% vs. 21%, p <0.001).
  • With the exception of local recurrence rates, downstaging resulted in significantly improved cancer outcomes for cIII but not cII ( Table ).
  • CONCLUSIONS: Downstaging without pCR is a significant prognostic factor for patients with stage cIII rectal cancer.
  • A larger sample size is required to confirm lack of downstaging benefits in stage cII.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961176.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Eng C, Chang GJ, Das P, Rodriguez-Bigas M, Skibber JM, Qiao W, Rosner GL, Ukegbu LT, Wolff RA, Crane CH: Phase II study of capecitabine and oxaliplatin with concurrent radiation therapy (XELOX-XRT) for squamous cell carcinoma of the anal canal. J Clin Oncol; 2009 May 20;27(15_suppl):4116

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of capecitabine and oxaliplatin with concurrent radiation therapy (XELOX-XRT) for squamous cell carcinoma of the anal canal.
  • : 4116 Background: Definitive therapy for squamous cell carcinoma (SCC) of the anal canal consists of external beam radiotherapy with concurrent 5-fluorouracil and mitomycin C or cisplatin.
  • The purpose of this study was to evaluate the tolerability and efficacy of XELOX-XRT as definitive treatment for anal cancer.
  • METHODS: Patients with histologically proven SCC of the anal canal, AJCC Stage II-IIIB (T<sub>2-4</sub> or N+M<sub>0</sub>), ECOG PS 0-1, HIV<sup>-</sup>, and no prior therapy were eligible for XELOX-based chemoradiotherapy.
  • Five of 11 (45%) patients developed grade 3 treatment-related diarrhea (Group 1).
  • Therefore, the chemotherapy schedule was modified and only 1 of 9 patients in Group 2 developed grade 3 diarrhea.
  • CONCLUSIONS: The combination of capecitabine, oxaliplatin, and radiation therapy (XELOX-XRT) is effective for locally advanced squamous cell carcinoma of the anal canal.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961220.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Kazmi SS, Azfar M, Syed AA, Yusuf MA: Oxaliplatin-based neoadjuvant chemoradiation for locally advanced rectal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15102

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxaliplatin-based neoadjuvant chemoradiation for locally advanced rectal cancer.
  • : e15102 Background: Preoperative chemoradiation improves local recurrence in patients with locally advanced rectal cancer<sup>1</sup>.
  • We report our experience with addition of Oxaliplatin to neoadjuvant chemoradiation for rectal cancer.
  • METHODS: For this retrospective study, thirty-six consecutive patients referred for neoadjuvant chemoradiation for rectal cancer between May 2007 and March 2008 were identified.
  • All patients had histologically proven adenocarcinoma, and were clinical stage T3/T4 or N+, except for one who was T2N0.
  • In patients with low rectal cancer (0-5cm from anal verge), 16/26(62%) underwent resection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964336.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Wang JP, Wu XJ, Song XM, Wang L, Huang MJ, Lan P: [Changes of sphincter preserving rate in lower rectal cancer and analysis of their related factors]. Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Mar;9(2):107-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Changes of sphincter preserving rate in lower rectal cancer and analysis of their related factors].
  • OBJECTIVE: To analyze the factors related to sphincter preserving(SP) operation for lower rectal cancer.
  • METHODS: Clinicopathological data of 316 patients with lower rectal cancer 1-5 cm from the anorectal line who underwent surgical resection from Aug.
  • Significant differences were detected between the two period in sex, volume of blood transfusion, Dukes' stage (P< 0.05).
  • [MeSH-major] Anal Canal / surgery. Rectal Neoplasms / surgery. Rectum / surgery

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16555145.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


21. Liang JT, Lai HS, Lee PH: Multimedia article. Laparoscopic abdominoperineal resection for lower rectal cancers: how do we do it? Surg Endosc; 2006 Apr;20(4):695-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The appropriateness of the laparoscopic approach for the resection of rectal cancer has been controversial, although it is well established in colon cancer.
  • METHODS: Patients with lower rectal adenocarcinoma located within 6 cm above the anal verge were recruited and subjected to laparoscopic APR.
  • The surgical principle included en bloc resection with high ligation of inferior mesenteric vessels by no-touch isolation and total mesorectal excision.
  • Physical status (American Society of Anesthesiology classification) was class I in 12, class II in eight, and class III in two patients.
  • Two patients were in pathologic TNM stage I, 14 in stage II, and six in stage III.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16502195.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Video-Audio Media
  • [Publication-country] Germany
  •  go-up   go-down


22. Yagi H, Miyamoto S, Tanaka Y, Sonoda K, Kobayashi H, Kishikawa T, Iwamoto R, Mekada E, Nakano H: Clinical significance of heparin-binding epidermal growth factor-like growth factor in peritoneal fluid of ovarian cancer. Br J Cancer; 2005 May 9;92(9):1737-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of heparin-binding epidermal growth factor-like growth factor in peritoneal fluid of ovarian cancer.
  • Epidermal growth factor receptor (EGFR) has been implicated in tumour growth and extension of ovarian cancer.
  • Peritoneal fluid in ovarian cancer patients contains various growth factors that can promote tumour growth and extension.
  • In order to investigate the clinical significance of EGFR ligands as activating factors of ovarian cancer, we examined the cell proliferation-promoting activity and the level of EGFR ligands in peritoneal fluid obtained from 99 patients.
  • Proliferation-promoting activity in peritoneal fluid from 63 ovarian cancer patients (OVCA) was much higher than peritoneal fluid from 18 ovarian cyst patients (OVC) and 18 normal ovary patients (NO), and the activity was suppressed only by antibodies against EGFR or heparin-binding epidermal growth factor (HB-EGF).
  • In peritoneal fluid, HB-EGF is sufficiently elevated to activate cancer cells even at an early stage of OVCA.
  • These results suggested that HB-EGF in peritoneal fluid might play a key role in cell survival and in the proliferation of OVCA.
  • [MeSH-minor] Amphiregulin. Cell Proliferation / drug effects. Cell Survival / drug effects. Dose-Response Relationship, Drug. EGF Family of Proteins. Female. Glycoproteins / metabolism. Heparin-binding EGF-like Growth Factor. Humans. Intercellular Signaling Peptides and Proteins / metabolism. Middle Aged. Transforming Growth Factor alpha / metabolism

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Compr Ther. 1998 Oct;24(10):477-87 [9801846.001]
  • [Cites] J Biol Chem. 1995 Feb 24;270(8):3980-8 [7876145.001]
  • [Cites] Proc Assoc Am Physicians. 1999 May-Jun;111(3):259-69 [10354366.001]
  • [Cites] Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232 [7612182.001]
  • [Cites] Nature. 1999 Dec 23-30;402(6764):884-8 [10622253.001]
  • [Cites] Cancer Treat Rev. 1997 Mar;23(2):113-31 [9225962.001]
  • [Cites] Biochim Biophys Acta. 1997 Dec 9;1333(3):F179-99 [9426203.001]
  • [Cites] Ann Oncol. 1998 Apr;9(4):437-42 [9636836.001]
  • [Cites] Br J Cancer. 2000 Mar;82(6):1233-8 [10735511.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2482-91 [10873103.001]
  • [Cites] Cytokine Growth Factor Rev. 2000 Dec;11(4):335-44 [10959080.001]
  • [Cites] Anal Biochem. 2001 Mar15;290(2):302-13 [11237333.001]
  • [Cites] J Biol Chem. 2001 May 25;276(21):18265-71 [11278323.001]
  • [Cites] J Biol Chem. 2001 Aug 10;276(32):30475-82 [11402047.001]
  • [Cites] Int J Oncol. 2002 Nov;21(5):941-8 [12370739.001]
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4292-302 [12409327.001]
  • [Cites] Endocr Relat Cancer. 2003 Mar;10(1):1-21 [12653668.001]
  • [Cites] EMBO J. 2003 May 15;22(10):2411-21 [12743035.001]
  • [Cites] Nat Rev Cancer. 2003 Aug;3(8):582-91 [12894246.001]
  • [Cites] Biochem Soc Trans. 2003 Dec;31(Pt 6):1203-8 [14641026.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5720-7 [15313912.001]
  • [Cites] Cancer Res. 1988 Mar 1;48(5):1066-71 [3422589.001]
  • [Cites] Cancer Res. 1991 Oct 1;51(19):5322-8 [1717146.001]
  • [Cites] J Immunol. 1991 Oct 15;147(8):2609-16 [1918981.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):529-35 [1548517.001]
  • [Cites] EMBO J. 1994 May 15;13(10):2322-30 [8194524.001]
  • [Cites] Kidney Int. 1994 Sep;46(3):690-5 [7996789.001]
  • [Cites] Clin Cancer Res. 1995 Oct;1(10):1223-32 [9815916.001]
  • (PMID = 15827558.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AREG protein, human; 0 / Amphiregulin; 0 / EGF Family of Proteins; 0 / Glycoproteins; 0 / HBEGF protein, human; 0 / Heparin-binding EGF-like Growth Factor; 0 / Intercellular Signaling Peptides and Proteins; 0 / Transforming Growth Factor alpha; 62229-50-9 / Epidermal Growth Factor
  • [Other-IDs] NLM/ PMC2362036
  •  go-up   go-down


23. Thysell E, Surowiec I, Hörnberg E, Crnalic S, Widmark A, Johansson AI, Stattin P, Bergh A, Moritz T, Antti H, Wikström P: Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One; 2010;5(12):e14175
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol.
  • BACKGROUND: Metastasis to the bone is one clinically important features of prostate cancer (PCa).
  • Current diagnostic methods cannot predict metastatic PCa at a curable stage of the disease.
  • Immunohistochemical staining of PCa bone metastases showed intense staining of the low density lipoprotein receptor and variable levels of the scavenger receptor class B type 1 and 3-hydroxy-3-methylglutaryl-coenzyme reductase in tumor epithelial cells, indicating possibilities for influx and de novo synthesis of cholesterol.

  • Genetic Alliance. consumer health - Bone Cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Cholesterol.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer Prev. 2001 Dec;10(6):507-13 [11916349.001]
  • [Cites] PLoS One. 2009;4(9):e7075 [19763266.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12027-32 [14512514.001]
  • [Cites] Magn Reson Med. 2003 Nov;50(5):944-54 [14587005.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Jan;36(1):39-77 [14592533.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2004 Jul;24(7):1150-60 [15130918.001]
  • [Cites] Prog Clin Biol Res. 1981;75A:279-324 [6175978.001]
  • [Cites] Science. 1986 Apr 4;232(4746):34-47 [3513311.001]
  • [Cites] Prostate. 1992;20(2):151-8 [1549552.001]
  • [Cites] Magn Reson Med. 1992 May;25(1):140-7 [1375702.001]
  • [Cites] Magn Reson Med. 1993 Feb;29(2):149-57 [8429778.001]
  • [Cites] J Urol. 1993 Dec;150(6):2019-24 [7693985.001]
  • [Cites] JAMA. 1998 May 20;279(19):1542-7 [9605898.001]
  • [Cites] Anticancer Res. 1998 May-Jun;18(3A):1429-34 [9673351.001]
  • [Cites] J Urol. 1999 Jan;161(1):152-5 [10037388.001]
  • [Cites] J Clin Invest. 2005 Apr;115(4):959-68 [15776112.001]
  • [Cites] Anal Chem. 2005 Sep 1;77(17):5635-42 [16131076.001]
  • [Cites] Anal Chem. 2005 Dec 15;77(24):8086-94 [16351159.001]
  • [Cites] J Proteome Res. 2006 Jun;5(6):1407-14 [16739992.001]
  • [Cites] Urology. 2006 Jun;67(6):1205-11 [16765180.001]
  • [Cites] Curr Treat Options Oncol. 2006 Sep;7(5):355-62 [16904052.001]
  • [Cites] Mol Cancer Ther. 2006 Sep;5(9):2310-6 [16985065.001]
  • [Cites] Mol Endocrinol. 2006 Oct;20(10):2265-77 [16455816.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10795-804 [17108116.001]
  • [Cites] J Natl Cancer Inst. 2006 Dec 20;98(24):1819-25 [17179483.001]
  • [Cites] Nat Genet. 2007 Jan;39(1):41-51 [17173048.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):256-69 [17384581.001]
  • [Cites] J Urol. 2007 Dec;178(6):2252-9 [17936845.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2213-7 [17971518.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2218-25 [17971519.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2226-32 [18006910.001]
  • [Cites] J Pharmacol Sci. 2008 Apr;106(4):536-41 [18431036.001]
  • [Cites] Trends Endocrinol Metab. 2008 May-Jun;19(4):113-21 [18356074.001]
  • [Cites] J Urol. 2008 Jun;179(6):2422-6 [18433783.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4447-54 [18519708.001]
  • [Cites] Mol Cancer. 2008;7:72 [18799019.001]
  • [Cites] Cancer Biomark. 2008;4(4-5):263-76 [18957715.001]
  • [Cites] Mol Cell Endocrinol. 2008 Nov 25;295(1-2):115-20 [18782595.001]
  • [Cites] Cancer Causes Control. 2008 Dec;19(10):1259-66 [18704722.001]
  • [Cites] J Proteome Res. 2009 Jan;8(1):352-61 [19063642.001]
  • [Cites] Cancer Treat Rev. 2009 Feb;35(1):1-8 [18778896.001]
  • [Cites] Nature. 2009 Feb 12;457(7231):910-4 [19212411.001]
  • [Cites] Am J Pathol. 2009 Mar;174(3):1017-26 [19179610.001]
  • [Cites] Cancer. 2009 Jul 1;115(13 Suppl):3058-67 [19544547.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):2807-13 [19887582.001]
  • [Cites] Clin Exp Metastasis. 2009;26(7):781-7 [19526315.001]
  • [Cites] Endocr Relat Cancer. 2010 Dec;17(4):885-95 [20688881.001]
  • [Cites] Cancer Res. 2002 Apr 15;62(8):2227-31 [11956073.001]
  • (PMID = 21151972.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 97C5T2UQ7J / Cholesterol; Z711V88R5F / Sarcosine
  • [Other-IDs] NLM/ PMC2997052
  •  go-up   go-down


24. Roy HK, Subramanian H, Damania D, Hensing TA, Rom WN, Pass HI, Ray D, Rogers JD, Bogojevic A, Shah M, Kuzniar T, Pradhan P, Backman V: Optical detection of buccal epithelial nanoarchitectural alterations in patients harboring lung cancer: implications for screening. Cancer Res; 2010 Oct 15;70(20):7748-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optical detection of buccal epithelial nanoarchitectural alterations in patients harboring lung cancer: implications for screening.
  • Our approach was to screen for lung cancer by assessing the cheek cells based on emerging genetic/epigenetic data which suggests that the buccal epithelium is altered in lung field carcinogenesis.
  • We performed PWS analysis from microscopically normal buccal epithelial brushings from smokers with and without lung cancer (n = 135).
  • The PWS parameter, disorder strength of cell nanoarchitecture (L(d)), was markedly (>50%) elevated in patients harboring lung cancer compared with neoplasia-free smokers.
  • The performance characteristic was excellent with an area under the receiver operator characteristic curve of >0.80 and was equivalent for both disease stage (early versus late) and histologies (small cell versus non-small cell lung cancers).
  • Our results offer proof of concept that buccal PWS may potentially herald a minimally intrusive prescreening test that could be integral to the success of lung cancer population screening programs.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] Nat Med. 2007 Mar;13(3):361-6 [17334370.001]
  • [Cites] Histol Histopathol. 2007 May;22(5):541-5 [17330809.001]
  • [Cites] Chest. 2007 Sep;132(3 Suppl):29S-55S [17873159.001]
  • [Cites] Chest. 2007 Sep;132(3 Suppl):69S-77S [17873161.001]
  • [Cites] BMC Genomics. 2008;9:259 [18513428.001]
  • [Cites] N Engl J Med. 2008 Sep 25;359(13):1367-80 [18815398.001]
  • [Cites] J Cell Biochem. 2008 Oct 15;105(3):670-7 [18773413.001]
  • [Cites] Acta Cytol. 2008 Sep-Oct;52(5):584-90 [18833822.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20118-23 [19073935.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Jun;1(1):12-4 [19138931.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Nov;1(6):396-403 [19138985.001]
  • [Cites] Opt Lett. 2009 Feb 15;34(4):518-20 [19373360.001]
  • [Cites] Science. 2009 May 22;324(5930):1029-33 [19460998.001]
  • [Cites] Cancer Res. 2009 Jul 1;69(13):5357-63 [19549915.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] N Engl J Med. 2009 Sep 3;361(10):1018-20 [19692681.001]
  • [Cites] Cancer Res. 2009 Nov 15;69(22):8629-35 [19887610.001]
  • [Cites] Cancer Prev Res (Phila). 2010 Mar;3(3):266-78 [20179299.001]
  • [Cites] Clin Cancer Res. 1999 Dec;5(12):3899-905 [10632318.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5131-6 [15297416.001]
  • [Cites] Anal Quant Cytol Histol. 2005 Oct;27(5):254-62 [16447817.001]
  • [Cites] J Natl Cancer Inst. 2007 May 2;99(9):715-26 [17470739.001]
  • (PMID = 20924114.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA086137-10; United States / NCI NIH HHS / CA / CA086137-10; United States / NCI NIH HHS / CA / U01 CA111257; United States / PHS HHS / / T32ESES007267; United States / NCI NIH HHS / CA / U01CA111257; United States / NCI NIH HHS / CA / U01 CA086137
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS275336; NLM/ PMC3703950
  •  go-up   go-down


25. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, Bast MA, Rosenwald A, Muller-Hermelink HK, Rimsza LM, Campo E, Delabie J, Braziel RM, Cook JR, Tubbs RR, Jaffe ES, Lenz G, Connors JM, Staudt LM, Chan WC, Gascoyne RD: Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med; 2010 Mar 11;362(10):875-85
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In an independent cohort of patients, we found that an increased number of CD68+ macrophages was correlated with a shortened progression-free survival (P=0.03) and with an increased likelihood of relapse after autologous hematopoietic stem-cell transplantation (P=0.008), resulting in shortened disease-specific survival (P=0.003).
  • The absence of an elevated number of CD68+ cells in patients with limited-stage disease defined a subgroup of patients with a long-term disease-specific survival of 100% with the use of current treatment strategies.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Massachusetts Medical Society
  • [Cites] Ann Oncol. 2006 Jan;17(1):110-6 [16291580.001]
  • [Cites] Immunol Rev. 2006 Apr;210:67-85 [16623765.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2431-42 [16760443.001]
  • [Cites] Blood. 2006 Jul 15;108(2):662-8 [16551964.001]
  • [Cites] Bone Marrow Transplant. 2007 Jan;39(1):41-7 [17115062.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3101-8 [17536082.001]
  • [Cites] J Surg Res. 2007 Sep;142(1):119-28 [17597158.001]
  • [Cites] Eur J Haematol. 2007 Nov;79(5):455-61 [17908180.001]
  • [Cites] Am J Clin Pathol. 2007 Dec;128(6):958-65 [18024321.001]
  • [Cites] Haematologica. 2008 Feb;93(2):193-200 [18223287.001]
  • [Cites] Clin Cancer Res. 2008 Mar 15;14(6):1759-66 [18347177.001]
  • [Cites] N Engl J Med. 2008 Nov 27;359(22):2313-23 [19038878.001]
  • [Cites] Nat Rev Cancer. 2009 Jan;9(1):15-27 [19078975.001]
  • [Cites] Blood. 2009 Mar 19;113(12):2765-3775 [19096012.001]
  • [Cites] Blood. 2009 Jun 4;113(23):5920-6 [19188663.001]
  • [Cites] Oncogene. 2002 May 2;21(19):3095-102 [12082542.001]
  • [Cites] Trends Immunol. 2002 Nov;23(11):549-55 [12401408.001]
  • [Cites] Cancer. 2003 Jul 15;98(2):310-4 [12872350.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2003;:225-47 [14633784.001]
  • [Cites] J Nutr. 2004 Apr;134(4):762-70 [15051823.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6062-7 [15075390.001]
  • [Cites] N Engl J Med. 1992 Nov 19;327(21):1478-84 [1383821.001]
  • [Cites] Ann Oncol. 1995 Nov;6(9):895-9 [8624292.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1506-14 [9819449.001]
  • [Cites] N Engl J Med. 2004 Nov 18;351(21):2159-69 [15548776.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1467-73 [15746048.001]
  • [Cites] Blood. 2005 May 15;105(10):3979-86 [15677569.001]
  • [Cites] J Clin Oncol. 2005 Jun 1;23(16):3773-9 [15809450.001]
  • [Cites] IEEE Trans Pattern Anal Mach Intell. 2005 Jun;27(6):957-68 [15943426.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2169-74 [15933054.001]
  • [Cites] Cell Immunol. 2005 May;235(1):21-8 [16165118.001]
  • [Cites] Leuk Lymphoma. 2005 Nov;46(11):1581-91 [16236613.001]
  • [CommentIn] N Engl J Med. 2010 Mar 11;362(10):942-3 [20220189.001]
  • [CommentIn] N Engl J Med. 2010 Jun 3;362(22):2135; author reply 2136 [20527079.001]
  • [CommentIn] N Engl J Med. 2010 Jun 3;362(22):2135-6; author reply 2136 [20527059.001]
  • [CommentIn] N Engl J Med. 2010 Jun 3;362(22):2135; author reply 2136 [20519687.001]
  • (PMID = 20220182.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA114778; Canada / Canadian Institutes of Health Research / / 178536; United States / NCI NIH HHS / CA / U01 CA114778-05; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CA / U01-CA114778-01; United States / NCI NIH HHS / CA / CA114778-05; United States / NCI NIH HHS / CA / U01-CA 114778
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Biomarkers, Tumor; 0 / CD68 antigen, human; 0 / RNA, Neoplasm
  • [Other-IDs] NLM/ NIHMS194035; NLM/ PMC2897174
  •  go-up   go-down


26. Nilsson PJ, Ragnarsson-Olding BK: Importance of clear resection margins in anorectal malignant melanoma. Br J Surg; 2010 Jan;97(1):98-103
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: From the Swedish National Cancer Registry, 251 patients with anorectal melanoma were identified from 1960 to 1999.
  • Multivariable analysis showed resection status and tumour stage to be independent prognostic variables.
  • [MeSH-major] Anal Canal / surgery. Anus Neoplasms / surgery. Melanoma / surgery. Rectal Neoplasms / surgery. Rectum / surgery

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • (PMID = 20013935.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


27. Lefevre JH, Parc Y, Kernéis S, Shields C, Touboul E, Chaouat M, Tiret E: Abdomino-perineal resection for anal cancer: impact of a vertical rectus abdominis myocutaneus flap on survival, recurrence, morbidity, and wound healing. Ann Surg; 2009 Nov;250(5):707-11
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abdomino-perineal resection for anal cancer: impact of a vertical rectus abdominis myocutaneus flap on survival, recurrence, morbidity, and wound healing.
  • OBJECTIVES: To evaluate the results of a vertical rectus abdominis myocutaneus (VRAM) flap after abdomino-perineal resection (APR) for anal cancer (AC).
  • The groups (VRAM vs. No VRAM) differed in age at surgery (56.3 vs. 62.1; P = 0.0263); administration of chemotherapy in addition to radiotherapy (81% vs. 59%; P = 0.0218); and stage (ypT3-T4 67.6% vs. 38.4%; P = 0.0394).
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Postoperative Complications. Surgical Flaps. Wound Healing

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19801930.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Choi JY, James SR, Link PA, McCann SE, Hong CC, Davis W, Nesline MK, Ambrosone CB, Karpf AR: Association between global DNA hypomethylation in leukocytes and risk of breast cancer. Carcinogenesis; 2009 Nov;30(11):1889-97
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between global DNA hypomethylation in leukocytes and risk of breast cancer.
  • BACKGROUND: Global DNA hypomethylation may result in chromosomal instability and oncogene activation, and as a surrogate of systemic methylation activity, may be associated with breast cancer risk.
  • METHODS: Samples and data were obtained from women with incident early-stage breast cancer (I-IIIa) and women who were cancer free, frequency matched on age and race.
  • Logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for risk of breast cancer in relation to amounts of methylation.
  • 5-mdC level in leukocyte DNA was significantly lower in breast cancer cases than healthy controls (P = 0.001), but no significant case-control differences were observed with LINE-1 methylation (P = 0.176).
  • Compared with women in the highest 5-mdC tertile (T3), women in the second (T2; OR = 1.49, 95% CI = 0.84-2.65) and lowest tertile (T1; OR = 2.86, 95% CI = 1.65-4.94) had higher risk of breast cancer (P for trend < or = 0.001).
  • CONCLUSION: These findings suggest that leukocyte DNA hypomethylation is independently associated with development of breast cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Carcinogenesis. 2008 Jul;29(7):1367-72 [18566018.001]
  • [Cites] PLoS One. 2008;3(7):e2656 [18628976.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Sep;17(9):2306-10 [18768498.001]
  • [Cites] Br J Nutr. 2009 Mar;101(5):743-9 [18684339.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Apr 1;118(1):52-6 [10731591.001]
  • [Cites] Am J Clin Nutr. 2000 Oct;72(4):998-1003 [11010943.001]
  • [Cites] Nat Rev Genet. 2000 Nov;1(2):134-44 [11253653.001]
  • [Cites] Oncogene. 2001 May 28;20(24):3139-55 [11420731.001]
  • [Cites] Hum Mol Genet. 2001 Dec 15;10(26):3001-7 [11751682.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5380-7 [12154400.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5400-13 [12154403.001]
  • [Cites] Am J Pathol. 2002 Sep;161(3):859-66 [12213714.001]
  • [Cites] Nat Rev Cancer. 2003 Apr;3(4):253-66 [12671664.001]
  • [Cites] Science. 2003 Apr 18;300(5618):489-92 [12702876.001]
  • [Cites] Cancer Causes Control. 2003 Feb;14(1):37-42 [12708723.001]
  • [Cites] Ann N Y Acad Sci. 2003 Mar;983:28-42 [12724210.001]
  • [Cites] Gastroenterology. 2003 May;124(5):1240-8 [12730865.001]
  • [Cites] Biotechniques. 2003 Jul;35(1):146-50 [12866414.001]
  • [Cites] Nat Rev Cancer. 2004 Feb;4(2):143-53 [14732866.001]
  • [Cites] Nucleic Acids Res. 2004;32(3):e38 [14973332.001]
  • [Cites] Biochem Pharmacol. 2004 Sep 15;68(6):1187-97 [15313416.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Sep;13(9):1436-43 [15342443.001]
  • [Cites] Science. 1975 Jan 24;187(4173):226-32 [1111098.001]
  • [Cites] Nature. 1983 Jan 6;301(5895):89-92 [6185846.001]
  • [Cites] Nucleic Acids Res. 1983 Oct 11;11(19):6883-94 [6314264.001]
  • [Cites] Cancer Genet Cytogenet. 1997 Sep;97(2):83-9 [9283586.001]
  • [Cites] Cancer. 1999 Jan 1;85(1):112-8 [9921982.001]
  • [Cites] Cancer Res. 1999 Jul 1;59(13):3251-6 [10397273.001]
  • [Cites] Oncogene. 2004 Nov 18;23(54):8841-6 [15480421.001]
  • [Cites] Anal Chem. 2005 Jan 15;77(2):504-10 [15649046.001]
  • [Cites] Gut. 2005 May;54(5):648-53 [15831910.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1524-30 [15812544.001]
  • [Cites] Cancer Biol Ther. 2004 Dec;3(12):1225-31 [15539937.001]
  • [Cites] Biochem Cell Biol. 2005 Jun;83(3):296-321 [15959557.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 26;102(30):10604-9 [16009939.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8635-9 [16204030.001]
  • [Cites] Nucleic Acids Res. 2005;33(21):6823-36 [16326863.001]
  • [Cites] Nat Rev Genet. 2006 Jan;7(1):21-33 [16369569.001]
  • [Cites] Mutagenesis. 2006 Jan;21(1):41-7 [16339195.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):199-207 [16530704.001]
  • [Cites] Environ Health Perspect. 2006 Apr;114(4):567-72 [16581547.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1575-7 [16985014.001]
  • [Cites] Biochim Biophys Acta. 2007 Jan;1775(1):138-62 [17045745.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):108-14 [17220338.001]
  • [Cites] Int J Cancer. 2007 Oct 15;121(8):1724-8 [17582607.001]
  • [Cites] Oncol Rep. 2007 Oct;18(4):873-8 [17786349.001]
  • [Cites] Gastroenterology. 2008 Jan;134(1):47-55 [18166347.001]
  • [Cites] Pharmacogenomics. 2008 Feb;9(2):215-34 [18370850.001]
  • [Cites] Lancet Oncol. 2008 Apr;9(4):359-66 [18339581.001]
  • [Cites] Int J Cancer. 2008 Jun 15;122(12):2767-73 [18366060.001]
  • [Cites] Clin Cancer Res. 2008 Jun 1;14(11):3283-90 [18519754.001]
  • [Cites] JAMA. 2008 Jun 25;299(24):2877-83 [18577732.001]
  • [Cites] Mutat Res. 2008 Sep-Oct;659(3):274-83 [18582599.001]
  • (PMID = 19584139.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA116674-04; United States / NCI NIH HHS / CA / R01 CA116674; United States / NCI NIH HHS / CA / R01 CA116674-04; United States / NCI NIH HHS / CA / R01CA11674
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 5-methyldeoxycytosine; 0 / DNA, Neoplasm; 6R795CQT4H / 5-Methylcytosine
  • [Other-IDs] NLM/ PMC2783000
  •  go-up   go-down


29. Kiran RP, Pokala N, Rottoli M, Fazio VW: Is survival reduced for patients with anal cancer requiring surgery after failure of radiation? Analysis from a population study over two decades. Am Surg; 2009 Feb;75(2):163-8
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is survival reduced for patients with anal cancer requiring surgery after failure of radiation? Analysis from a population study over two decades.
  • Chemoradiotherapy is the standard treatment for anal cancer.
  • From a prospective population-based database on radiation and surgical therapy, we compare outcomes for patients with anal cancer undergoing rectal resection after radiation with patients undergoing radiation alone.
  • Patients undergoing surgical resection of the rectum after initial radiation (SRT) for squamous cell carcinoma of the anus, anal canal, cloacogenic zone, and overlapping lesions of the rectum and anal canal from 1983 to 2002 were identified from the Surveillance, Epidemiology and End Results database.
  • RT and SRT had similar median age, gender, and grade of tumor.
  • SRT had more patients with regional stage of disease (66.7 vs 42.4%, P = 0.001).
  • For patients with localized stage, survival for SRT and RT was similar (105 vs 98 months, P = 0.7).
  • For patients with regional stage, survival for SRT and RT was similar (95 vs 83 months, P = 0.6).
  • [MeSH-major] Anus Neoplasms / mortality. Anus Neoplasms / surgery. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / surgery

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19280811.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Myerson RJ, Outlaw ED, Chang A, Birnbaum EH, Fleshman JW, Grigsby PW, Kodner IJ, Malayapa RS, Mutch MG, Parikh P, Picus J, Tan BR: Radiotherapy for epidermoid carcinoma of the anus: thirty years' experience. Int J Radiat Oncol Biol Phys; 2009 Oct 1;75(2):428-35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy for epidermoid carcinoma of the anus: thirty years' experience.
  • PURPOSE: To evaluate the factors associated with disease control and morbidity after radiotherapy for anal carcinoma.
  • METHODS AND MATERIALS: Between 1975 and 2005, 194 patients with localized epidermoid anal carcinoma underwent radiotherapy.
  • Univariate analysis for UNED survival showed a strong association with the T and N stage (5-year UNED rate, 88.5% +/- 3.4% for those with Stage T1-T2N0; 70.1% +/- 4.2% for Stage T3N0; and 52.7% +/- 6.6% for Stage III; p > .001) and mobility on palpation (5-year UNED rate, 89.2% +/- 4.6% for those with mobile tumors vs. 59.3% +/- 6.1% for those with tethered/fixed tumor; p > .001).
  • The radiotherapy factors associated with Grade 3 or greater late morbidity included anorectal morbidity with tumor dose (29% with a dose > or =55 Gy vs. 9% otherwise), small bowel injury with technique (9% with anteroposterior-posteroanterior supine vs. 0.7% with multiple fields prone), and bone injury with femoral head dose (9% with a dose of > or =44 Gy vs. 0.7% otherwise).
  • Of the 194 patients, 56 had 68 additional malignancies, mainly either antedating the anal cancer or outside the radiation fields.
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19251377.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


31. Horisberger K, Treschl A, Mai S, Barreto-Miranda M, Kienle P, Ströbel P, Erben P, Woernle C, Dinter D, Kähler G, Hochhaus A, Post S, Willeke F, Wenz F, Hofheinz RD, MARGIT (Mannheimer Arbeitsgruppe für Gastrointestinale Tumoren): Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial. Int J Radiat Oncol Biol Phys; 2009 Aug 1;74(5):1487-93
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial.
  • PURPOSE: To evaluate the safety and efficacy of preoperative radiotherapy (RT) in combination with cetuximab, capecitabine, and irinotecan in patients with locally advanced rectal cancer.
  • METHODS AND MATERIALS: Patients with rectal cancer (clinical stage T3/4 or N+) were scheduled to receive cetuximab (400 mg/m(2) Day 1, 250 mg/m(2) Days 8, 15, 22, 29) in combination with weekly irinotecan 40 mg/m(2) and capecitabine 500 mg/m(2) twice daily (Days 1-38).
  • RESULTS: Fifty patients were enrolled; 88% showed T3 or T4 and 76% nodal-positive tumors with a median distance from the anal verge of 7.5 cm.
  • Main adverse events Grades 2/3/4 were (National Cancer Institute common toxicity criteria version 3.0, %): leukocytopenia 6/2/2, nausea/vomiting 4/2/0, diarrhea 34/30/0, proctitis 26/2/0, elevation of liver transaminases 8/10/0, and acnelike skin rash 46/6/0.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19131187.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; 7673326042 / irinotecan; PQX0D8J21J / Cetuximab; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


32. Maw MK, Fujimoto J, Tamaya T: Expression of the inhibitor of DNA-binding (ID)-1 protein as an angiogenic mediator in tumour advancement of uterine cervical cancers. Br J Cancer; 2008 Nov 18;99(10):1557-63
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ID-1 histoscores and mRNA levels both significantly (P<0.05) increased in uterine cervical cancers according to clinical stage regardless of histopathological type or lymph node metastasis.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Squamous Cell / metabolism. Inhibitor of Differentiation Protein 1 / biosynthesis. Neovascularization, Pathologic / metabolism. Uterine Cervical Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Cancer Res. 1985;43:175-203 [2581424.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12718-23 [14555767.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Nucleic Acids Res. 1994 Mar 11;22(5):749-55 [8139914.001]
  • [Cites] Cancer Res. 1994 Dec 1;54(23):6065-8 [7954447.001]
  • [Cites] Cell Growth Differ. 1995 Jul;6(7):837-43 [7547505.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13543-8 [14578451.001]
  • [Cites] Cancer J. 2004 Jan-Feb;10(1):27-32 [15000492.001]
  • [Cites] Br J Cancer. 2004 Mar 22;90(6):1198-203 [15026801.001]
  • [Cites] Br J Cancer. 1996 Apr;73(8):884-8 [8611421.001]
  • [Cites] Mol Cell Biol. 1997 Dec;17(12):7317-27 [9372963.001]
  • [Cites] Mol Cell Biol. 1998 Apr;18(4):2371-81 [9528806.001]
  • [Cites] Mol Cell Biol. 1998 Aug;18(8):4577-88 [9671467.001]
  • [Cites] Trends Cell Biol. 1998 Feb;8(2):58-65 [9695810.001]
  • [Cites] EMBO J. 1999 Feb 15;18(4):968-76 [10022839.001]
  • [Cites] Br J Cancer. 1999 Mar;79(7-8):1249-54 [10098767.001]
  • [Cites] Br J Cancer. 1999 May;80(5-6):827-33 [10360662.001]
  • [Cites] Cancer Res. 1999 Jul 1;59(13):3041-4 [10397240.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9637-41 [10449746.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):815-22 [10487839.001]
  • [Cites] Br J Cancer. 2005 Oct 17;93(8):933-8 [16189525.001]
  • [Cites] Gynecol Oncol. 2006 Oct;103(1):186-9 [16595146.001]
  • [Cites] Cancer Lett. 2006 Dec 8;244(2):203-10 [16469432.001]
  • [Cites] Arch Pathol Lab Med. 1985 Aug;109(8):716-21 [3893381.001]
  • [Cites] Nature. 1999 Oct 14;401(6754):670-7 [10537105.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1332-40 [10728695.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3662-5 [10910083.001]
  • [Cites] Nature. 2000 Oct 5;407(6804):592-8 [11034201.001]
  • [Cites] J Cell Sci. 2000 Nov;113 ( Pt 22):3897-905 [11058077.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):5929-33 [11085505.001]
  • [Cites] Nature. 2001 Feb 22;409(6823):1067-70 [11234019.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):7812-6 [11427735.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5703-6 [11479201.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6008-11 [11507043.001]
  • [Cites] Nat Med. 2001 Nov;7(11):1194-201 [11689883.001]
  • [Cites] Cancer. 2001 Nov 15;92(10):2569-77 [11745191.001]
  • [Cites] Oncogene. 2002 Mar 14;21(12):1812-22 [11896613.001]
  • [Cites] J Urol. 2002 Jun;167(6):2598-602 [11992094.001]
  • [Cites] Carcinogenesis. 2002 May;23(5):721-5 [12016143.001]
  • [Cites] Mol Carcinog. 2002 Sep;35(1):42-9 [12203366.001]
  • [Cites] Ann Oncol. 2002 Oct;13(10):1598-604 [12377648.001]
  • [Cites] Cancer Cell. 2002 Dec;2(6):473-83 [12498716.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):779-85 [12576450.001]
  • [Cites] Int J Cancer. 2003 May 10;104(6):677-82 [12640673.001]
  • [Cites] Oncogene. 2003 Jul 17;22(29):4498-508 [12881706.001]
  • [Cites] J Pathol. 2003 Aug;200(5):561-7 [12898591.001]
  • [ErratumIn] Br J Cancer. 2009 Jul 21;101(2):377-8
  • (PMID = 19002177.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Modulating Agents; 0 / Biomarkers, Tumor; 0 / Inhibitor of Differentiation Protein 1; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2584935
  •  go-up   go-down


33. Yun HR, Lee LJ, Park JH, Cho YK, Cho YB, Lee WY, Kim HC, Chun HK, Yun SH: Local recurrence after curative resection in patients with colon and rectal cancers. Int J Colorectal Dis; 2008 Nov;23(11):1081-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND AIMS: There are a range of rates and a number of prognostic factors associated with the local recurrence of colorectal cancer after curative resection.
  • MATERIALS AND METHODS: A retrospective review of 1,838 patients who underwent curative resection of non-metastatic colorectal cancer was conducted.
  • RESULTS: There were 994 patients with colon cancer and 844 patients with rectal cancer.
  • With respect to colon cancer, the local recurrence rate was 6.1% (61 patients).
  • With respect to rectal cancer, 95 patients had a local recurrence (11.3%), the rate of which was statistically greater than the local recurrence rate for colon cancer (p < 0.001).
  • In patients with colon and rectal cancer, the pathologic T stage (p = 0.044 and p = 0.034, respectively), pathologic N stage (p = 0.001 and p < 0.001, respectively), and lymphovascular invasion (p = 0.013 and p = 0.004, respectively) were adverse risk factors for local recurrence.
  • The level of the anastomosis from the anal verge was an additional prognostic factor (p = 0.007) in patients with rectal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18688621.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


34. Scott H, Khoury J, Moore BA, Weissman S: Routine anal cytology screening for anal squamous intraepithelial lesions in an urban HIV clinic. Sex Transm Dis; 2008 Feb;35(2):197-202
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Routine anal cytology screening for anal squamous intraepithelial lesions in an urban HIV clinic.
  • OBJECTIVES: The purpose of this study is to describe our experience with routine anal cancer screening using anal cytology, determine risk factors for abnormal anal cytology, and determine if an association exists between cytology and histology in patients with HIV infection.
  • METHODS: Demographics, CD4+ T-cell count, STD history, and cytology and histology data were extracted from medical charts of patients seen between November 1, 2002, and November 30, 2004.
  • Multivariate analysis was conducted using logistic regression controlling for age, race, sex, CD4+ T-cell nadir, and HIV exposure category.
  • RESULTS: Overall, 276 of 560 of the clinic patients received a screening anal cytology during the study period.
  • Of these patients, 11 were excluded from the analysis and 74 of 265 (27.9%) patients screened had an abnormal anal cytology.
  • They were also more likely to have a lower CD4+ nadir (142 cells/mm3 vs. 223 cells/mm3, P = 0.005) and CD4+ at time of anal cytology (353 cells/mm3 vs. 497 cells/mm3, P <0.001).
  • Those with an abnormal anal cytology also had higher occurrence of anal disease on perianal visual inspection (30% vs. 9%, P <0.001) and were more likely to have a history of genital warts (23% vs. 12%, P = 0.02) or herpes (35% vs. 22%, P = 0.02).
  • Two patients had anal intraepithelial neoplasia (AIN) I, 2 AIN II, 3 AIN III, and 2 squamous cell carcinoma in situ on histology.
  • CONCLUSION: Routine anal cytology screening is a feasible tool to incorporate into HIV care for patients regardless of gender and HIV risk factors.
  • [MeSH-major] Anus Neoplasms / diagnosis. HIV Infections / complications. Neoplasms, Squamous Cell / pathology. Urban Health Services / organization & administration
  • [MeSH-minor] Adult. Aged. Anal Canal / pathology. Colonoscopy / methods. Female. Follow-Up Studies. Humans. Logistic Models. Male. Middle Aged. Multivariate Analysis

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18216727.001).
  • [ISSN] 0148-5717
  • [Journal-full-title] Sexually transmitted diseases
  • [ISO-abbreviation] Sex Transm Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Biffi R, Marsiglia H, Fossa BJ, Leonardi MC, Cante D, Lazzari R, Chiappa A, Cenciarelli S, Andreoni B, Zampino MG, Orecchia R: Preoperative bi-fractionated accelerated radiation therapy for combined treatment of locally advanced rectal cancer in a consectutive series of unselected patients. Int Semin Surg Oncol; 2007;4:23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative bi-fractionated accelerated radiation therapy for combined treatment of locally advanced rectal cancer in a consectutive series of unselected patients.
  • METHODS: patients were screened following these eligibility criteria: histology-proven adenocarcinoma of the rectum; distal tumour extent at 12 cm or less from the anal verge; clinical stage T3-4/anyN, or anyT/N1-2; ECOG Performance Status 0-2.
  • Twenty-eight patients were stage II and 19 stage III.
  • 2 patients experienced a severe grade 4 gastrointestinal toxicity (a colo-vaginal fistula and an intestinal obstruction, both successfully treated).
  • CONCLUSION: bifractionated accelerated RT administered in the preoperative setting to patients bearing locally advanced rectal cancer is reliable and safe, as its immediate and late toxicity (mainly infectious) is acceptably low and long-term survivals are achievable.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2396 [10561302.001]
  • [Cites] Ann Surg. 1998 Feb;227(2):157-67 [9488510.001]
  • [Cites] Lancet. 2000 Jul 8;356(9224):93-6 [10963244.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] Lancet. 2001 Oct 20;358(9290):1291-304 [11684209.001]
  • [Cites] Ann Surg. 2001 Nov;234(5):633-40 [11685026.001]
  • [Cites] Strahlenther Onkol. 2002 May;178(5):259-62 [12082685.001]
  • [Cites] Strahlenther Onkol. 2004 Jan;180(1):5-14 [14704839.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(2):387-92 [1587760.001]
  • [Cites] Dis Colon Rectum. 1992 Aug;35(8):757-61 [1643999.001]
  • [Cites] Ann Surg. 1990 Feb;211(2):187-95 [2405793.001]
  • [Cites] Br J Radiol. 1989 Aug;62(740):679-94 [2670032.001]
  • [Cites] Clin Radiol. 1971 Apr;22(2):145-55 [5575251.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1984 May;10(5):593-8 [6735750.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):67-73 [7826163.001]
  • [Cites] N Engl J Med. 1994 Aug 25;331(8):502-7 [8041415.001]
  • [Cites] Am J Surg. 1994 Jan;167(1):90-4; discussion 94-5 [8311145.001]
  • [Cites] Br J Surg. 1996 Jul;83(7):964-8 [8813788.001]
  • [Cites] N Engl J Med. 1997 Apr 3;336(14):980-7 [9091798.001]
  • [Cites] J Natl Cancer Inst. 2000 Mar 1;92(5):388-96 [10699069.001]
  • (PMID = 17883838.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2063497
  •  go-up   go-down


36. Best S, Sawers Y, Fu VX, Almassi N, Huang W, Jarrard DF: Integrity of prostatic tissue for molecular analysis after robotic-assisted laparoscopic and open prostatectomy. Urology; 2007 Aug;70(2):328-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: The warm ischemia time of tissue before fixation for pathologic analysis has been linked to changes in cell morphology and nucleic acid and protein integrity.
  • Tissue integrity was suitable for the assessment of pathologic grade and stage for all samples.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Biospecimen Research Database. Biospecimen Research Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Lett. 2002 Nov 28;185(2):191-9 [12169393.001]
  • [Cites] Urology. 2002 Oct;60(4):569-72 [12385908.001]
  • [Cites] Am J Clin Pathol. 2002 Nov;118(5):733-41 [12428794.001]
  • [Cites] Nephron Exp Nephrol. 2003;95(4):e144-51 [14694268.001]
  • [Cites] Anal Biochem. 2004 May 15;328(2):101-8 [15113684.001]
  • [Cites] Exp Mol Pathol. 2004 Oct;77(2):98-103 [15351232.001]
  • [Cites] Mod Pathol. 1993 Mar;6(2):201-7 [8483892.001]
  • [Cites] Mod Pathol. 1998 Mar;11(3):276-81 [9521475.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):2957-64 [10383161.001]
  • [Cites] Nucleic Acids Res. 2005;33(6):e56 [15800207.001]
  • [Cites] Int J Mol Med. 2005 Dec;16(6):979-85 [16273275.001]
  • [Cites] Mol Aspects Med. 2006 Apr-Jun;27(2-3):126-39 [16469371.001]
  • [Cites] Mod Pathol. 2001 Feb;14(2):116-28 [11235903.001]
  • (PMID = 17826499.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / P50 DK065303; United States / NCI NIH HHS / CA / R01 CA097131; United States / NCI NIH HHS / CA / R01 CA097131-05; United States / NIDDK NIH HHS / DK / P50 DK065303-010003; United States / NIDDK NIH HHS / DK / 1P50DK065303; United States / NCI NIH HHS / CA / CA097131-05; United States / NIDDK NIH HHS / DK / DK065303-010003; United States / NCI NIH HHS / CA / R01CA97131
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS30002; NLM/ PMC2693382
  •  go-up   go-down


37. Biondo S, Kreisler E, Millan M, Martí-Ragué J, Fraccalvieri D, Golda T, De Oca J, Osorio A, Fradera R, Salazar R, Rodriguez-Moranta F, Sanjuán X: [Long-term results of emergency surgery for colon cancer compared with elective surgery]. Cir Esp; 2007 Aug;82(2):89-98

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term results of emergency surgery for colon cancer compared with elective surgery].
  • [Transliterated title] Resultados a largo plazo de la cirugía urgente y electiva del cáncer de colon. Estudio comparativo.
  • AIMS: The aim of the present study was to analyze the 5-year efficacy of curative oncological surgery for complicated colon cancer performed in an emergency setting in terms of tumor recurrence and survival compared with elective surgery of uncomplicated tumors.
  • PATIENTS AND METHOD: We performed a prospective observational cohort study in patients who underwent emergency surgery for complicated colon cancer (group 1) and patients who underwent elective surgery (group 2).
  • Exclusion criteria were tumors of less than 15 cm from the anal verge, palliative surgery, and distant metastases.
  • Significant differences were found in disease stage between the 2 groups (P = 0.003).
  • When patients were stratified by TNM stage, worse 5-year cancer-related and disease-free survival rates were observed in group 1 patients with stage II tumors.
  • No differences were found in cancer-related survival rates in stage III patients (P = 0.178).
  • There were no significant differences in overall survival, cancer-related survival or tumor recurrence rates when group 1 was compared with a subgroup of patients in group 2 with factors of poor prognosis.
  • CONCLUSIONS: Complicated colon cancer presents in more advanced stages and had a worse overall long-term prognosis than uncomplicated tumour.
  • These differences decrease when patients are subclassified by tumoral stage.
  • Overall survival and cancer-related survival rates similar to those of elective surgery can be achieved in emergency surgery when curative oncological resection is performed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17785142.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


38. Gavioli M, Losi L, Luppi G, Iacchetta F, Zironi S, Bertolini F, Falchi AM, Bertoni F, Natalini G: Preoperative therapy for lower rectal cancer and modifications in distance from anal sphincter. Int J Radiat Oncol Biol Phys; 2007 Oct 1;69(2):370-5
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative therapy for lower rectal cancer and modifications in distance from anal sphincter.
  • PURPOSE: To assess the frequency and magnitude of changes in lower rectal cancer resulting from preoperative therapy and its impact on sphincter-saving surgery.
  • Preoperative therapy can increase the rate of preserving surgery by shrinking the tumor and enhancing its distance from the anal sphincter.
  • METHODS AND MATERIALS: A total of 98 cases of locally advanced cancer of the lower rectum (90 Stage uT3-T4N0-N+ and 8 uT2N+M0) that had undergone preoperative therapy were studied by endorectal ultrasonography.
  • The maximal size of the tumor and its distance from the anal sphincter were measured in millimeters before and after preoperative therapy.
  • The distance between the tumor and the anal sphincter increased in 60.2% of cases.
  • It was possible in nearly 30% of patients in whom the cancer had reached the anal sphincter before the preoperative therapy.
  • CONCLUSION: The results of our study have shown that in very low rectal cancer, preoperative therapy causes tumor downsizing in >80% of cases and in more than one-half enhances the distance between the tumor and anal sphincter.
  • [MeSH-major] Anal Canal / pathology. Rectal Neoplasms / pathology. Rectal Neoplasms / therapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17524570.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


39. Tsao KC, Wu TL, Chang PY, Hong JH, Wu JT: Detection of carcinomas in an asymptomatic Chinese population: advantage of screening with multiple tumor markers. J Clin Lab Anal; 2006;20(2):42-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 73,443 asymptomatic individuals were screened on a voluntary basis for cancer at Chang Gung Memorial Hospital in Taiwan using a panel of tumor markers, including alpha fetoprotein (AFP), CA 125, CA 15-3, CA 19-9, carcinoembryonic antigen (CEA), prostate specific antigen (PSA), chromogranin A (CgA), and squamous cell specific antigen (SCC).
  • Of the tumor markers monitored, elevated CA 19-9, CEA, and CA 125 were the most frequently detected in a variety of cancers.
  • Screening with multiple circulating tumor markers provides improved sensitivity for cancer detection in asymptomatic individuals before they reach the fatal advanced stage.
  • [MeSH-major] Asian Continental Ancestry Group. Biomarkers, Tumor / analysis. Carcinoma / diagnosis. Mass Screening / methods
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. CA-19-9 Antigen / analysis. Cohort Studies. Female. Humans. Male. Middle Aged. Sensitivity and Specificity. Sex Distribution. Taiwan / epidemiology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16538643.001).
  • [ISSN] 0887-8013
  • [Journal-full-title] Journal of clinical laboratory analysis
  • [ISO-abbreviation] J. Clin. Lab. Anal.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen
  •  go-up   go-down


40. Baxter NN, Habermann EB, Tepper JE, Durham SB, Virnig BA: Risk of pelvic fractures in older women following pelvic irradiation. JAMA; 2005 Nov 23;294(20):2587-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To determine if women who undergo pelvic irradiation for pelvic malignancies (anal, cervical, or rectal cancers) have a higher rate of pelvic fracture than women with pelvic malignancies who do not undergo irradiation.
  • DESIGN, SETTING, AND PARTICIPANTS: We conducted a retrospective cohort study using Surveillance, Epidemiology, and End Results (SEER) cancer registry data linked to Medicare claims data.
  • RESULTS: Women who underwent radiation therapy were more likely to have a pelvic fracture than women who did not undergo radiation therapy (cumulative 5-year fracture rate, 14.0% vs 7.5% in women with anal cancer, 8.2% vs 5.9% in women with cervical cancer, and 11.2% vs 8.7% in women with rectal cancer); the difference was statistically significant and most fractures (90%) were hip fractures.
  • We controlled for potential confounders including age, race, cancer stage, and geographic location.
  • The impact of irradiation varied by cancer site: treatment for anal cancer was associated with a higher risk of pelvic fractures (hazard ratio, 3.16; 95% confidence interval, 1.48-6.73); than for cervical cancer (hazard ratio, 1.66; 95% confidence interval, 1.06-2.59); or rectal cancer (hazard ratio, 1.65; 95% confidence interval, 1.33-2.05).

  • MedlinePlus Health Information. consumer health - Fractures.
  • MedlinePlus Health Information. consumer health - Hip Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] JAMA. 2005 Nov 23;294(20):2635-7 [16304079.001]
  • (PMID = 16304072.001).
  • [ISSN] 1538-3598
  • [Journal-full-title] JAMA
  • [ISO-abbreviation] JAMA
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


41. Faria MR, Hoshida MS, Ferro EA, Ietta F, Paulesu L, Bevilacqua E: Spatiotemporal patterns of macrophage migration inhibitory factor (Mif) expression in the mouse placenta. Reprod Biol Endocrinol; 2010;8:95
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSIONS: The up-regulation of Mif on gd10.5 coincides with the stage in which the placenta assumes its three-layered organization (giant cells, spongiotrophoblast and labyrinth zones), fetal blood circulation begins and population of uNK cells reaches high proportions at the maternal counter part of the placenta, suggesting that Mif may play a role in either the placentation or in the adaptation of the differentiated placenta to the uterus or still in gestational immunomodulatory responses.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dev Dyn. 2003 Jun;227(2):185-91 [12761846.001]
  • [Cites] Hum Reprod. 2005 Dec;20(12):3518-25 [16085663.001]
  • [Cites] Dev Biol. 2003 Aug 1;260(1):176-90 [12885563.001]
  • [Cites] Circ Res. 2003 Aug 22;93(4):321-9 [12881477.001]
  • [Cites] Nat Rev Immunol. 2003 Oct;3(10):791-800 [14502271.001]
  • [Cites] J Reprod Immunol. 2004 Apr;61(2):129-31 [15063635.001]
  • [Cites] Biol Reprod. 2004 Jun;70(6):1806-13 [14973263.001]
  • [Cites] J Embryol Exp Morphol. 1973 Dec;30(3):561-72 [4772385.001]
  • [Cites] Ann N Y Acad Sci. 1977 Mar 11;286:384-97 [152594.001]
  • [Cites] Placenta. 1981 Jan-Mar;2(1):71-91 [7010344.001]
  • [Cites] J Reprod Immunol. 1985 Feb;7(2):121-8 [3981485.001]
  • [Cites] Anal Biochem. 1986 Aug 1;156(2):341-7 [2429581.001]
  • [Cites] Int Rev Cytol. 1988;112:1-65 [3045043.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Dec;69(6):1195-9 [2584354.001]
  • [Cites] Am J Obstet Gynecol. 1992 Jan;166(1 Pt 1):87-90 [1733224.001]
  • [Cites] J Exp Med. 1994 Jun 1;179(6):1895-902 [8195715.001]
  • [Cites] Science. 1994 Dec 2;266(5190):1508-18 [7985020.001]
  • [Cites] Nature. 1995 Sep 7;377(6544):68-71 [7659164.001]
  • [Cites] Immunol Lett. 1996 Jul;51(3):141-7 [8832282.001]
  • [Cites] Biochem Mol Biol Int. 1996 Feb;38(2):409-16 [8850537.001]
  • [Cites] J Histochem Cytochem. 1998 Feb;46(2):221-9 [9446829.001]
  • [Cites] J Immunol. 1998 Jun 15;160(12):5693-6 [9637476.001]
  • [Cites] Eur J Immunol. 2005 Dec;35(12):3405-13 [16224818.001]
  • [Cites] Reproduction. 2006 Jan;131(1):175-82 [16388020.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4807-16 [16484589.001]
  • [Cites] Rheumatology (Oxford). 2006 Aug;45(8):937-43 [16705047.001]
  • [Cites] Microb Pathog. 2006 Aug-Sep;41(2-3):111-8 [16863687.001]
  • [Cites] Immunity. 2006 Oct;25(4):595-606 [17045821.001]
  • [Cites] J Immunol. 2006 Dec 15;177(12):8730-9 [17142775.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2007 Jan;292(1):E272-80 [16940473.001]
  • [Cites] Reproduction. 2007 Feb;133(2):405-14 [17307908.001]
  • [Cites] J Biol Chem. 2007 Mar 16;282(11):8157-64 [17224449.001]
  • [Cites] Gastroenterology. 2007 Mar;132(3):982-93 [17324399.001]
  • [Cites] Cell Cycle. 2007 May 2;6(9):1030-4 [17426455.001]
  • [Cites] Mol Endocrinol. 2007 Jun;21(6):1267-80 [17389748.001]
  • [Cites] Oncogene. 2007 Aug 2;26(35):5046-59 [17310986.001]
  • [Cites] J Dermatol Sci. 2008 Jan;49(1):63-72 [18060744.001]
  • [Cites] J Biol Chem. 2008 Feb 1;283(5):2784-92 [18056708.001]
  • [Cites] Reprod Biomed Online. 2008 Feb;16(2):218-26 [18284876.001]
  • [Cites] J Immunol. 2008 Jun 1;180(11):7338-48 [18490733.001]
  • [Cites] Fertil Steril. 2008 Oct;90(4 Suppl):1433-43 [18022162.001]
  • [Cites] BMC Cancer. 2009;9:230 [19602265.001]
  • [Cites] J Neuroinflammation. 2010;7:26 [20398244.001]
  • [Cites] Growth Horm IGF Res. 2010 Jun;20(3):255-63 [20382057.001]
  • [Cites] Biochim Biophys Acta. 2000 Jan 3;1500(1):1-9 [10564712.001]
  • [Cites] Biol Reprod. 2000 Aug;63(2):570-4 [10906066.001]
  • [Cites] Biol Reprod. 2001 Apr;64(4):1200-5 [11259268.001]
  • [Cites] J Biol Chem. 2001 Mar 30;276(13):10253-62 [11113146.001]
  • [Cites] Nature. 2001 Dec 20-27;414(6866):920-4 [11780066.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):345-50 [11756671.001]
  • [Cites] Placenta. 2002 Jan;23(1):3-19 [11869088.001]
  • [Cites] J Biol Chem. 2002 Mar 8;277(10):7865-74 [11751895.001]
  • [Cites] Mol Cell Endocrinol. 2002 Feb 22;187(1-2):207-12 [11988329.001]
  • [Cites] Dev Biol. 2002 Oct 15;250(2):358-73 [12376109.001]
  • [Cites] Am J Pathol. 2003 Jan;162(1):47-56 [12507889.001]
  • [Cites] Microsc Res Tech. 2003 Mar 1;60(4):420-9 [12567399.001]
  • [Cites] Circ Res. 2003 Feb 7;92(2):133-5 [12574139.001]
  • [Cites] Am J Reprod Immunol. 2002 Dec;48(6):404-9 [12607777.001]
  • [Cites] J Exp Med. 1999 Jan 18;189(2):341-6 [9892616.001]
  • [Cites] Biol Reprod. 1999 Jun;60(6):1299-303 [10330084.001]
  • [Cites] Endocrinology. 1999 Jun;140(6):2711-20 [10342862.001]
  • [Cites] Biol Reprod. 2005 Apr;72(4):949-53 [15564603.001]
  • [Cites] Placenta. 2005 Apr;26 Suppl A:S3-9 [15837063.001]
  • [Cites] J Exp Med. 2003 Jun 2;197(11):1467-76 [12782713.001]
  • (PMID = 20684790.001).
  • [ISSN] 1477-7827
  • [Journal-full-title] Reproductive biology and endocrinology : RB&E
  • [ISO-abbreviation] Reprod. Biol. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Macrophage Migration-Inhibitory Factors; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.2.1 / Mif protein, mouse
  • [Other-IDs] NLM/ PMC2922212
  •  go-up   go-down


42. Park JS, Choi GS, Lim KH, Jang YS, Jun SH: Robotic-assisted versus laparoscopic surgery for low rectal cancer: case-matched analysis of short-term outcomes. Ann Surg Oncol; 2010 Dec;17(12):3195-202
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robotic-assisted versus laparoscopic surgery for low rectal cancer: case-matched analysis of short-term outcomes.
  • PURPOSE: The aim of this study is to compare short-term outcomes and surgical quality of robot-assisted (RAP) and laparoscopic (LAP) total mesorectal excision (TME) in patients with low rectal cancer.
  • METHODS: From December 2007 to June 2009, 41 consecutive patients with low rectal cancer underwent TME by robot-assisted procedures.
  • The lowest tumor margins were below peritoneal reflection and 1.0-8.0 cm above the anal verge.
  • These patients were matched 1:2 by age, gender, body mass index, date of surgery, American Society of Anesthesiologists score, and tumor stage, with 82 patients who underwent conventional LAP.
  • CONCLUSIONS: RAP was safe and effective for patients with low rectal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20589436.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Chen R, Pan S, Duan X, Nelson BH, Sahota RA, de Rham S, Kozarek RA, McIntosh M, Brentnall TA: Elevated level of anterior gradient-2 in pancreatic juice from patients with pre-malignant pancreatic neoplasia. Mol Cancer; 2010 Jun 15;9:149
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated level of anterior gradient-2 in pancreatic juice from patients with pre-malignant pancreatic neoplasia.
  • BACKGROUND: Pancreatic intraepithelial neoplasias (PanINs) are precursors of malignant pancreatic cancer, an ideal stage for early cancer detection.
  • An ELISA assay was developed to evaluate AGR2 levels in 51 pancreatic juice samples and 23 serum samples from patients with pancreatic cancer, pre-malignant lesions (including PanIN3, PanIN2, Intraductal Papillary Mucinous Neoplasms (IPMNs)) and benign disease controls (including chronic pancreatitis).
  • AGR2 levels in the pancreatic juice samples were found significantly elevated in patients with pre-malignant conditions (PanINs and IPMNs) as well as pancreatic cancer compared to control samples (p < or = 0.03).
  • CONCLUSIONS: These results suggest that elevation of AGR2 levels in pancreatic juice occurs in early pancreatic cancer progression and could be further investigated as a potential candidate juice biomarker for early detection of pancreatic cancer.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47 [11814064.001]
  • [Cites] Clin Sci (Lond). 2010 Jun;118(12):717-25 [20136634.001]
  • [Cites] Anal Chem. 2002 Oct 15;74(20):5383-92 [12403597.001]
  • [Cites] Anal Chem. 2003 Sep 1;75(17):4646-58 [14632076.001]
  • [Cites] Pancreas. 1994 Nov;9(6):741-7 [7846018.001]
  • [Cites] Mech Dev. 1998 Mar;72(1-2):115-30 [9533957.001]
  • [Cites] Ann Intern Med. 1999 Aug 17;131(4):247-55 [10454945.001]
  • [Cites] Mol Cell Proteomics. 2004 Dec;3(12):1154-69 [15385600.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):523-33 [15684406.001]
  • [Cites] Oncogene. 2005 Oct 6;24(44):6626-36 [16103885.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):405-11 [16052519.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1208-17 [16424060.001]
  • [Cites] Clin Cancer Res. 2006 Mar 15;12(6):1728-34 [16551856.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2066-9 [16609017.001]
  • [Cites] Histol Histopathol. 2007 Jul;22(7):703-8 [17455144.001]
  • [Cites] Semin Oncol. 2007 Aug;34(4):303-10 [17674958.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2007;10(3):293-300 [17457305.001]
  • [Cites] Curr Opin Gastroenterol. 2007 Sep;23(5):508-14 [17762556.001]
  • [Cites] J Natl Compr Canc Netw. 2007 Nov;5(10):1034-41 [18053427.001]
  • [Cites] Cancer Res. 2008 Jan 15;68(2):492-7 [18199544.001]
  • [Cites] EMBO Rep. 2008 May;9(5):429-34 [18451766.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7811-8 [18829536.001]
  • [Cites] Cancer Detect Prev. 2008;32(3):236-50 [18801625.001]
  • [Cites] Cancer Biol Ther. 2009 Feb;8(4):340-6 [19106647.001]
  • [Cites] PLoS Med. 2009 Apr 7;6(4):e1000046 [19360088.001]
  • [Cites] Electrophoresis. 2009 Apr;30(7):1132-44 [19373808.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):6950-5 [19359471.001]
  • [Cites] Histol Histopathol. 2009 Sep;24(9):1121-8 [19609859.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1868-75 [11912167.001]
  • (PMID = 20550709.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01DK081368; United States / NCI NIH HHS / CA / CA116296-02; United States / NCI NIH HHS / CA / K07 CA116296-02; United States / NCI NIH HHS / CA / K07 CA116296; United States / NCI NIH HHS / CA / R01CA107209; United States / NCI NIH HHS / CA / K07CA116296; United States / NCI NIH HHS / CA / K25CA137222
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proteins; EC 5.3.4.1 / AGR2 protein, human
  • [Other-IDs] NLM/ PMC2893103
  •  go-up   go-down


44. Cañadas MP, Darwich L, Sirera G, Cirigliano V, Bofill M, Clotet B, Videla S, HIV-HPV Study Group: New molecular method for the detection of human papillomavirus type 16 integration. Clin Microbiol Infect; 2010 Jul;16(7):836-42
MedlinePlus Health Information. consumer health - Anal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human papillomavirus (HPV) infection is the cause of cervical cancer.
  • Integration of HPV-16 DNA in cervical cells is considered to be a key event in the progression towards invasive cancer, but little is known about this event in anal carcinogenesis.
  • The integration could be a useful biomarker for cancer progression.
  • The aim of this study was to develop a new multiplex real-time PCR assay based on simultaneous amplification of the E2 and E6 HPV open reading frames (ORFs) in order to assess the physical status (episomal and/or integrated) of HPV-16 in anal cells of HIV-positive men.
  • The multiplex real-time PCR was tested in 77 consecutive samples from individual HIV-infected patients with HPV-16 anal infection.
  • The integration occurs in the early stage of anal lesions and was associated with the severity of the lesions (p 0.004).
  • [MeSH-major] Anal Canal / virology. Anus Diseases / virology. Human papillomavirus 16 / genetics. Human papillomavirus 16 / physiology. Papillomavirus Infections / virology. Polymerase Chain Reaction. Virus Integration
  • [MeSH-minor] Cell Line, Tumor. DNA, Viral / analysis. DNA, Viral / genetics. DNA-Binding Proteins / genetics. Female. HIV Infections / complications. Humans. Male. Oncogene Proteins, Viral / genetics. Open Reading Frames. Repressor Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19840031.001).
  • [ISSN] 1469-0691
  • [Journal-full-title] Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
  • [ISO-abbreviation] Clin. Microbiol. Infect.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / DNA-Binding Proteins; 0 / E2 protein, Human papillomavirus type 16; 0 / E6 protein, Human papillomavirus type 16; 0 / Oncogene Proteins, Viral; 0 / Repressor Proteins
  • [Investigator] Piñol M; García-Cuyas F; Castella E; Llatjós M; Rey-Joly C; Bonjoch A; Jabaloyas M; Jou T; Moltó J; Negredo E; Romeu J; Tural C; Cobarsi P; Fernández I; Rueda L; Ordoñez E
  •  go-up   go-down


45. Kalinina J, Byron SA, Makarenkova HP, Olsen SK, Eliseenkova AV, Larochelle WJ, Dhanabal M, Blais S, Ornitz DM, Day LA, Neubert TA, Pollock PM, Mohammadi M: Homodimerization controls the fibroblast growth factor 9 subfamily's receptor binding and heparan sulfate-dependent diffusion in the extracellular matrix. Mol Cell Biol; 2009 Sep;29(17):4663-78
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our study is the first to implicate ligand dimerization as an autoregulatory mechanism for growth factor bioactivity and sets the stage for engineering modified FGF9 subfamily ligands, with desired activity for use in both basic and translational research.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Genet Dev. 1998 Aug;8(4):481-6 [9729726.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 1998 Sep 1;54(Pt 5):905-21 [9757107.001]
  • [Cites] Curr Opin Struct Biol. 1998 Oct;8(5):578-86 [9818261.001]
  • [Cites] Cell. 1999 Sep 3;98(5):641-50 [10490103.001]
  • [Cites] Dev Cell. 2005 Jan;8(1):85-95 [15621532.001]
  • [Cites] J Clin Invest. 2005 Jan;115(1):102-9 [15630449.001]
  • [Cites] Endocr Rev. 2005 Feb;26(1):63-77 [15689573.001]
  • [Cites] Development. 2005 Mar;132(6):1223-34 [15716343.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Apr;16(2):107-37 [15863029.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Apr;16(2):179-86 [15863033.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Apr;16(2):187-203 [15863034.001]
  • [Cites] J Clin Invest. 2005 Jun;115(6):1627-35 [15902306.001]
  • [Cites] Curr Opin Struct Biol. 2005 Oct;15(5):506-16 [16154740.001]
  • [Cites] Cell Metab. 2005 Oct;2(4):217-25 [16213224.001]
  • [Cites] Int J Radiat Biol. 2005 Aug;81(8):567-79 [16298938.001]
  • [Cites] Dev Biol. 2005 Nov 15;287(2):390-402 [16216232.001]
  • [Cites] Curr Opin Investig Drugs. 2005 Nov;6(11):1179-85 [16312140.001]
  • [Cites] Development. 2006 Jan;133(1):173-80 [16308329.001]
  • [Cites] Science. 2005 Dec 23;310(5756):1957-60 [16373575.001]
  • [Cites] Development. 2006 Apr;133(8):1507-17 [16540513.001]
  • [Cites] Dev Biol. 2006 May 1;293(1):77-89 [16494859.001]
  • [Cites] Biochem Soc Trans. 2006 Jun;34(Pt 3):442-5 [16709182.001]
  • [Cites] Genes Dev. 2006 Jun 15;20(12):1651-66 [16778080.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Aug 18;347(1):340-6 [16815307.001]
  • [Cites] Development. 2007 Feb;134(3):557-65 [17202188.001]
  • [Cites] Mol Cell Biol. 2007 May;27(9):3417-28 [17339340.001]
  • [Cites] Mol Cell. 2007 Sep 7;27(5):717-30 [17803937.001]
  • [Cites] Front Biosci. 2008;13:2842-65 [17981758.001]
  • [Cites] Neurosci Lett. 2008 Jan 10;430(2):147-50 [18061349.001]
  • [Cites] Int J Radiat Biol. 2008 May;84(5):401-12 [18464069.001]
  • [Cites] Brain. 2008 Aug;131(Pt 8):2127-39 [18669499.001]
  • [Cites] Development. 2008 Sep;135(17):2959-68 [18653563.001]
  • [Cites] Cell. 2000 May 12;101(4):413-24 [10830168.001]
  • [Cites] Mol Cell. 2000 Sep;6(3):743-50 [11030354.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Oct 22;277(2):355-60 [11032730.001]
  • [Cites] Genome Biol. 2001;2(3):REVIEWS3005 [11276432.001]
  • [Cites] J Biol Chem. 2001 Feb 9;276(6):4322-9 [11060292.001]
  • [Cites] Development. 2001 Jun;128(11):2095-106 [11493531.001]
  • [Cites] Development. 2002 Jan;129(1):53-60 [11782400.001]
  • [Cites] Science. 2002 Aug 23;297(5585):1330-3 [12154198.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2266-71 [12591959.001]
  • [Cites] Mol Cell. 2003 Feb;11(2):507-17 [12620237.001]
  • [Cites] J Neurosci Res. 2003 May 15;72(4):436-43 [12704805.001]
  • [Cites] Anal Biochem. 2003 Sep 1;320(1):104-24 [12895474.001]
  • [Cites] Clin Cancer Res. 2003 Aug 15;9(9):3454-61 [12960137.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 27;101(4):935-40 [14732692.001]
  • [Cites] J Clin Invest. 2004 Feb;113(4):561-8 [14966565.001]
  • [Cites] Am J Hum Genet. 2004 Jun;74(6):1121-7 [15122513.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Jun;5(6):464-71 [15173825.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4555-62 [15231666.001]
  • [Cites] Dev Biol. 2004 Sep 15;273(2):350-60 [15328018.001]
  • [Cites] Hum Mol Genet. 2004 Oct 1;13(19):2313-24 [15282208.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Oct 26;101(43):15506-11 [15483108.001]
  • [Cites] Biochemistry. 1985 Mar 12;24(6):1501-9 [3986190.001]
  • [Cites] Cell. 1991 Feb 22;64(4):841-8 [1847668.001]
  • [Cites] Acta Crystallogr A. 1991 Mar 1;47 ( Pt 2):110-9 [2025413.001]
  • [Cites] Trends Endocrinol Metab. 2008 Sep;19(7):239-45 [18692401.001]
  • [Cites] Mol Cancer Res. 2009 Jan;7(1):41-54 [19147536.001]
  • [Cites] Nat Genet. 2009 Mar;41(3):289-98 [19219044.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):49-54 [10618369.001]
  • [Cites] Development. 2000 Jun;127(12):2563-72 [10821755.001]
  • [Cites] Science. 1991 Jun 21;252(5013):1705-8 [1646484.001]
  • [Cites] J Mol Biol. 1992 Jan 20;223(2):531-43 [1738162.001]
  • [Cites] J Biol Chem. 1992 Sep 5;267(25):17804-8 [1325450.001]
  • [Cites] Dev Biol. 1993 Aug;158(2):475-86 [8393815.001]
  • [Cites] J Mol Biol. 1993 Dec 20;234(4):946-50 [8263940.001]
  • [Cites] J Biol Chem. 1996 Jun 21;271(25):15292-7 [8663044.001]
  • [Cites] Development. 1997 Sep;124(17):3375-84 [9310332.001]
  • [Cites] Development. 1998 Feb;125(4):753-65 [9435295.001]
  • (PMID = 19564416.001).
  • [ISSN] 1098-5549
  • [Journal-full-title] Molecular and cellular biology
  • [ISO-abbreviation] Mol. Cell. Biol.
  • [Language] ENG
  • [Grant] United States / NIDCR NIH HHS / DE / R01 DE013686; United States / NIDCR NIH HHS / DE / DE13686
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FGF16 protein, human; 0 / FGF20 protein, human; 0 / Fibroblast Growth Factor 9; 0 / Ligands; 62031-54-3 / Fibroblast Growth Factors; 9050-30-0 / Heparitin Sulfate; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 1
  • [Other-IDs] NLM/ PMC2725704
  •  go-up   go-down


46. Alvarez-Manilla G, Warren NL, Atwood J 3rd, Orlando R, Dalton S, Pierce M: Glycoproteomic analysis of embryonic stem cells: identification of potential glycobiomarkers using lectin affinity chromatography of glycopeptides. J Proteome Res; 2010 May 7;9(5):2062-75
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The absence of some of these lectin-bound glycopeptides in a cell stage suggested that they were derived from proteins that were either expressed exclusively on a defined developmental stage or were expressed in both cell stages but carried the lectin-bound oligosaccharides in only one of them.
  • Therefore, these lectin-bound glycopeptides can be considered as stage-specific glycobiomarkers.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proteomics. 2004 Feb;4(2):454-65 [14760718.001]
  • [Cites] Mamm Genome. 1999 Nov;10(11):1085-8 [10556428.001]
  • [Cites] Anal Chem. 2004 Jul 15;76(14):4193-201 [15253663.001]
  • [Cites] Int J Cancer. 2004 Dec 10;112(5):815-22 [15386373.001]
  • [Cites] FEBS Lett. 1976 Nov 15;72(1):117-20 [62678.001]
  • [Cites] Biochim Biophys Acta. 1980 Jan 18;617(1):97-109 [7353026.001]
  • [Cites] J Biol Chem. 1982 Oct 10;257(19):11235-40 [7118881.001]
  • [Cites] Methods Enzymol. 1987;138:232-59 [3600324.001]
  • [Cites] Annu Rev Biochem. 1987;56:21-42 [3304133.001]
  • [Cites] Methods Enzymol. 1994;230:108-32 [8139492.001]
  • [Cites] Biochem Soc Trans. 1995 Feb;23(1):1-25 [7758655.001]
  • [Cites] Mol Biotechnol. 1995 Feb;3(1):25-36 [7541703.001]
  • [Cites] Biochim Biophys Acta. 1995 Jul 17;1241(2):177-94 [7640295.001]
  • [Cites] Cancer Res. 1997 May 1;57(9):1798-806 [9135025.001]
  • [Cites] Trends Biochem Sci. 1998 Sep;23(9):321-4 [9787635.001]
  • [Cites] Mech Dev. 1998 Aug;76(1-2):79-90 [9867352.001]
  • [Cites] Physiol Rev. 1999 Jan;79(1):181-213 [9922371.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):779-84 [15642945.001]
  • [Cites] J Biol Chem. 2005 Mar 4;280(9):8332-42 [15615721.001]
  • [Cites] Drug Discov Today. 2005 Mar 1;10(5):307-9 [15749278.001]
  • [Cites] J Proteome Res. 2008 Apr;7(4):1542-54 [18336003.001]
  • [Cites] J Cell Biochem. 2008 May 1;104(1):136-49 [18004786.001]
  • [Cites] Mol Biol Cell. 2008 Jun;19(6):2413-23 [18337472.001]
  • [Cites] Stem Cells Dev. 2005 Apr;14(2):188-98 [15910245.001]
  • [Cites] Mol Cell Proteomics. 2005 Jun;4(6):762-72 [15703444.001]
  • [Cites] Anal Chem. 2005 Jul 1;77(13):4081-90 [15987113.001]
  • [Cites] J Sep Sci. 2005 Oct;28(15):1956-68 [16276785.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Nov;14(11 Pt 1):2517-23 [16284372.001]
  • [Cites] Rapid Commun Mass Spectrom. 2005;19(23):3421-8 [16252310.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):845-56 [16239904.001]
  • [Cites] Oncology. 2005;69(4):301-10 [16282710.001]
  • [Cites] J Proteome Res. 2006 Sep;5(9):2348-63 [16944947.001]
  • [Cites] Mol Cell Proteomics. 2006 Oct;5(10):1957-67 [16760258.001]
  • [Cites] J Proteome Res. 2006 Dec;5(12):3376-84 [17137339.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jan 1;845(1):121-37 [16987717.001]
  • [Cites] Biochim Biophys Acta. 2006 Dec;1764(12):1870-80 [17118724.001]
  • [Cites] Mol Cell Biochem. 2007 Jan;295(1-2):1-7 [16841181.001]
  • [Cites] J Proteome Res. 2007 Feb;6(2):662-71 [17269723.001]
  • [Cites] Nat Methods. 2007 Mar;4(3):207-14 [17327847.001]
  • [Cites] J Proteome Res. 2007 Mar;6(3):1126-38 [17249709.001]
  • [Cites] J Biol Chem. 2007 Mar 23;282(12):9127-42 [17264077.001]
  • [Cites] Stem Cells. 2007 Apr;25(4):974-82 [17170066.001]
  • [Cites] J Proteome Res. 2007 Jul;6(7):2631-9 [17518487.001]
  • [Cites] Exp Hematol. 2007 Aug;35(8):1279-92 [17662891.001]
  • [Cites] Mol Cell Proteomics. 2007 Oct;6(10):1809-17 [17644760.001]
  • [Cites] Mol Cell Proteomics. 2007 Dec;6(12):2132-8 [17823199.001]
  • [Cites] J Proteome Res. 2008 Jan;7(1):367-74 [18047270.001]
  • [Cites] Mol Cell Proteomics. 2008 Jan;7(1):1-14 [17878270.001]
  • [Cites] J Proteome Res. 2008 Apr;7(4):1693-703 [18311904.001]
  • [Cites] J Cell Sci. 2000 Feb;113 ( Pt 3):555-66 [10639341.001]
  • [Cites] Boll Chim Farm. 2003 Mar-Apr;142(2):50 [12705089.001]
  • [Cites] Nat Biotechnol. 2003 Jun;21(6):667-72 [12754521.001]
  • [Cites] J Biol Chem. 2003 Dec 26;278(52):52412-24 [14561752.001]
  • [Cites] J Proteome Res. 2003 Nov-Dec;2(6):618-25 [14692455.001]
  • [Cites] J Immunol. 2004 Jan 15;172(2):1125-31 [14707087.001]
  • [Cites] J Biol Chem. 2008 Jun 20;283(25):17298-313 [18411279.001]
  • [Cites] Physiol Rev. 2008 Jul;88(3):841-86 [18626062.001]
  • [Cites] J Proteome Res. 2008 Oct;7(10):4313-25 [18729497.001]
  • [Cites] Oncogene. 2002 Nov 28;21(54):8320-33 [12447695.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Apr;36(4):555-67 [15010323.001]
  • (PMID = 19545112.001).
  • [ISSN] 1535-3907
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P41 RR018502; United States / NCRR NIH HHS / RR / P41 RR018502-09; United States / NCRR NIH HHS / RR / P41RR 018502
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Glycoproteins; 0 / Peptide Fragments; 11028-71-0 / Concanavalin A; EC 3.4.21.4 / Trypsin
  • [Other-IDs] NLM/ NIHMS132612; NLM/ PMC3086009
  •  go-up   go-down


47. Iancu C, Mocan LC, Todea-Iancu D, Mocan T, Acalovschi I, Ionescu D, Zaharie FV, Osian G, Puia CI, Muntean V: Host-related predictive factors for anastomotic leakage following large bowel resections for colorectal cancer. J Gastrointestin Liver Dis; 2008 Sep;17(3):299-303
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Host-related predictive factors for anastomotic leakage following large bowel resections for colorectal cancer.
  • AIM: To identify the risk, the host-related prognostic factors and their predictive value for anastomotic leakage after colorectal resections following cancer.
  • METHOD: 993 patients who underwent large bowel resection and primary anastomosis above 12 centimeters from the anal verge, without a temporary or permanent stoma at the Surgical Hospital No.3 (Cluj-Napoca, Romania) were retrospectively reviewed.
  • Alcohol use, cerebrovascular disease, bowel preparation, type of anastomosis, tumor location, stage and histology were not significant variables.
  • CONCLUSION. A serum protein level lower than 5.5 g/dl and serum hemoglobin lower than 9.4 g/dl could be considered as host-related predictive markers for anastomotic leak in large bowel resections for cancer.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18836623.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Blood Proteins; 0 / Hemoglobins
  •  go-up   go-down


48. Mathews C, Caperna J, Cachay ER, Cosman B: Early impact and performance characteristics of an established anal dysplasia screening program: program evaluation considerations. Open AIDS J; 2007;1:11-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early impact and performance characteristics of an established anal dysplasia screening program: program evaluation considerations.
  • BACKGROUND: Screening for invasive anal cancer and its precursors is being increasingly advocated as a response to increasing incidence among HIV-infected persons.
  • (1) to estimate incidence of and mortality from invasive anal cancer (IAC) before (1995-2000) and after (2001-2005) screening program implementation and (2) to examine potential screening program quality indicators.
  • There was no routine treatment of high grade squamous intraepithelial lesions (HSIL) during the study period.
  • (2) stage shift to IAC of more favorable prognosis is a reasonable screening goal;.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Epidemiol. 2007 May 15;165(10):1143-53 [17344204.001]
  • [Cites] Int J Gynecol Pathol. 1993 Apr;12(2):186-92 [8463044.001]
  • [Cites] Health Qual Life Outcomes. 2007;5:3 [17210071.001]
  • [Cites] Dis Colon Rectum. 2006 Oct;49(10):1648-9; author reply 1649-50 [16972138.001]
  • [Cites] Surg Today. 2006;36(10):885-91 [16998682.001]
  • [Cites] Clin Infect Dis. 2006 Jul 15;43(2):223-33 [16779751.001]
  • [Cites] Br J Surg. 2006 May;93(5):531-8 [16607677.001]
  • [Cites] Am J Obstet Gynecol. 2006 Mar;194(3):704-10 [16522401.001]
  • [Cites] Crit Rev Oncol Hematol. 2006 Mar;57(3):215-24 [16371251.001]
  • [Cites] Oncology (Williston Park). 2005 Nov;19(12):1634-8; discussion 1638-40, 1645 passim [16396154.001]
  • [Cites] Dis Colon Rectum. 2006 Jan;49(1):36-40 [16283561.001]
  • [Cites] Sex Health. 2004;1(3):137-40 [16335300.001]
  • [Cites] Surg Oncol. 2005 Nov;14(3):121-32 [16165347.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):451-5 [16280701.001]
  • [Cites] Sex Transm Infect. 2005 Oct;81(5):415-8 [16199742.001]
  • [Cites] Acta Cytol. 2005 Jul-Aug;49(4):405-15 [16124170.001]
  • [Cites] Br J Surg. 2005 Sep;92(9):1133-6 [16044425.001]
  • [Cites] Diagn Cytopathol. 2005 Sep;33(3):152-6 [16078257.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2005 Aug 1;121(2):226-32 [16054967.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):479-85 [15890590.001]
  • [Cites] Fam Med. 2005 May;37(5):360-3 [15883903.001]
  • [Cites] Sex Transm Dis. 2005 May;32(5):314-20 [15849533.001]
  • [Cites] J Med Screen. 2005;12(1):12-9 [15825234.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2004 Dec;16(8):530-5 [15630846.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1610-5 [15577418.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1563-5 [15577408.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Apr 1;44(1):127-31 [10219805.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] Med J Aust. 1999 Mar 15;170(6):255-8 [10212646.001]
  • [Cites] J Natl Cancer Inst. 1999 Feb 3;91(3):252-8 [10037103.001]
  • [Cites] Eur J Cancer. 1998 Sep;34(10):1598-601 [9893635.001]
  • [Cites] Obstet Gynecol. 1998 Oct;92(4 Pt 2):727-35 [9764690.001]
  • [Cites] Fam Med. 1998 May;30(5):350-5 [9597533.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9 [9525431.001]
  • [Cites] Dis Colon Rectum. 1997 Aug;40(8):919-28 [9269808.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1992 May;14(2):117-28 [1530116.001]
  • [Cites] J Gen Intern Med. 1990 Sep-Oct;5(5 Suppl):S14-6 [2231057.001]
  • [Cites] Am J Epidemiol. 1988 Dec;128(6):1185-97 [3057878.001]
  • [Cites] IARC Sci Publ. 1986;(76):185-98 [3570404.001]
  • [Cites] IARC Sci Publ. 1985;(66):45-63 [4093187.001]
  • [Cites] Am J Public Health. 1978 Feb;68(2):125-34 [626255.001]
  • [Cites] Prev Med. 1977 Dec;6(4):487-99 [600908.001]
  • [Cites] Cancer. 2004 Sep 1;101(5 Suppl):1131-45 [15316907.001]
  • [Cites] Prev Med. 2004 Aug;39(2):404-12 [15226053.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] J Infect Dis. 2003 Jul 1;188(1):128-36 [12825181.001]
  • [Cites] Gynecol Oncol. 2003 Jul;90(1):137-44 [12821354.001]
  • [Cites] Colorectal Dis. 2003 May;5(3):206-13 [12780879.001]
  • [Cites] Top HIV Med. 2003 Mar-Apr;11(2):45-9 [12717041.001]
  • [Cites] Ann Intern Med. 2002 Sep 3;137(5 Pt 2):435-78 [12617574.001]
  • [Cites] Obstet Gynecol. 2003 Jan;101(1):29-37 [12517642.001]
  • [Cites] Epidemiology. 2002 Nov;13(6):713-7 [12410014.001]
  • [Cites] Clin Infect Dis. 2002 Nov 1;35(9):1127-34 [12384848.001]
  • [Cites] Int J Colorectal Dis. 2002 Jul;17(4):203-15 [12073068.001]
  • [Cites] Am J Obstet Gynecol. 2001 Aug;185(2):507-13 [11518918.001]
  • [Cites] Ned Tijdschr Geneeskd. 2000 Dec 2;144(49):2345-8 [11129969.001]
  • [Cites] N Engl J Med. 2007 Oct 18;357(16):1589-97 [17942872.001]
  • [Cites] Oncologist. 2007 May;12(5):524-34 [17522240.001]
  • [Cites] N Engl J Med. 2007 Oct 18;357(16):1579-88 [17942871.001]
  • [Cites] BMJ. 1998 Aug 1;317(7154):307-12 [9685274.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Oct-Nov;3(7):619-26 [7827594.001]
  • [Cites] Sex Transm Dis. 2007 Mar;34(3):170-3 [16837830.001]
  • (PMID = 18776956.001).
  • [ISSN] 1874-6136
  • [Journal-full-title] The open AIDS journal
  • [ISO-abbreviation] Open AIDS J
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / AI067039-02; United States / NIAID NIH HHS / AI / R24 AI067039-02; United States / NIAID NIH HHS / AI / R24 AI067039; United States / NIAID NIH HHS / AI / P30 AI036214; United States / NIAID NIH HHS / AI / P30 AI036214-09A1
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Anal dysplasia / HIV. / screening
  •  go-up   go-down


49. Beretta G, Furlanetto S, Regazzoni L, Zarrella M, Facino RM: Quenching of alpha,beta-unsaturated aldehydes by green tea polyphenols: HPLC-ESI-MS/MS studies. J Pharm Biomed Anal; 2008 Nov 4;48(3):606-11
Hazardous Substances Data Bank. Green tea .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HNE is the most abundant and genotoxic product of oxidation of dietary polyunsaturated fatty acids, and is believed to be involved in the early stage of colorectal carcinogenesis on account of its genotoxic potential.
  • These results suggest that EGCG and green tea extract, beside the proposed mechanisms of chemoprevention that target multiple cell-signaling pathways that control cell proliferation and apoptosis in cancer cells, can also prevent protein carbonylation in the tumor tissue environment, depending on the pH of the medium surrounding the tissue, the type of tumor, the stage of dysregulation of lipid peroxidation and, finally, the stage of carcinoma development.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18619756.001).
  • [ISSN] 0731-7085
  • [Journal-full-title] Journal of pharmaceutical and biomedical analysis
  • [ISO-abbreviation] J Pharm Biomed Anal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aldehydes; 0 / Flavonoids; 0 / Phenols; 0 / Polyphenols; 0 / Tea
  •  go-up   go-down


50. Wu XJ, Wang JP, Wang L, He XS, Zou YF, Lian L, Zhang LJ, Lan P: Increased rate change over time of a sphincter-saving procedure for lower rectal cancer. Chin Med J (Engl); 2008 Apr 5;121(7):636-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased rate change over time of a sphincter-saving procedure for lower rectal cancer.
  • BACKGROUND: Total mesorectal excision (TME) has increased the rate of sphincter-preservation (SP) for more patients with low-lying rectal cancer.
  • Here, we analyze the change of sphincter preserving rates in lower rectal cancer and their related factors.
  • Significant differences were detected between the two time periods in gender, blood transfusion volume and Dukes' stage (P < 0.05).
  • [MeSH-minor] Adult. Aged. Anal Canal / surgery. Anastomosis, Surgical. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18466685.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


51. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS, Halverson AL: Squamous cell carcinoma of the anal canal: utilization and outcomes of recommended treatment in the United States. Ann Surg Oncol; 2008 Jul;15(7):1948-58
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the anal canal: utilization and outcomes of recommended treatment in the United States.
  • BACKGROUND: Over the past two decades, recommended treatment for squamous cell carcinoma of the anal canal has shifted from surgery to primary chemoradiation.
  • METHODS: From the National Cancer Data Base (1985-2005), 38,882 patients with anal canal cancer were identified.
  • Patients were significantly less likely to receive guideline treatment if male, older, black or Hispanic, more severe comorbidities, or Stage I (vs Stage II or III).
  • [MeSH-major] Anus Neoplasms / therapy. Neoplasms, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18414951.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


52. Chiappa A, Biffi R, Zbar AP, Bertani E, Luca F, Pace U, Biella F, Grassi C, Zampino G, Fazio N, Pruneri G, Poldi D, Venturino M, Andreoni B: The influence of type of operation for distal rectal cancer: survival, outcomes, and recurrence. Hepatogastroenterology; 2007 Mar;54(74):400-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The influence of type of operation for distal rectal cancer: survival, outcomes, and recurrence.
  • BACKGROUND/AIMS: This study analyzed the results of treatment of rectal cancer (tumor within 12 cm of the anal verge) with different techniques.
  • METHODOLOGY: Two hundred and sixty-four patients who had undergone elective curative surgical resection of rectal cancer within 12cm of the anal verge were evaluated.
  • On multivariate analysis reconstruction with Knight-Griffen anastomosis (p = 0.013) and tumor distance from the anal verge <6 cm (p = 0.001), were associated with local recurrence but only stage was a significant prognosticator of overall survival (p = 0.012).

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17523284.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


53. Kim DW, Lim SB, Kim DY, Kim TH, Jung KH, Kim DH, Chang HJ, Sohn DK, Hong CW, Choi HS, Jeong SY, Park JG: Pre-operative chemo-radiotherapy improves the sphincter preservation rate in patients with rectal cancer located within 3 cm of the anal verge. Eur J Surg Oncol; 2006 Mar;32(2):162-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pre-operative chemo-radiotherapy improves the sphincter preservation rate in patients with rectal cancer located within 3 cm of the anal verge.
  • AIMS: To evaluate whether pre-operative chemo-radiotherapy (CRT) improves the sphincter preservation rate for distal rectal cancers within 3 cm of the anal verge.
  • METHODS: Between January 2001 and December 2004, 49 patients underwent surgery with or without pre-operative CRT for primary rectal adenocarcinoma within 3 cm of the anal verge.
  • Clinical data were retrospectively reviewed, including stage workups, surgical records and pathology records to determine sphincter preservation rate and the factors influencing sphincter preservation.
  • RESULTS: Of 49 patients with rectal tumours within 3 cm of the anal verge, 31 underwent pre-operative CRT followed by surgery (CRT group), and 18 underwent surgery alone (non-CRT group).
  • Sphincter preservation was possible in 11 of 31 CRT patients, and only one of 18 non-CRT patients (p=0.036).
  • CONCLUSION: We could observe that sphincter preservation was improved in CRT group with statistical significance when compared to non-CRT group in our study patients with rectal cancer within 3 cm of the anal verge.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Anal Canal / drug effects. Anal Canal / radiation effects. Neoadjuvant Therapy. Rectal Neoplasms / pathology. Rectal Neoplasms / therapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • Genetic Alliance. consumer health - Rectal Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16289718.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


54. Walts AE, Lechago J, Hu B, Shwayder M, Sandweiss L, Bose S: P16 and Ki67 Immunostains Decrease Intra- and Interobserver Variability in the Diagnosis and Grading of Anal Intraepithelial Neoplasia (AIN). Clin Med Pathol; 2008;1:7-13

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P16 and Ki67 Immunostains Decrease Intra- and Interobserver Variability in the Diagnosis and Grading of Anal Intraepithelial Neoplasia (AIN).
  • BACKGROUND: Significant variation is reported in the diagnosis of HPV-associated AIN.
  • We previously observed that band-like positivity for p16 in >90% of contiguous cells coupled with Ki67 positivity in >50% of lesional cells is strongly associated with high grade AIN.
  • This study was undertaken to determine if addition of p16 and Ki67 immunostaining would reduce inter- and intraobserver variability in diagnosis and grading of AIN.
  • DESIGN: H&E stained slides of 60 anal biopsies were reviewed by three pathologists and consensus diagnoses were achieved: 25 negative, 12 low (condyloma and/or AIN I) and 23 high (9 AIN II and 14 AIN III) grade lesions.
  • RESULTS: Addition of p16 and Ki67 immunostains reduced intra- and interobserver variability, improved concurrence with consensus diagnoses and reduced two-step differences in diagnosis.
  • Negative and high grade AIN diagnoses showed the most improvement in concurrence levels.
  • CONCLUSION: Addition of p16 and Ki67 immunostains is helpful in the diagnosis and grading of AIN.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2000 Aug;27(4):471-9 [10950374.001]
  • [Cites] JAMA. 1982 Apr 9;247(14):1988-90 [7062503.001]
  • [Cites] JAMA. 2002 Apr 24;287(16):2114-9 [11966386.001]
  • [Cites] Bull Cancer. 2003 May;90(5):405-11 [12850763.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1447-56 [15726546.001]
  • [Cites] Obstet Gynecol. 1990 Jan;75(1):131-3 [2296409.001]
  • [Cites] J Clin Pathol. 1994 Nov;47(11):1032-4 [7829679.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] Am J Pathol. 1998 Dec;153(6):1741-8 [9846965.001]
  • [Cites] Lancet. 1994 Mar 12;343(8898):636-9 [7906812.001]
  • [Cites] Dis Colon Rectum. 2003 Oct;46(10):1332-6; discussion 1336-8 [14530670.001]
  • [Cites] Am J Surg Pathol. 2006 Jul;30(7):795-801 [16819320.001]
  • [Cites] Gastroenterol Clin North Am. 2007 Dec;36(4):969-87, ix [17996800.001]
  • [Cites] Acta Pathol Microbiol Immunol Scand A. 1986 Sep;94(5):343-9 [3766143.001]
  • [Cites] Clin Obstet Gynecol. 1967 Dec;10(4):748-84 [4172733.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):422-8 [11744829.001]
  • (PMID = 21876646.001).
  • [ISSN] 1178-1181
  • [Journal-full-title] Clinical medicine. Pathology
  • [ISO-abbreviation] Clin Med Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3159996
  • [Keywords] NOTNLM ; Ki67 / P16 / anal intraepithelial neoplasia (AIN) / condyloma / human papilloma virus (HPV) / interobserver variability / intraobserver variability
  •  go-up   go-down


55. Yatsuoka T, Suto Y, Yokoyama Y, Yamaura T, Nishimura Y, Sakamoto H, Tanaka Y, Nozu S, Nishimura Y, Kurosumi M: [Intramucosal colorectal carcinomas treated by surgical resection]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2563-5
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Stage 0 colorectal cancer was found only in the innermost lining of the colon and rectum.
  • Treatments for an early stage colorectal cancer were available including endoscopic polypectomy, endoscopic mucosal resection (EMR) and trans-anal or -sacral local excision, laparoscopy-assisted colectomy and open colectomy.
  • Our study indicated that endoscopic therapy for the early stage colorectal cancer was more advantageous than the conventional operative treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224640.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


56. Maw MK, Fujimoto J, Tamaya T: Overexpression of inhibitor of DNA-binding (ID)-1 protein related to angiogenesis in tumor advancement of ovarian cancers. BMC Cancer; 2009;9:430
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The inhibitor of DNA-binding (ID) has been involved in cell cycle regulation, apoptosis and angiogenesis.
  • RESULTS: ID-1 histoscores and mRNA levels both significantly (p < 0.001) increased in ovarian cancers according to clinical stage, regardless of histopathological type.
  • CONCLUSION: ID-1 increased in ovarian cancer cells during tumor progression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Sci. 2006 Sep;97(9):861-7 [16805819.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9637-41 [10449746.001]
  • [Cites] Mol Cancer Res. 2007 Apr;5(4):321-9 [17426247.001]
  • [Cites] Br J Cancer. 2007 Nov 19;97(10):1409-15 [18000500.001]
  • [Cites] Br J Cancer. 2008 Nov 18;99(10):1557-63 [19002177.001]
  • [Cites] Nature. 1999 Oct 14;401(6754):670-7 [10537105.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1332-40 [10728695.001]
  • [Cites] Nature. 2001 Feb 22;409(6823):1067-70 [11234019.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):7812-6 [11427735.001]
  • [Cites] Cancer. 2001 Nov 15;92(10):2569-77 [11745191.001]
  • [Cites] Oncogene. 2001 Dec 20;20(58):8317-25 [11840324.001]
  • [Cites] Oncogene. 2001 Dec 20;20(58):8334-41 [11840326.001]
  • [Cites] J Urol. 2002 Jun;167(6):2598-602 [11992094.001]
  • [Cites] Carcinogenesis. 2002 May;23(5):721-5 [12016143.001]
  • [Cites] Cancer Biol Ther. 2002 Mar-Apr;1(2):91-6 [12170780.001]
  • [Cites] Cancer Cell. 2002 Dec;2(6):473-83 [12498716.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):779-85 [12576450.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):525-30 [12842081.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13543-8 [14578451.001]
  • [Cites] Carcinogenesis. 2004 Jun;25(6):881-7 [14742319.001]
  • [Cites] Apoptosis. 2004 May;9(3):279-89 [15258459.001]
  • [Cites] Trends Mol Med. 2004 Aug;10(8):387-92 [15310459.001]
  • [Cites] Arch Pathol Lab Med. 1985 Aug;109(8):716-21 [3893381.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):815-22 [10487839.001]
  • [Cites] J Virol. 2004 Dec;78(24):13470-8 [15564458.001]
  • [Cites] Oncol Rep. 2005 May;13(5):983-8 [15809768.001]
  • [Cites] Nat Rev Cancer. 2005 Aug;5(8):603-14 [16034366.001]
  • [Cites] Carcinogenesis. 2005 Oct;26(10):1668-76 [15905202.001]
  • [Cites] Cancer Sci. 2005 Nov;96(11):784-90 [16271072.001]
  • [Cites] Int J Cancer. 2006 Mar 15;118(6):1356-63 [16184548.001]
  • [Cites] Int J Cancer. 2006 Apr 15;118(8):2072-81 [16287090.001]
  • [Cites] Mod Pathol. 2006 Jul;19(7):931-41 [16575399.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):843-5 [1279431.001]
  • [Cites] Nucleic Acids Res. 1994 Mar 11;22(5):749-55 [8139914.001]
  • [Cites] Cancer Res. 1994 Dec 1;54(23):6065-8 [7954447.001]
  • [Cites] Cell Growth Differ. 1995 Jul;6(7):837-43 [7547505.001]
  • [Cites] Br J Cancer. 1996 Apr;73(8):884-8 [8611421.001]
  • [Cites] Mol Cell Biol. 1996 Sep;16(9):4604-13 [8756616.001]
  • [Cites] Mol Cell Biol. 1997 Oct;17(10):5888-96 [9315646.001]
  • [Cites] Mol Cell Biol. 1998 Apr;18(4):2371-81 [9528806.001]
  • [Cites] Trends Cell Biol. 1998 Feb;8(2):58-65 [9695810.001]
  • [Cites] Cancer Lett. 2006 Dec 8;244(2):203-10 [16469432.001]
  • (PMID = 20003244.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / ID1 protein, human; 0 / ID2 protein, human; 0 / Inhibitor of Differentiation Protein 1; 0 / Inhibitor of Differentiation Protein 2; 0 / Inhibitor of Differentiation Proteins; 0 / Neoplasm Proteins; 147785-34-0 / ID3 protein, human
  • [Other-IDs] NLM/ PMC2796680
  •  go-up   go-down


57. Bessette EE, Yasa I, Dunbar D, Wilkens LR, Le Marchand L, Turesky RJ: Biomonitoring of carcinogenic heterocyclic aromatic amines in hair: a validation study. Chem Res Toxicol; 2009 Aug;22(8):1454-63
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Quantification was done by liquid chromatography/tandem mass spectrometry, using a triple stage quadrupole mass spectrometer in the selected reaction monitoring mode.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 Oct 15;59(20):5154-9 [10537291.001]
  • [Cites] Anal Chem. 2009 Jan 15;81(2):809-19 [19086795.001]
  • [Cites] J Expo Anal Environ Epidemiol. 2001 May-Jun;11(3):155-68 [11477514.001]
  • [Cites] Chem Res Toxicol. 2002 Apr;15(4):551-61 [11952342.001]
  • [Cites] Food Chem Toxicol. 2002 Aug;40(8):1131-7 [12067575.001]
  • [Cites] Mutat Res. 2002 Sep 30;506-507:197-204 [12351159.001]
  • [Cites] Pharmacol Toxicol. 2002 Jun;90(6):333-7 [12403055.001]
  • [Cites] Chem Res Toxicol. 2003 Sep;16(9):1162-73 [12971805.001]
  • [Cites] Int J Cancer. 2003 Dec 20;107(6):878-84 [14601045.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Mar 25;802(1):143-53 [15036006.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Mar 25;802(1):155-66 [15036007.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Apr 25;803(2):209-13 [15063327.001]
  • [Cites] Cancer Sci. 2004 Apr;95(4):290-9 [15072585.001]
  • [Cites] Toxicology. 2004 May 20;198(1-3):135-45 [15138037.001]
  • [Cites] Carcinogenesis. 2004 Aug;25(8):1525-33 [15059926.001]
  • [Cites] Chem Res Toxicol. 2004 Aug;17(8):1121-36 [15310244.001]
  • [Cites] Carcinogenesis. 1982;3(9):1081-92 [7139866.001]
  • [Cites] Carcinogenesis. 1992 May;13(5):827-30 [1586994.001]
  • [Cites] Cancer Res. 1992 Sep 1;52(17):4682-7 [1511434.001]
  • [Cites] Chem Res Toxicol. 1992 Jul-Aug;5(4):479-90 [1391614.001]
  • [Cites] Chem Res Toxicol. 1992 Sep-Oct;5(5):691-7 [1446011.001]
  • [Cites] Carcinogenesis. 1993 May;14(5):899-901 [8504483.001]
  • [Cites] Cancer Res. 1994 Jan 1;54(1):89-94 [8261468.001]
  • [Cites] Carcinogenesis. 1995 Feb;16(2):367-73 [7859370.001]
  • [Cites] Forensic Sci Int. 1995 Jan 5;70(1-3):63-76 [7860037.001]
  • [Cites] Chem Res Toxicol. 1994 Nov-Dec;7(6):733-9 [7696526.001]
  • [Cites] Biol Pharm Bull. 1995 Sep;18(9):1223-7 [8845810.001]
  • [Cites] Carcinogenesis. 1996 May;17(5):1029-34 [8640908.001]
  • [Cites] Pigment Cell Res. 1996 Oct;9(5):265-70 [9014213.001]
  • [Cites] Food Chem Toxicol. 1998 Apr;36(4):279-87 [9651044.001]
  • [Cites] Chem Res Toxicol. 1998 Aug;11(8):925-36 [9705755.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 May;8(5):439-45 [10350440.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Jun;8(6):507-12 [10385140.001]
  • [Cites] Mutat Res. 2005 Dec 30;588(2):136-42 [16289877.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2826-8 [16364996.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Apr 13;834(1-2):14-25 [16564753.001]
  • [Cites] Chem Res Toxicol. 2007 Feb;20(2):263-76 [17305409.001]
  • [Cites] Mutat Res. 2007 Jun 15;630(1-2):14-9 [17392018.001]
  • [Cites] J Agric Food Chem. 2008 Jan 9;56(1):68-78 [18069786.001]
  • [Cites] J Agric Food Chem. 2008 Jan 9;56(1):35-43 [18078314.001]
  • [Cites] Int J Cancer. 2000 Oct 1;88(1):1-6 [10962432.001]
  • (PMID = 19588936.001).
  • [ISSN] 1520-5010
  • [Journal-full-title] Chemical research in toxicology
  • [ISO-abbreviation] Chem. Res. Toxicol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA122320-01A1; United States / NCI NIH HHS / CA / R01 CA122320; United States / NCI NIH HHS / CA / R01 CA122320-01A1; United States / NCI NIH HHS / CA / R01CA-122320
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amines; 0 / Carcinogens; 0 / DNA Adducts; 0 / Quinoxalines; 63478-55-7 / TANDEM (quinoxaline)
  • [Other-IDs] NLM/ NIHMS132583; NLM/ PMC2787961
  •  go-up   go-down


58. Fukunaga Y, Higashino M, Tanimura S, Takemura M, Fujiwara Y: Laparoscopic rectal surgery for middle and lower rectal cancer. Surg Endosc; 2010 Jan;24(1):145-51
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic rectal surgery for middle and lower rectal cancer.
  • BACKGROUND: The usefulness of laparoscopic low anterior resection for middle and lower rectal cancer remains controversial.
  • METHODS: Retrospective assessment was performed on 98 patients (51 with middle and 47 with lower rectal cancer) who underwent laparoscopic rectal surgery since 1998.
  • Cancers were classified as middle or lower rectal based on distance from the distal tumor border to the anal verge (<8 cm or >or=8 cm).
  • The 5-year disease-free/overall survival rates were 82.3/95.7% in stage I, 55.1/72.0% in stage II, and 59.5/80.7% in stage III.
  • It is a useful option even for advanced lower rectal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Surg Endosc. 2010 Dec;24(12):3241-3 [20372934.001]
  • (PMID = 19517172.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


59. Shanafelt TD, Call TG, Zent CS, LaPlant B, Bowen DA, Roos M, Secreto CR, Ghosh AK, Kabat BF, Lee MJ, Yang CS, Jelinek DF, Erlichman C, Kay NE: Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia. J Clin Oncol; 2009 Aug 10;27(23):3808-14
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia.
  • PATIENTS AND METHODS: Previously untreated patients with asymptomatic Rai stage 0 to II CLL were eligible for participation.
  • Response was classified using the National Cancer Institute (NCI) Working Group (WG) Criteria.
  • The most common adverse effects included transaminitis (33%, all grade 1), abdominal pain (30% grade 1, 0% grade 2, and 3% grade 3), and nausea (39% grade 1 and 9% grade 2).
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Catechin / analogs & derivatives. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / pathology

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Biochem. 2000 Mar 15;279(2):164-9 [10706785.001]
  • [Cites] Blood. 2008 Nov 1;112(9):3807-17 [18599795.001]
  • [Cites] Br J Cancer. 2001 Mar 23;84(6):844-50 [11259102.001]
  • [Cites] J Biol Chem. 2001 Apr 20;276(16):13322-30 [11278274.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2002;42:25-54 [11807163.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):381-5 [11809684.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 2):10-24 [11842384.001]
  • [Cites] Br J Haematol. 2001 Dec;115(4):854-61 [11843819.001]
  • [Cites] Arch Pharm Res. 2002 Oct;25(5):561-71 [12433185.001]
  • [Cites] Cancer Res. 2003 Feb 15;63(4):824-30 [12591733.001]
  • [Cites] Br J Haematol. 2003 Apr;121(2):287-95 [12694251.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1466-71 [12697868.001]
  • [Cites] Curr Treat Options Oncol. 2003 Jun;4(3):211-8 [12718798.001]
  • [Cites] Clin Cancer Res. 2003 Aug 15;9(9):3312-9 [12960117.001]
  • [Cites] Biochem Pharmacol. 2003 Nov 1;66(9):1769-78 [14563487.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7563-70 [14633667.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8118-21 [14678963.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1202-10 [14576043.001]
  • [Cites] Toxicol In Vitro. 2004 Oct;18(5):555-61 [15251172.001]
  • [Cites] Blood. 2004 Aug 1;104(3):788-94 [14996703.001]
  • [Cites] Carcinogenesis. 2004 Sep;25(9):1567-74 [15090467.001]
  • [Cites] Hematol Oncol. 1988 Jan-Mar;6(1):7-12 [3277904.001]
  • [Cites] Br J Haematol. 1989 Jun;72(2):141-9 [2757960.001]
  • [Cites] Mayo Clin Proc. 1994 Apr;69(4):323-8 [8170175.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Jun;4(4):393-9 [7655336.001]
  • [Cites] Leukemia. 1996 Mar;10(3):456-9 [8642861.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Nature. 1997 Sep 11;389(6647):134-5 [9296488.001]
  • [Cites] J Natl Cancer Inst. 1997 Dec 17;89(24):1881-6 [9414176.001]
  • [Cites] Leuk Lymphoma. 1997 Nov;27(5-6):523-32 [9477135.001]
  • [Cites] N Engl J Med. 1998 May 21;338(21):1506-14 [9593789.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Aug 19;249(2):391-6 [9712707.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1848-54 [10477713.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2059-64 [15781612.001]
  • [Cites] Clin Cancer Res. 2005 Jun 15;11(12):4627-33 [15958649.001]
  • [Cites] Leuk Res. 2006 Jun;30(6):707-12 [16325256.001]
  • [Cites] Mol Cancer Ther. 2006 May;5(5):1227-38 [16731755.001]
  • [Cites] Cell Death Differ. 2006 Aug;13(8):1419-21 [16645636.001]
  • [Cites] Ann Intern Med. 2006 Sep 19;145(6):435-47 [16983131.001]
  • [Cites] Blood. 2006 Oct 15;108(8):2804-10 [16809610.001]
  • [Cites] J Nutr. 2007 Jan;137(1 Suppl):223S-228S [17182830.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2144-50 [17404098.001]
  • [Cites] J Cell Physiol. 2007 Oct;213(1):252-60 [17477351.001]
  • [Cites] Life Sci. 2007 Jul 26;81(7):519-33 [17655876.001]
  • [Cites] Semin Cancer Biol. 2007 Oct;17(5):395-402 [17686632.001]
  • [Cites] Blood. 2008 Jan 15;111(2):846-55 [17928528.001]
  • [Cites] J Cell Biochem. 2008 Feb 1;103(2):509-19 [17570133.001]
  • [Cites] Br J Haematol. 2008 Mar;140(5):537-46 [18275431.001]
  • [Cites] Antioxid Redox Signal. 2008 Mar;10(3):475-510 [18154485.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5446-56 [18216293.001]
  • [Cites] Blood. 2008 Sep 1;112(5):1923-30 [18577710.001]
  • [Cites] Cancer Lett. 2008 Oct 8;269(2):269-80 [18501505.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1830-8 [11251015.001]
  • (PMID = 19470922.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K23 CA113408; United States / NCI NIH HHS / CA / R01 CA136591; United States / NCI NIH HHS / CA / CA113408; United States / NCI NIH HHS / CA / CA6912
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Tea; 0 / polyphenon E; 8R1V1STN48 / Catechin; BQM438CTEL / epigallocatechin gallate
  • [Other-IDs] NLM/ PMC2727287
  •  go-up   go-down


60. Voss M, Trojan L, Steidler A, Weiss C, Grobholz R, Alken P, Michel MS: Serum vascular endothelial growth factor C level in patients with prostate cancer and benign prostatic hyperplasia. Anal Quant Cytol Histol; 2008 Aug;30(4):199-202
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum vascular endothelial growth factor C level in patients with prostate cancer and benign prostatic hyperplasia.
  • OBJECTIVE: To compare serum vascular endothelial growth factor C (VEGF-C) levels in patients with benign prostatic hyperplasia (BPH) and prostate cancer (PCa) and analyze VEGF-C levels in relation to clinicopathologic parameters.
  • There was no correlation of VEGF-C to tumor stage, grading or the preoperative prostate-specific antigen values.

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Benign Prostatic Hyperplasia.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18773737.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor C
  •  go-up   go-down


61. Pasetto LM, Basso U, Sinigaglia G, Pucciarelli S, Friso ML, Rugge M, Toppan P, Agostini M, Monfardini S: Rectal cancer adjuvant chemotherapy: when is more useful? Anticancer Res; 2008 May-Jun;28(3B):1805-12
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rectal cancer adjuvant chemotherapy: when is more useful?
  • THE AIM of the study was to evaluate time-to-progression (TTP) of rectal cancer in a group of patients receiving adjuvant chemotherapy (CHT) after combined neoadjuvant treatment.
  • PATIENTS AND METHODS: From January 2000 to December 2005, 101 consecutive rectal cancer patients who had been neoadjuvantly treated and had underne adjuvant CHT were retrospectively examined.
  • Forty-two patients had a lower (< or =5 cm from the anal verge), 54 a middle (from 6 to 10 cm) and 5 a higher (=10 cm) rectal lesion.
  • CONCLUSION: In our series, neither administration of oxaliplatin-based adjuvant chemotherapy (p=0.44) nor age > or =70 years (p=0.51), clinical stage III (p=0.67), tumour down-staging (p=0.44) and achievement of pCR (p=0.66) appeared to have a significant impact on TTP; only pN+ (patients "not responders" to a neoadjuvant CHT-RT) influenced local relapse requiring more accurate postoperative treatment and confirming the literature data about the utility of adjuvant therapy in stage III disease.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18630464.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


62. Shamamian P, Goldberg JD, Ye XY, Stewart JD, White PJ, Gilvarg C: Evaluation of pro-carboxypeptidase A and carboxypeptidase A as serologic markers for adenocarcinoma of the pancreas. HPB (Oxford); 2006;8(6):451-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: A serological marker for pancreatic cancer may allow for early detection and potentially more effective treatments.
  • We hypothesized that alterations in serum pro-CPA and/or CPA may be useful as a diagnostic test for pancreatic cancer.
  • All pancreatic cancer patients had ln(CPA) levels within or below the normal range defined as two standard deviations from the control group mean (-2.714+/-0.413).
  • Ln(pro-CPA) levels in 24 of 34 cancer patients were outside the normal range of the control group (0.306+/-0.33).
  • Pancreatic cancer patients with ln pro-CPA values within the control range had low ln CPA, advanced stage and/or evidence of pancreatic insufficiency.
  • While each of these individual values (ln pro-CPA or ln CPA) does not adequately separate all control from cancer patients, a bivariate classification rule is presented that uses both ln pro-CPA and ln CPA simultaneously to predict the presence of pancreatic cancer with a sensitivity of 91% and a specificity of 95%.
  • CONCLUSIONS: The data presented suggest that abnormalities in serum pro-CPA and CPA levels are associated with the presence of pancreatic cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Oncol Clin N Am. 1998 Jan;7(1):103-24 [9443989.001]
  • [Cites] Ann Surg Oncol. 1997 Dec;4(8):639-43 [9416411.001]
  • [Cites] Clin Chim Acta. 1999 Mar;281(1-2):19-28 [10217623.001]
  • [Cites] J Gastrointest Surg. 1999 Sep-Oct;3(5):506-11 [10482707.001]
  • [Cites] Clin Chim Acta. 2000 Feb 25;292(1-2):107-15 [10686280.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47 [11814064.001]
  • [Cites] Surg Oncol Clin N Am. 2002 Jan;11(1):207-29, x [11930875.001]
  • [Cites] Clin Chem. 1989 Feb;35(2):251-5 [2464445.001]
  • [Cites] Anal Biochem. 1987 Feb 15;161(1):219-25 [3578784.001]
  • [Cites] Clin Chim Acta. 1983 Nov 30;135(1):65-71 [6197212.001]
  • [Cites] Anal Biochem. 1982 Sep 15;125(2):420-6 [7181100.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):721-31; discussion 731-3 [7794076.001]
  • [Cites] Surg Oncol. 1996 Apr;5(2):49-63 [8853239.001]
  • [Cites] J Gastrointest Surg. 1997 Mar-Apr;1(2):106-12 [9834336.001]
  • (PMID = 18333101.001).
  • [ISSN] 1365-182X
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016087
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2020764
  •  go-up   go-down


63. Huh JW, Jung EJ, Park YA, Lee KY, Sohn SK: Sphincter-preserving operations following preoperative chemoradiation: an alternative to abdominoperineal resection for lower rectal cancer? World J Surg; 2008 Jun;32(6):1116-23
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sphincter-preserving operations following preoperative chemoradiation: an alternative to abdominoperineal resection for lower rectal cancer?
  • BACKGROUND: Sphincter-preserving operations (SPO) for lower rectal cancer are on the rise.
  • In the study reported here, we compared the oncologic outcomes of patients who underwent sphincter-preserving operations following preoperative chemoradiation for lower rectal cancer with the outcome for patients who underwent abdominoperineal resection (APR).
  • METHODS: This prospective study included 87 patients who underwent proctectomy with curative intent for locally advanced rectal cancer that was located less than 6 cm from the anal verge.
  • By multivariate analysis, only the pathologic N stage was significantly associated with overall survival (p < 0.001).
  • CONCLUSIONS: Sphincter-preserving operation with CCRT could be another option for the treatment of locally advanced lower rectal cancer in patients who are clinically considered for APR, with no deterioration of oncologic outcomes.
  • For patients undergoing curative resection for lower rectal cancer, the pathologic N stage can provide valuable prognostic information about survival.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / surgery. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Prospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18330627.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; U3P01618RT / Fluorouracil
  •  go-up   go-down


64. Larsen SG, Wiig JN, Dueland S, Giercksky KE: Prognostic factors after preoperative irradiation and surgery for locally advanced rectal cancer. Eur J Surg Oncol; 2008 Apr;34(4):410-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors after preoperative irradiation and surgery for locally advanced rectal cancer.
  • AIMS: The experience of preoperative irradiation in clinically locally advanced rectal cancer for the period 1991-2003 is reported.
  • METHODS: A prospective cohort study of 204 M0 patients given >45 Gy preoperatively (median age 66 years; 29% women; tumour level <16 cm from the anal verge).
  • R-stage, N-stage, age, type of rectal resection and pelvic wall resection remained significant in Cox multivariate analysis for survival.
  • Regarding local recurrence, the following parameters were independent: N-stage, carcinoembryonic antigen (CEA) response and pelvic wall resection.
  • CONCLUSIONS: After preoperative irradiation and surgery, about 50% of the patients with locally advanced rectal cancer without overt metastases (M0) can be cured.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17614249.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


65. Shrikhande SV, Saoji RR, Barreto SG, Kakade AC, Waterford SD, Ahire SB, Goliwale FM, Shukla PJ: Outcomes of resection for rectal cancer in India: the impact of the double stapling technique. World J Surg Oncol; 2007;5:35
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of resection for rectal cancer in India: the impact of the double stapling technique.
  • Data on the double-stapling technique (DST) has been widely published in the West where the incidence of colorectal cancer is high.
  • The mean distance of the tumor from anal verge was 7.6 cm (2.5-15 cm) and 8.0 cm (4-15 cm) in the DST and SST groups, respectively.
  • CONCLUSION: This study, perhaps the first from India, demonstrates the feasibility of the DST in a country where the incidence of colorectal cancer is increasing.
  • The observed improvement of surgical outcomes with DST needs further studies to significantly prove these findings in a population where the tumors at presentation are predominantly Astler Coller Stage B and C.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1983 Feb;26(2):87-90 [6822175.001]
  • [Cites] Surgery. 1980 Nov;88(5):710-4 [7434211.001]
  • [Cites] Am J Surg. 1984 Apr;147(4):524-30 [6711755.001]
  • [Cites] Br J Surg. 1985 Aug;72(8):603-5 [3896372.001]
  • [Cites] Lancet. 1986 Jun 28;1(8496):1479-82 [2425199.001]
  • [Cites] Dis Colon Rectum. 1986 Dec;29(12):885-90 [2431844.001]
  • [Cites] Int Surg. 1988 Jan-Mar;73(1):19-22 [3360572.001]
  • [Cites] Br J Surg. 1990 May;77(5):510-2 [2354332.001]
  • [Cites] Dis Colon Rectum. 1991 Apr;34(4):317-22 [2007349.001]
  • [Cites] Br J Surg. 1991 Mar;78(3):308-11 [2021845.001]
  • [Cites] Dis Colon Rectum. 1991 Jun;34(6):495-7 [2036929.001]
  • [Cites] Am Surg. 1992 Apr;58(4):270-2 [1586088.001]
  • [Cites] Br J Surg. 1992 Aug;79(8):836-8 [1393488.001]
  • [Cites] Surg Gynecol Obstet. 1992 Oct;175(4):333-6 [1329243.001]
  • [Cites] World J Surg. 1992 Sep-Oct;16(5):866-71 [1462621.001]
  • [Cites] Br J Surg. 1993 Jul;80(7):924-7 [8369941.001]
  • [Cites] Dis Colon Rectum. 1994 Feb;37(2 Suppl):S35-41 [8313790.001]
  • [Cites] Dis Colon Rectum. 1995 May;38(5):480-6; discussion 486-7 [7736878.001]
  • [Cites] Dis Colon Rectum. 1995 Dec;38(12):1246-50 [7497834.001]
  • [Cites] Dis Colon Rectum. 1997 Jan;40(1):25-9 [9102256.001]
  • [Cites] Br J Surg. 1997 Apr;84(4):525-8 [9112908.001]
  • [Cites] Dis Colon Rectum. 1997 Jul;40(7):747-51 [9221846.001]
  • [Cites] Surg Today. 1997;27(8):706-9 [9306583.001]
  • [Cites] Aust N Z J Surg. 1997 Sep;67(9):599-602 [9322694.001]
  • [Cites] Surgery. 1997 Oct;122(4):779-84; discussion 784-5 [9347856.001]
  • [Cites] Br J Surg. 1998 Aug;85(8):1118-20 [9718010.001]
  • [Cites] Oncology. 1999 Apr;56(3):193-7 [10202273.001]
  • [Cites] Eur J Surg Oncol. 1999 Jun;25(3):284-91 [10336809.001]
  • [Cites] Indian J Gastroenterol. 1999 Jul-Sep;18(3):118-21 [10407566.001]
  • [Cites] Tech Coloproctol. 2004 Nov;8 Suppl 1:s79-81 [15655652.001]
  • [Cites] Trop Gastroenterol. 2001 Apr-Jun;22(2):83-6 [11552491.001]
  • [Cites] Br J Surg. 2001 Dec;88(12):1607-12 [11736973.001]
  • [Cites] Surg Clin North Am. 2002 Oct;82(5):983-93 [12507204.001]
  • [Cites] Int J Colorectal Dis. 2003 Nov;18(6):463-9 [14517685.001]
  • [Cites] Surg Today. 2004;34(1):32-9 [14714226.001]
  • [Cites] Br J Surg. 1980 Mar;67(3):198-200 [7362961.001]
  • [Cites] Dis Colon Rectum. 1983 Apr;26(4):231-5 [6839891.001]
  • (PMID = 17374176.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1839092
  • [General-notes] NLM/ Original DateCompleted: 20070726
  •  go-up   go-down


66. Chiappa A, Biffi R, Bertani E, Zbar AP, Pace U, Crotti C, Biella F, Viale G, Orecchia R, Pruneri G, Poldi D, Andreoni B: Surgical outcomes after total mesorectal excision for rectal cancer. J Surg Oncol; 2006 Sep 1;94(3):182-93; discussion 181
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical outcomes after total mesorectal excision for rectal cancer.
  • BACKGROUND AND OBJECTIVES: This study reviewed the results of surgery for distal rectal cancer following the introduction of total mesorectal excision (TME) for rectal cancer.
  • METHODS: Two hundred sixty-four patients who had undergone elective curative surgical resection of rectal cancer within 12 cm of the anal verge were included.
  • On multivariate analysis, only stage was a significant prognosticator of overall survival (P = 0.012).
  • CONCLUSIONS: With the practice of TME, APR was still necessary in 25% of patients with rectal cancer within 12 cm of the anal verge.
  • Type of surgery and tumor distance from the anal verge influenced local recurrence rates, but only initial tumor stage was associated with long-term survival.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 Wiley-Liss, Inc.
  • (PMID = 16900534.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Ren N, Ye QH, Qin LX, Zhang BH, Liu YK, Tang ZY: Circulating DNA level is negatively associated with the long-term survival of hepatocellular carcinoma patients. World J Gastroenterol; 2006 Jun 28;12(24):3911-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating DNA level is negatively associated with the long-term survival of hepatocellular carcinoma patients.
  • AIM: To quantify the circulating DNA in plasma from patients with hepatocellular carcinoma (HCC) and to evaluate its prognostic value.
  • The circulating DNA level was closely associated with tumor size (P = 0.008) and TNM stage (P = 0.040), negatively associated with the 3-year disease-free survival (DFS) (P = 0.017) and overall survival (OS) (P = 0.001).
  • [MeSH-major] Carcinoma, Hepatocellular / blood. Carcinoma, Hepatocellular / pathology. DNA, Neoplasm / blood. Liver Neoplasms / blood. Liver Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1047-52 [12631605.001]
  • [Cites] Int J Cancer. 2003 Jan 10;103(2):149-52 [12455027.001]
  • [Cites] N Engl J Med. 2004 Jun 10;350(24):2461-70 [15190138.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1022:17-24 [15251934.001]
  • [Cites] Cancer Res. 1977 Mar;37(3):646-50 [837366.001]
  • [Cites] Oncology. 1989;46(5):318-22 [2779946.001]
  • [Cites] Cancer. 1990 Nov 15;66(10):2174-9 [2171748.001]
  • [Cites] Mol Med. 1995 May;1(4):344-65 [8521292.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):578-84 [10080602.001]
  • [Cites] Hepatology. 1999 Oct;30(4):1027-36 [10498656.001]
  • [Cites] Nature. 1953 Apr 25;171(4356):737-8 [13054692.001]
  • [Cites] Anal Biochem. 1999 Dec 1;276(1):59-64 [10585744.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1805-11 [11078757.001]
  • [Cites] Transfusion. 2001 Feb;41(2):276-82 [11239235.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4675-8 [11406535.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5723-6 [11479206.001]
  • [Cites] Clin Chem. 2001 Sep;47(9):1607-13 [11514393.001]
  • [Cites] CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36 [11577478.001]
  • [Cites] World J Gastroenterol. 2002 Apr;8(2):193-9 [11925590.001]
  • [Cites] World J Gastroenterol. 2001 Aug;7(4):445-54 [11819809.001]
  • [Cites] Anticancer Res. 2002 Jan-Feb;22(1A):421-5 [12017326.001]
  • [Cites] Br J Cancer. 2002 Dec 2;87(12):1449-53 [12454776.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1579-82 [14571790.001]
  • (PMID = 16804981.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC4087944
  •  go-up   go-down


68. Yu J, Ohuchida K, Mizumoto K, Ishikawa N, Ogura Y, Yamada D, Egami T, Fujita H, Ohashi S, Nagai E, Tanaka M: Overexpression of c-met in the early stage of pancreatic carcinogenesis; altered expression is not sufficient for progression from chronic pancreatitis to pancreatic cancer. World J Gastroenterol; 2006 Jun 28;12(24):3878-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of c-met in the early stage of pancreatic carcinogenesis; altered expression is not sufficient for progression from chronic pancreatitis to pancreatic cancer.
  • METHODS: We used 46 bulk tissues and 36 micro-dissected samples, including normal pancreas, chronic pancreatitis, and pancreatic cancer, for quantitative real-time reverse transcription-polymerase chain reaction.
  • RESULTS: In bulk tissue analyses, pancreatic cancer tissues expressed significantly higher levels of c-met than did chronic pancreatitis and normal pancreas tissues. c-met levels did not differ between chronic pancreatitis and normal pancreas tissues.
  • In microdissection-based analyses, c-met was expressed at higher levels in microdissected pancreatic cancer cells and pancreatitis-affected epithelial cells than in normal ductal epithelial cells (both, P < 0.01).
  • Interestingly, pancreatitis-affected epithelial cells expressed levels of c-met similar to those of pancreatic cancer cells.
  • CONCLUSION: Overexpression of c-met occurs during the early stage of pancreatic carcinogenesis, and a single alteration of c-met expression is not sufficient for progression of chronic pancreatitis-affected epithelial cells to pancreatic cancer cells.
  • [MeSH-minor] Biomarkers, Tumor / analysis. Cell Line, Tumor. Cell Transformation, Neoplastic. Cells, Cultured. DNA, Neoplasm / analysis. DNA, Neoplasm / genetics. Disease Progression. Epithelial Cells / chemistry. Epithelial Cells / cytology. Epithelial Cells / pathology. Fibroblasts / chemistry. Fibroblasts / cytology. Fibroblasts / pathology. Gene Expression Regulation, Neoplastic. Humans. RNA, Messenger / analysis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction


69. Hohenberger W, Merkel S, Matzel K, Bittorf B, Papadopoulos T, Göhl J: The influence of abdomino-peranal (intersphincteric) resection of lower third rectal carcinoma on the rates of sphincter preservation and locoregional recurrence. Colorectal Dis; 2006 Jan;8(1):23-33

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The influence of abdomino-peranal (intersphincteric) resection of lower third rectal carcinoma on the rates of sphincter preservation and locoregional recurrence.
  • PATIENTS AND METHODS: The data of 476 patients with a carcinoma in the lower third of the rectum who underwent primary treatment for stage I-III disease by low anterior resection, abdomino-peranal (intersphincteric) resection or abdominoperineal excision between 1985 and 2001 were analysed.
  • The cancer-related 5-year survival rate was not altered by intersphincteric resection.
  • [MeSH-major] Anal Canal / surgery. Carcinoma / surgery. Colectomy / methods. Neoplasm Recurrence, Local / epidemiology. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16519634.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


70. Heidenreich WF: Heterogeneity of cancer risk due to stochastic effects. Risk Anal; 2005 Dec;25(6):1589-94

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heterogeneity of cancer risk due to stochastic effects.
  • Persons with exactly the same genetic background, behavior, environment, etc. may have differences in cancer risk due to a different number of cells on the way to malignancy.
  • These differences are estimated quantitatively by using the two-stage clonal expansion model.
  • For liver cancer the estimated relative risk for persons without intermediate cells at age 40 is less than 10% when compared to the risk of the total population, while the top 0.1% risk group has a more than 100-fold risk compared to the population.
  • [MeSH-minor] Adult. Aged. Cell Transformation, Neoplastic. Female. Humans. Liver Neoplasms / etiology. Liver Neoplasms / pathology. Male. Mathematics. Middle Aged. Proportional Hazards Models. Risk Factors. Stochastic Processes

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16506984.001).
  • [ISSN] 0272-4332
  • [Journal-full-title] Risk analysis : an official publication of the Society for Risk Analysis
  • [ISO-abbreviation] Risk Anal.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


71. Kouzu Y, Uzawa K, Koike H, Saito K, Nakashima D, Higo M, Endo Y, Kasamatsu A, Shiiba M, Bukawa H, Yokoe H, Tanzawa H: Overexpression of stathmin in oral squamous-cell carcinoma: correlation with tumour progression and poor prognosis. Br J Cancer; 2006 Mar 13;94(5):717-23
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of stathmin in oral squamous-cell carcinoma: correlation with tumour progression and poor prognosis.
  • Our previous study using proteomic profiling showed that significant upregulation of stathmin occurs in oral squamous-cell carcinoma (OSCC)-derived cell lines.
  • In the current study, to determine the potential involvement of stathmin in OSCC, we evaluated the state of stathmin protein and mRNA expression in OSCC-derived cell lines and human primary OSCCs.
  • A significant increase in stathmin expression was observed in all OSCC-derived cell lines examined compared to human normal oral keratinocytes.
  • Moreover, stathmin expression status was correlated with the TNM stage grading.
  • These results suggest that expression of stathmin could contribute to cancer progression/prognosis, and that stathmin may have potential as a biomarker and a therapeutic target for OSCC.
  • [MeSH-major] Carcinoma, Squamous Cell / genetics. Mouth Neoplasms / genetics. Stathmin / biosynthesis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1993 Oct;8(10):2869-72 [8397372.001]
  • [Cites] J Biol Chem. 1991 Nov 5;266(31):21004-10 [1939149.001]
  • [Cites] Prostate. 1995 Aug;27(2):102-9 [7638082.001]
  • [Cites] Cell. 1996 Feb 23;84(4):623-31 [8598048.001]
  • [Cites] Biotechnol Genet Eng Rev. 1996;13:19-50 [8948108.001]
  • [Cites] Cell Signal. 1997 May-Jun;9(3-4):249-55 [9218124.001]
  • [Cites] Br J Cancer. 1998 Sep;78(6):701-9 [9743287.001]
  • [Cites] J Clin Oncol. 2005 Jan 10;23(2):346-56 [15637397.001]
  • [Cites] Br J Cancer. 2005 May 23;92(10):1915-21 [15870709.001]
  • [Cites] Int J Oncol. 2005 Jul;27(1):59-67 [15942644.001]
  • [Cites] Int J Mol Med. 2005 Aug;16(2):269-73 [16012760.001]
  • [Cites] Int J Cancer. 2006 Feb 1;118(3):704-13 [16094606.001]
  • [Cites] Mol Carcinog. 2000 Mar;27(3):158-65 [10708477.001]
  • [Cites] FEBS Lett. 2000 Mar 10;469(2-3):155-8 [10713262.001]
  • [Cites] Electrophoresis. 2000 Apr;21(6):1202-9 [10786892.001]
  • [Cites] Nature. 2000 Jun 15;405(6788):837-46 [10866210.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3537-41 [10910066.001]
  • [Cites] Br J Cancer. 2000 Aug;83(3):311-8 [10917544.001]
  • [Cites] Anal Biochem. 2000 Aug 15;284(1):49-59 [10933855.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):3949-56 [11051243.001]
  • [Cites] Cancer Invest. 2000;18(8):722-30 [11107442.001]
  • [Cites] Curr Opin Mol Ther. 2000 Dec;2(6):633-42 [11249740.001]
  • [Cites] Nat Rev Genet. 2000 Oct;1(1):48-56 [11262874.001]
  • [Cites] Cancer. 2001 Apr 15;91(8):1494-9 [11301397.001]
  • [Cites] Mt Sinai J Med. 2002 Oct;69(5):299-304 [12415323.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6598-605 [12438255.001]
  • [Cites] J Dent Res. 2003 Aug;82(8):607-11 [12885844.001]
  • [Cites] Int J Cancer. 2004 Jun 10;110(2):225-31 [15069686.001]
  • [Cites] J Cell Biochem. 2004 Oct 1;93(2):242-50 [15368352.001]
  • [Cites] J Biol Chem. 1983 Sep 10;258(17):10786-93 [6577004.001]
  • [Cites] J Biol Chem. 1988 Sep 15;263(26):12813-5 [3417633.001]
  • [Cites] Leukemia. 1993 Oct;7(10):1538-46 [8412315.001]
  • (PMID = 16495930.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / STMN1 protein, human; 0 / Stathmin
  • [Other-IDs] NLM/ PMC2361217
  •  go-up   go-down


72. Park RM, Stayner LT: A search for thresholds and other nonlinearities in the relationship between hexavalent chromium and lung cancer. Risk Anal; 2006 Feb;26(1):79-88
Hazardous Substances Data Bank. CHROMIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A search for thresholds and other nonlinearities in the relationship between hexavalent chromium and lung cancer.
  • The exposure-response relationship for airborne hexavalent chromium exposure and lung cancer mortality is well described by a linear relative rate model.
  • This study investigates nonlinear features of the exposure response in a cohort of 2,357 chemical workers with 122 lung cancer deaths.
  • In a one-stage context, fractional polynomials were investigated.
  • A simple two-stage model of carcinogenesis provided no improvement in fit.
  • The best-fitting one-stage models used simple cumulative exposure with no threshold for exposure intensity and had sufficient power to rule out thresholds as large as 30 microg/m3 CrO3 (16 microg/m3 as Cr+6) (one-sided 95% confidence limit, likelihood ratio test).
  • Examination of nonlinear features of the hexavalent chromium-lung cancer exposure response in a population used in a recent risk assessment supports using the traditional (lagged) cumulative exposure paradigm: no intensity (concentration) threshold, linearity in intensity, and constant increment in risk following exposure.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16492182.001).
  • [ISSN] 0272-4332
  • [Journal-full-title] Risk analysis : an official publication of the Society for Risk Analysis
  • [ISO-abbreviation] Risk Anal.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Air Pollutants, Occupational; 0 / Carcinogens; 0R0008Q3JB / Chromium; 18540-29-9 / chromium hexavalent ion
  •  go-up   go-down


73. Kalina T, Vaskova M, Mejstrikova E, Madzo J, Trka J, Stary J, Hrusak O: Myeloid antigens in childhood lymphoblastic leukemia: clinical data point to regulation of CD66c distinct from other myeloid antigens. BMC Cancer; 2005;5:38
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MyAgs in ALL are interpreted e.g. as hallmarks of early differentiation stage and/or lineage indecisiveness.
  • Granulocytic marker CD66c -- Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) is aberrantly expressed on ALL with strong correlation to genotype (negative in TEL/AML1 and MLL/AF4, positive in BCR/ABL and hyperdiploid cases).
  • The most frequent MyAg (CD66c) is studied further regarding its stability from diagnosis to relapse, prognostic significance and regulation of surface expression.
  • We chose the most frequent and tightly genotype-associated MyAg CD66c to show its stabile expression in patients from diagnosis to relapse, which differs from what is known on the other MyAgs.
  • [MeSH-major] Antigens, CD / biosynthesis. Cell Adhesion Molecules / biosynthesis. Gene Expression Regulation, Neoplastic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism
  • [MeSH-minor] Adolescent. Antigens, CD13 / biosynthesis. Antigens, CD15 / biosynthesis. Antigens, Differentiation, Myelomonocytic / biosynthesis. Blotting, Western. Cell Membrane / metabolism. Child. Child, Preschool. Cohort Studies. Cytoplasm / metabolism. Czech Republic. Disease-Free Survival. Flow Cytometry. GPI-Linked Proteins. Genotype. Glycosylation. Humans. Immunophenotyping. Infant. Prognosis. RNA / metabolism. Recurrence. Reverse Transcriptase Polymerase Chain Reaction. Sialic Acid Binding Ig-like Lectin 3. Time Factors. Transcription, Genetic

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Crit Rev Oncol Hematol. 1999 Dec;32(3):175-85 [10633847.001]
  • [Cites] Leukemia. 2005 Jun;19(6):1092-4 [15830012.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3419-24 [10910050.001]
  • [Cites] Br J Haematol. 2001 Sep;114(4):794-9 [11564065.001]
  • [Cites] Blood. 2002 Mar 15;99(6):1952-8 [11877265.001]
  • [Cites] Best Pract Res Clin Haematol. 2002 Mar;15(1):1-19 [11987913.001]
  • [Cites] Leukemia. 2002 Jul;16(7):1233-58 [12094248.001]
  • [Cites] Cancer. 2003 Jan 1;97(1):105-13 [12491511.001]
  • [Cites] J Clin Oncol. 2003 Oct 1;21(19):3638-46 [14512395.001]
  • [Cites] Oncogene. 2004 Jan 15;23(2):465-73 [14724575.001]
  • [Cites] Biochem Biophys Res Commun. 2004 May 7;317(3):837-43 [15081416.001]
  • [Cites] Oncogene. 2004 Jul 29;23(34):5834-42 [15208677.001]
  • [Cites] Cancer Res. 1968 Sep;28(9):1908-14 [5676741.001]
  • [Cites] Science. 1986 Nov 7;234(4777):697-704 [3535067.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Cancer Res. 1994 Jun 15;54(12):3305-14 [8205554.001]
  • [Cites] Leukemia. 1994 Dec;8(12):2127-33 [7808000.001]
  • [Cites] Leukemia. 1995 Jul;9(7):1233-9 [7543176.001]
  • [Cites] Leukemia. 1995 Oct;9(10):1783-6 [7564526.001]
  • [Cites] J Leukoc Biol. 1996 Jul;60(1):106-17 [8699114.001]
  • [Cites] Infect Immun. 1996 Nov;64(11):4574-9 [8890209.001]
  • [Cites] Leukemia. 1998 Jul;12(7):1064-70 [9665191.001]
  • [Cites] Blood. 1998 Aug 1;92(3):795-801 [9680347.001]
  • [Cites] Tissue Antigens. 1998 Jul;52(1):1-8 [9714468.001]
  • [Cites] Leukemia. 1999 May;13(5):779-85 [10374883.001]
  • [Cites] Cytometry. 1999 Aug 15;38(4):139-52 [10440852.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):595-605 [10666389.001]
  • (PMID = 15826304.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD15; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD33 protein, human; 0 / CD65s antigen, human; 0 / CEACAM6 protein, human; 0 / Cell Adhesion Molecules; 0 / GPI-Linked Proteins; 0 / Sialic Acid Binding Ig-like Lectin 3; 63231-63-0 / RNA; EC 3.4.11.2 / Antigens, CD13
  • [Other-IDs] NLM/ PMC1112585
  •  go-up   go-down


74. Renehan AG, Saunders MP, Schofield PF, O'Dwyer ST: Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer. Br J Surg; 2005 May;92(5):605-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer.
  • BACKGROUND: Salvage surgery for anal cancer is usually reserved for local disease failure, but issues relating to the prediction of local failure and surgical outcome are ill defined.
  • METHODS: Between 1988 and 2000, 254 patients with non-metastatic anal epidermoid carcinoma were treated at a regional cancer centre with radiotherapy (n = 127) or chemoradiotherapy (n = 127).
  • Increasing age (P < 0.001, Cox model), total radiation dose (P = 0.004) and tumour stage (P = 0.010) were independent predictors of local failure.
  • CONCLUSION: In the management of anal cancer, local disease failure is a major clinical problem requiring early detection followed by radical surgery, often accompanied by plastic reconstruction.
  • By implication, these factors favour the centralization of treatment for this uncommon cancer to a multidisciplinary oncology team.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Salvage Therapy / methods

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • (PMID = 15739215.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


75. Chen YC, Pu YS, Wu HC, Wu TT, Lai MK, Yang CY, Sung FC: Cadmium burden and the risk and phenotype of prostate cancer. BMC Cancer; 2009;9:429
Hazardous Substances Data Bank. CADMIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cadmium burden and the risk and phenotype of prostate cancer.
  • BACKGROUND: Studies on the association between prostate cancer and cadmium exposure have yielded conflicting results.
  • This study explored cadmium burden on the risk and phenotype of prostate cancer in men with no evident environmental exposure.
  • METHODS: Hospital-based 261 prostate cancer cases and 267 controls with benign diseases were recruited from four hospitals in Taiwan.
  • Statistical analyses measured the prostate cancer risk associated with BCd and CAUCd separately, controlling for age, smoking and institution.
  • BCd and CAUCd levels within cases were compared in relation to the disease stage and the Gleason score.
  • The prostate cancer cases with Gleason scores of > or = 8 had an odds ratio of 2.89 (95% confidence interval 1.25-6.70), compared with patients with scores of 2-6.
  • CONCLUSION: Higher CAUCd and BCd levels may be associated with advanced cancer phenotypes, but there was only a tenuous association between cadmium and prostate cancer.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1977 Sep 10;2(8037):566-7 [95781.001]
  • [Cites] Prostate. 2008 Feb 1;68(2):122-8 [18044729.001]
  • [Cites] J Natl Cancer Inst. 1993 Oct 6;85(19):1571-9 [8105097.001]
  • [Cites] Clin Chem. 1994 Jul;40(7 Pt 2):1391-4 [8013125.001]
  • [Cites] J Natl Cancer Inst. 1995 May 3;87(9):652-61 [7752270.001]
  • [Cites] Am J Epidemiol. 1996 Feb 15;143(4):363-73 [8633620.001]
  • [Cites] Am J Ind Med. 1997 May;31(5):645-52 [9099369.001]
  • [Cites] Cancer. 1999 Aug 1;86(3):484-91 [10430257.001]
  • [Cites] Ann Occup Hyg. 1965 Mar;8:55-61 [14287870.001]
  • [Cites] Cancer Invest. 2005;23(3):256-63 [15945511.001]
  • [Cites] Br J Cancer. 2005 Oct 31;93(9):1057-61 [16205693.001]
  • [Cites] Int J Androl. 2000;23 Suppl 2:34-6 [10849490.001]
  • [Cites] Environ Res. 1981 Oct;26(1):217-40 [7028475.001]
  • [Cites] Am J Ind Med. 1980;1(3-4):307-17 [7044111.001]
  • [Cites] Can J Public Health. 1982 Mar-Apr;73(2):92-4 [7104934.001]
  • [Cites] J Anal Toxicol. 1982 May-Jun;6(3):135-8 [7109556.001]
  • [Cites] Urol Res. 1982;10(6):301-3 [6186062.001]
  • [Cites] Environ Health Perspect. 1984 Mar;54:147-52 [6376088.001]
  • [Cites] Urol Res. 1984;12(2):147-50 [6204433.001]
  • [Cites] Br J Ind Med. 1985 Aug;42(8):540-5 [4016005.001]
  • [Cites] Cancer Res. 1988 Aug 15;48(16):4656-63 [3396014.001]
  • [Cites] Cancer. 1989 Apr 1;63(7):1388-92 [2465818.001]
  • [Cites] Nephron. 1989;52(1):45-54 [2565539.001]
  • [Cites] Sci Total Environ. 1992 May 15;116(3):243-51 [1615308.001]
  • [Cites] Crit Rev Toxicol. 1992;22(3-4):175-201 [1388705.001]
  • [Cites] Sci Total Environ. 2007 Feb 1;373(1):77-81 [17175009.001]
  • [Cites] IARC Sci Publ. 1992;(118):301-10 [1303956.001]
  • (PMID = 20003241.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 00BH33GNGH / Cadmium
  • [Other-IDs] NLM/ PMC2797022
  •  go-up   go-down


76. Cibula D, Velechovska P, Sláma J, Fischerova D, Pinkavova I, Pavlista D, Dundr P, Hill M, Freitag P, Zikan M: Late morbidity following nerve-sparing radical hysterectomy. Gynecol Oncol; 2010 Mar;116(3):506-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Nerve-sparing (NS) modification of radical hysterectomy (RH) has been developed with the main purpose of improving the quality of life after radical surgical treatment of early-stage cervical cancer.
  • [MeSH-minor] Adult. Aged. Anal Canal / physiology. Female. Humans. Middle Aged. Morbidity. Neoplasm Staging. Prospective Studies. Rectum / physiology. Surveys and Questionnaires. Urinary Bladder / innervation. Urinary Bladder / physiology. Young Adult


77. Wang Y, Wu R, Cho KR, Thomas DG, Gossner G, Liu JR, Giordano TJ, Shedden KA, Misek DE, Lubman DM: Differential protein mapping of ovarian serous adenocarcinomas: identification of potential markers for distinct tumor stage. J Proteome Res; 2009 Mar;8(3):1452-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential protein mapping of ovarian serous adenocarcinomas: identification of potential markers for distinct tumor stage.
  • Ovarian serous carcinomas (OSCs) comprise over half of all ovarian carcinomas and account for the majority of ovarian cancer-related deaths.
  • We used a 2-dimensional liquid-based protein mapping strategy to characterize global protein expression patterns in 19 OSC tumor samples from 15 different patients to facilitate molecular classification of tumor stage.
  • The 19 tumor samples could be classified into two different groups, one group associated with low stage (Stage 1) tumors and the other group associated with high stage (Stages 3/4) tumors.
  • Fourteen of the selected proteins were overexpressed in the low stage tumors; 46 of the proteins were overexpressed in the high stage tumors.
  • To further confirm the stage-dependent protein identifications, Lamin A/C and Vimentin expression in ovarian serous carcinomas was assessed by immunohistochemistry using ovarian tumor tissue microarrays for 66 samples.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2002 Apr 20;98(6):895-9 [11948469.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1223-8 [11943707.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4722-9 [12183431.001]
  • [Cites] Anal Chem. 2002 Oct 15;74(20):5383-92 [12403597.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6674-81 [12438266.001]
  • [Cites] Am J Surg Pathol. 2003 Jun;27(6):725-36 [12766576.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2913-22 [12782598.001]
  • [Cites] Mol Biol Cell. 2003 Nov;14(11):4376-86 [12960427.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1589-94 [14996714.001]
  • [Cites] Proteomics. 2004 Mar;4(3):562-77 [14997480.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1040-4 [15020606.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3814-22 [15172988.001]
  • [Cites] Anal Chem. 2004 Jul 15;76(14):4193-201 [15253663.001]
  • [Cites] Proteomics. 2004 Aug;4(8):2476-95 [15274142.001]
  • [Cites] Cancer Res. 1995 Jul 1;55(13):2896-903 [7796418.001]
  • [Cites] Obstet Gynecol. 1995 Aug;86(2):259-64 [7617357.001]
  • [Cites] Am J Surg Pathol. 1996 Nov;20(11):1331-45 [8898837.001]
  • [Cites] Mod Pathol. 1997 Jul;10(7):663-7 [9237175.001]
  • [Cites] J Urol. 1998 Jan;159(1):270-4 [9400493.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Dec 24;325(4):1115-21 [15555543.001]
  • [Cites] Int J Cancer. 2005 Dec 20;117(6):1049-54 [15986428.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10602-12 [16288054.001]
  • [Cites] Proteomics. 2005 Nov;5(17):4625-36 [16220531.001]
  • [Cites] Mol Cell Proteomics. 2006 Jan;5(1):43-52 [16141455.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Gynecol Oncol. 1999 Dec;75(3):476-9 [10600311.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Sep;29(1):48-57 [10918393.001]
  • [Cites] Proteomics. 2002 Jan;2(1):76-84 [11788994.001]
  • [Cites] Anal Chem. 2002 Apr 15;74(8):1779-91 [11985308.001]
  • (PMID = 19159301.001).
  • [ISSN] 1535-3893
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM049500-12; United States / NCI NIH HHS / CA / R01 CA100104; United States / NIGMS NIH HHS / GM / R01GM49500; United States / NIGMS NIH HHS / GM / GM049500-11A2; United States / NIGMS NIH HHS / GM / GM049500-12; United States / NIGMS NIH HHS / GM / R01 GM049500; United States / NCI NIH HHS / CA / R01CA100104; United States / NCI NIH HHS / CA / R01 CA100104-05; United States / NCI NIH HHS / CA / CA100104-05; United States / NIGMS NIH HHS / GM / R01 GM049500-11A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proteome
  • [Other-IDs] NLM/ NIHMS81647; NLM/ PMC2693455
  •  go-up   go-down


78. Joseph DA, Miller JW, Wu X, Chen VW, Morris CR, Goodman MT, Villalon-Gomez JM, Williams MA, Cress RD: Understanding the burden of human papillomavirus-associated anal cancers in the US. Cancer; 2008 Nov 15;113(10 Suppl):2892-900
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Understanding the burden of human papillomavirus-associated anal cancers in the US.
  • BACKGROUND: Anal cancer is an uncommon malignancy in the US; up to 93% of anal cancers are associated with human papillomavirus.
  • METHODS: Cases diagnosed between 1998 and 2003 from 39 population-based cancer registries were analyzed.
  • The following anal cancer histologies were included in the analysis: squamous cell, adenocarcinoma, and small cell/neuroendocrine carcinomas.
  • RESULTS: From 1998 through 2003, the annual age-adjusted invasive anal cancer incidence rate was 1.5 per 100,000 persons.
  • Squamous cell carcinoma (SCC) was the most common histology overall, accounting for 18,105 of 21,395 (84.6%) cases of anal cancer.
  • Incidence rates of anal SCC increased 2.6% per year on average.
  • The majority of SCC cases were diagnosed at the in situ or localized stage (58.1%).
  • API were more likely to be diagnosed with regional or distant stage disease than were other racial/ethnic groups (27.5% and 11.8%, respectively).
  • CONCLUSIONS: Rates of anal SCC varied by sex, race, and ethnicity.
  • A higher proportion of API were diagnosed at regional/distant stage.
  • Continued surveillance and additional research are needed to assess the potential impact of the HPV vaccine on the anal cancer burden in the US.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Cancer. 2000 Mar 15;88(6):1464-9 [10717631.001]
  • [Cites] Clin Infect Dis. 2002 Nov 1;35(9):1127-34 [12384848.001]
  • [Cites] AIDS. 2003 Feb 14;17(3):311-20 [12556684.001]
  • [Cites] Prev Med. 2003 May;36(5):555-60 [12689800.001]
  • [Cites] Dis Colon Rectum. 2003 Nov;46(11):1517-23; discussion 1523-4; author reply 1524 [14605572.001]
  • [Cites] Cancer Causes Control. 2003 Nov;14(9):837-46 [14682441.001]
  • [Cites] Lancet Oncol. 2004 Mar;5(3):149-57 [15003197.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] N Engl J Med. 1987 Oct 15;317(16):973-7 [2821396.001]
  • [Cites] Gastroenterology. 1988 Jul;95(1):107-11 [2836255.001]
  • [Cites] Am J Epidemiol. 1992 Jan 15;135(2):180-9 [1311142.001]
  • [Cites] Am J Epidemiol. 1992 Jul 1;136(1):54-8 [1329500.001]
  • [Cites] Am J Epidemiol. 1994 Apr 15;139(8):772-80 [8178790.001]
  • [Cites] Am J Epidemiol. 1994 Jul 1;140(1):12-9 [8017399.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] Semin Cancer Biol. 1998 Aug;8(4):307-13 [9870037.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):753-7 [9973228.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] Clin Infect Dis. 2006 Jul 15;43(2):223-33 [16779751.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2006 Oct 27;55(42):1145-8 [17065979.001]
  • [Cites] Stat Methods Med Res. 2006 Dec;15(6):547-69 [17260923.001]
  • [Cites] Lancet Oncol. 2007 Apr;8(4):311-6 [17395104.001]
  • [Cites] Am J Surg Pathol. 2007 Jun;31(6):919-25 [17527081.001]
  • [Cites] Clin Microbiol Rev. 2007 Jul;20(3):478-88, table of contents [17630336.001]
  • [Cites] Sex Transm Infect. 2007 Jul;83(4):257-66 [17664359.001]
  • [Cites] Cancer Causes Control. 2007 Dec;18(10):1175-86 [17805982.001]
  • [Cites] Cancer. 2008 Nov 15;113(10 Suppl):2841-54 [18980203.001]
  • [Cites] Dermatol Ther. 2005 Jan-Feb;18(1):67-76 [15842614.001]
  • [Cites] Dan Med Bull. 2002 Aug;49(3):194-209 [12238281.001]
  • (PMID = 18980293.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] None / None / / N01 PC035137; United States / NCCDPHP CDC HHS / DP / U50 DP424071; United States / NCI NIH HHS / PC / N01 PC035137; United States / NCCDPHP CDC HHS / DP / U50 DP424071-04
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS104103; NLM/ PMC2729501
  •  go-up   go-down


79. Selvindos PB, Ho YH: Multimedia article. Laparoscopic ultralow anterior resection with colonic J-pouch-anal anastomosis. Dis Colon Rectum; 2008 Nov;51(11):1710-1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimedia article. Laparoscopic ultralow anterior resection with colonic J-pouch-anal anastomosis.
  • PURPOSE: Optimal treatment of mid to distal rectal cancers includes total mesorectal excision for oncologic clearance and, where reanastomosis is feasible, a colonic J-pouch-anal anastomosis improves bowel function.
  • Bowel continuity was restored by an intracoporeal double-cross stapled colonic J-pouch-anal anastomosis, but where not possible a coloplasty with pull-through handsewn coloanal anastomosis was performed.
  • Ten patients (18 percent) had an American Society of Anesthesiologists' classification of III.
  • The indications were adenocarcinoma (n = 51), squamous-cell carcinoma of rectum (n = 1), dermoid tumor of mesorectum (n = 1), large villous adenoma (n = 1), and carcinoid with local lymph node metastases (n = 1).
  • The adenocarcinomas were a median distance of 6 (3-12) cm from the anal verge.
  • The histologic grading or the adenocarcinoma patients were: Stage I, n = 14; Stage II, n = 23; Stage III, n = 11; Stage IV, n = 3.
  • Of those who underwent curative resection (Stages I-III), the distal resection margin was 2.9 +/- 0.7 cm (mean +/- standard error) and the radial resection margins were at least 2 mm in all patients.
  • The level of the coloanal anastomosis was a median 3.5 (0-4.5) cm from the anal verge; a coloanal pull-through anastomosis was required in one patient who had a distal cancer.
  • Four other patients had smaller pelvic collections that resolved with antibiotics; pelvic collections were associated with advanced stage of cancer (P = 0.047).
  • This brought the rectum proximally and anteriorly, aiding with the laparoscopic stapler transection of the distal rectum, especially if the cancer was distal, the patient was obese, and the pelvis was narrow.
  • Further randomized, controlled studies that include assessing five-year cancer survival/recurrence, pelvic nerve dysfunction, and bowel function are needed before laparoscopic ultralow anterior resection becomes widely accepted.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Colonic Pouches. Laparoscopy / methods. Proctocolectomy, Restorative / methods. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18679748.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Interactive Tutorial
  • [Publication-country] United States
  •  go-up   go-down


80. de Graeff P, Crijns AP, Ten Hoor KA, Klip HG, Hollema H, Oien K, Bartlett JM, Wisman GB, de Bock GH, de Vries EG, de Jong S, van der Zee AG: The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. Br J Cancer; 2008 Jul 22;99(2):341-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer.
  • Ovarian cancer is the most frequent cause of death from gynaecological cancer in the Western world.
  • Current prognostic factors do not allow reliable prediction of response to chemotherapy and survival for individual ovarian cancer patients.
  • Epidermal growth factor receptor (EGFR) and HER-2/neu are frequently expressed in ovarian cancer but their prognostic value remains unclear.
  • In this study, we investigated the expression and prognostic value of EGFR, EGFR variant III (EGFRvIII), HER-2/neu and important downstream signalling components in a large series of epithelial ovarian cancer patients.
  • Our results show that negative PTEN immunostaining was associated with stage I/II disease (P=0.006), non-serous tumour type (P=0.042) and in multivariate analysis with a longer progression-free survival (P=0.015).
  • Negative PTEN staining also predicted improved progression-free survival in patients with grade III or undifferentiated serous carcinomas (P=0.011).
  • Positive pAKT staining was associated with advanced-stage disease (P=0.006).


81. Shao C, Xiong S, Li GM, Gu L, Mao G, Markesbery WR, Lovell MA: Altered 8-oxoguanine glycosylase in mild cognitive impairment and late-stage Alzheimer's disease brain. Free Radic Biol Med; 2008 Sep 15;45(6):813-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered 8-oxoguanine glycosylase in mild cognitive impairment and late-stage Alzheimer's disease brain.
  • Eight-hydroxy-2'-deoxyguanosine (8-OHdG) is increased in the brain in late-stage Alzheimer's disease (LAD) and mild cognitive impairment (MCI).

  • MedlinePlus Health Information. consumer health - Alzheimer's Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Neurol. 2006 Jan;63(1):38-46 [16401735.001]
  • [Cites] Neurology. 2005 Apr 12;64(7):1152-6 [15824339.001]
  • [Cites] Neurobiol Aging. 2006 May;27(5):657-62 [15979765.001]
  • [Cites] Neurochem Res. 2006 May;31(5):705-10 [16770743.001]
  • [Cites] Neurobiol Aging. 2006 Aug;27(8):1094-9 [15993986.001]
  • [Cites] Neurobiol Aging. 2006 Aug;27(8):1129-36 [16005114.001]
  • [Cites] Antioxid Redox Signal. 2006 Nov-Dec;8(11-12):2039-45 [17034348.001]
  • [Cites] Nucleic Acids Res. 2007;35(8):2759-66 [17426120.001]
  • [Cites] Nucleic Acids Res. 2007;35(16):5545-55 [17704129.001]
  • [Cites] Neurobiol Dis. 2008 Feb;29(2):169-75 [17920285.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4690-4 [2052552.001]
  • [Cites] Acta Neuropathol. 1991;82(4):239-59 [1759558.001]
  • [Cites] Free Radic Res Commun. 1992;16(2):75-87 [1321076.001]
  • [Cites] Ann Neurol. 1993 Oct;34(4):609-16 [8215249.001]
  • [Cites] Ann Neurol. 1994 Nov;36(5):747-51 [7979220.001]
  • [Cites] Free Radic Biol Med. 1995 Jun;18(6):1033-77 [7628729.001]
  • [Cites] Mutat Res. 1995 Oct;338(1-6):115-28 [7565867.001]
  • [Cites] J Neurochem. 1997 May;68(5):2061-9 [9109533.001]
  • [Cites] Cancer Res. 1997 Jun 1;57(11):2151-6 [9187114.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jul 8;94(14):7429-34 [9207108.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8016-20 [9223306.001]
  • [Cites] J Biol Chem. 1997 Oct 10;272(41):25409-12 [9325246.001]
  • [Cites] Neurobiol Aging. 1997 Jul-Aug;18(4 Suppl):S1-2 [9330978.001]
  • [Cites] Neurobiol Aging. 1997 Sep-Oct;18(5):457-61 [9390770.001]
  • [Cites] Neurobiol Aging. 1998 Jan-Feb;19(1):33-6 [9562500.001]
  • [Cites] Brain Res. 2000 Feb 7;855(1):116-23 [10650137.001]
  • [Cites] Ann N Y Acad Sci. 1999;893:362-4 [10672267.001]
  • [Cites] Arch Biochem Biophys. 2000 May 1;377(1):1-8 [10775435.001]
  • [Cites] Curr Biol. 2000 Jun 1;10(11):R412-5 [10837244.001]
  • [Cites] FASEB J. 2000 Jul;14(10):1325-34 [10877825.001]
  • [Cites] Neurobiol Aging. 2001 Mar-Apr;22(2):187-94 [11182468.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Aug;60(8):759-67 [11487050.001]
  • [Cites] Mutat Res. 2001 Nov 1;487(1-2):19-30 [11595405.001]
  • [Cites] Acta Neuropathol. 2002 Jan;103(1):20-5 [11837743.001]
  • [Cites] Free Radic Biol Med. 2002 Jun 1;32(11):1102-15 [12031895.001]
  • [Cites] Biochim Biophys Acta. 2002 Sep 2;1592(1):63-77 [12191769.001]
  • [Cites] Neuroreport. 2002 Nov 15;13(16):2035-9 [12438921.001]
  • [Cites] J Radiat Res. 2003 Mar;44(1):31-5 [12841596.001]
  • [Cites] J Am Chem Soc. 2003 Sep 24;125(38):11607-15 [13129365.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10670-5 [12960370.001]
  • [Cites] Neurology. 1984 Jul;34(7):939-44 [6610841.001]
  • [Cites] Neurology. 1989 Sep;39(9):1159-65 [2771064.001]
  • [Cites] Nature. 1991 Jan 31;349(6308):431-4 [1992344.001]
  • [Cites] Neurology. 1991 Apr;41(4):479-86 [2011243.001]
  • [Cites] J Neurochem. 2005 May;93(4):953-62 [15857398.001]
  • [Cites] Anal Chem. 2005 May 15;77(10):3383-9 [15889933.001]
  • [Cites] J Neurosci. 2005 Oct 5;25(40):9171-5 [16207876.001]
  • [Cites] Curr Alzheimer Res. 2005 Oct;2(4):403-8 [16248845.001]
  • [Cites] J Comp Physiol B. 1998 Apr;168(3):149-58 [9591361.001]
  • [Cites] J Neurochem. 1998 Nov;71(5):2034-40 [9798928.001]
  • [Cites] Nucleic Acids Res. 1999 Apr 15;27(8):1935-42 [10101204.001]
  • [Cites] Mol Biol Cell. 1999 May;10(5):1637-52 [10233168.001]
  • [Cites] Am J Pathol. 1999 May;154(5):1423-9 [10329595.001]
  • [Cites] J Neurochem. 2006 Feb;96(3):825-32 [16405502.001]
  • (PMID = 18598755.001).
  • [ISSN] 0891-5849
  • [Journal-full-title] Free radical biology & medicine
  • [ISO-abbreviation] Free Radic. Biol. Med.
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / 5-P30-AG028383; United States / NIA NIH HHS / AG / AG005119-20A10009; United States / NIA NIH HHS / AG / P01 AG005119; United States / NIA NIH HHS / AG / 5-P01-AG05119; United States / NIA NIH HHS / AG / P01 AG005119-20A10009; United States / NIA NIH HHS / AG / P01 AG005119-20A1; United States / NIA NIH HHS / AG / P30 AG028383; United States / NIA NIH HHS / AG / P30 AG028383-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.2.2.- / DNA Glycosylases; EC 3.2.2.- / oxoguanine glycosylase 1, human
  • [Other-IDs] NLM/ NIHMS105232; NLM/ PMC2745061
  •  go-up   go-down


82. Wang JP, Ding WX, Deng YH, Lan P, Pan K, Dong GH, Deng JZ, Wang L, Wu XJ, Guo XF, Zheng J: [Preoperative chemoradiotherapy with FOLFOX in low rectal cancer: a multicenter study]. Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Mar;11(2):116-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Preoperative chemoradiotherapy with FOLFOX in low rectal cancer: a multicenter study].
  • OBJECTIVE: To investigate the toxicity and safety of FOLFOX regimen concurrent with radiotherapy in neoadjuvant setting in patients with low rectal cancer.
  • METHODS: Fifty-six patients with stage T(3-4)N(0)M(0) and T(1-4)N(1-2)M(0) were eligible from Aug.
  • Fifty-two patients received operation after CRT, 50 with anal interior sphincter reservation, 19 with prophylactic ileac stoma.
  • CONCLUSION: Concomitant treatment of FOLFOX regimen and RT in neoadjuvant setting of rectal cancer was safe and tolerable, and it suggests that protective ileostomy for anastomotic leakage following anus-preserving operation should be performed.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18344075.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Formyltetrahydrofolates; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


83. Zuo FY, Li SY, Yu B, Liang ZJ, Yuan SJ, Chen G, Chen G, Bai X, Wei XJ, Wu E: [Clinical analysis of therapeutic effects of sphincter-preserving operation and Miles operation for rectal cancer]. Zhonghua Wai Ke Za Zhi; 2007 Sep 1;45(17):1176-8
MedlinePlus Health Information. consumer health - Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of therapeutic effects of sphincter-preserving operation and Miles operation for rectal cancer].
  • OBJECTIVE: To investigate and compare therapeutic effects of sphincter-preserving operation and Miles operation for rectal cancer.
  • METHODS: A retrospective analysis was carried out in 572 cases of rectal cancer operations performed from January 1980 to December 2006.
  • CONCLUSIONS: Sphincter-preserving operations can improve the quality of life in rectal cancer although with the same five-year survival rate and recurrence rate as Miles operation.
  • The operation for rectal cancer should be performed individually according to the location, the bionomics and the clinical stage.
  • [MeSH-major] Anal Canal. Rectal Neoplasms / surgery. Surgical Procedures, Operative / methods

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18067710.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


84. Ford CE, Lau SK, Zhu CQ, Andersson T, Tsao MS, Vogel WF: Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma. Br J Cancer; 2007 Mar 12;96(5):808-14
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma.
  • We sought to determine expression levels of DDRs in human lung cancer, investigate prognostic determinates, and determine the prevalence of recently reported mutations in these receptor tyrosine kinases.
  • Tumour samples from 146 non-small cell lung carcinoma (NSCLC) patients were analysed for relative expression of DDR1 and DDR2 using quantitative real-time PCR (qRT-PCR).
  • Multivariate analysis revealed DDR1 is an independent favourable predictor for prognosis independent of tumour differentiation, stage, histology, and patient age.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism. Receptor Protein-Tyrosine Kinases / biosynthesis. Receptors, Mitogen / biosynthesis
  • [MeSH-minor] Animals. Cell Line, Tumor. DNA Mutational Analysis. Humans. Male. Mice. Mutation. Polymorphism, Genetic. Prognosis. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):133-44 [16014883.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):123-32 [16014882.001]
  • [Cites] Hum Mol Genet. 2005 Oct 15;14 Spec No. 2:R197-205 [16244318.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):257-62 [16231326.001]
  • [Cites] J Immunol. 2006 Feb 1;176(3):1928-36 [16424224.001]
  • [Cites] Am J Pathol. 2006 Mar;168(3):866-77 [16507902.001]
  • [Cites] J Neurooncol. 2006 Feb;76(3):239-48 [16234985.001]
  • [Cites] Cell Signal. 2006 Aug;18(8):1108-16 [16626936.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5330-7 [16707459.001]
  • [Cites] Lancet Oncol. 2006 Jun;7(6):499-507 [16750500.001]
  • [Cites] Clin Lung Cancer. 2006 May;7 Suppl 4:S138-44 [16764754.001]
  • [Cites] Nucleic Acids Res. 2006;34(12):e85 [16840529.001]
  • [Cites] Am J Respir Crit Care Med. 2006 Aug 15;174(4):420-7 [16690978.001]
  • [Cites] Neurosurgery. 2000 Dec;47(6):1400-9 [11126911.001]
  • [Cites] J Clin Invest. 2001 Mar;107(6):727-35 [11254672.001]
  • [Cites] Circ Res. 2002 Jun 14;90(11):1147-9 [12065315.001]
  • [Cites] Int J Cancer. 2003 Jan 20;103(3):344-51 [12471617.001]
  • [Cites] EMBO J. 2003 Mar 17;22(6):1289-301 [12628922.001]
  • [Cites] Autoimmunity. 2002 Dec;35(8):521-9 [12765478.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1575-85 [15111304.001]
  • [Cites] Nephron Exp Nephrol. 2004;97(2):e62-70 [15218324.001]
  • [Cites] Clin Cancer Res. 2004 Jul 1;10(13):4427-36 [15240533.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Am J Pathol. 1993 Feb;142(2):413-23 [8382008.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5677-81 [8390675.001]
  • [Cites] Oncogene. 1995 Feb 2;10(3):569-75 [7845682.001]
  • [Cites] Oncogene. 1995 Feb 2;10(3):609-18 [7845687.001]
  • [Cites] Pathobiology. 1997;65(4):195-203 [9396043.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7591-5 [16140923.001]
  • (PMID = 17299390.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Mitogen; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / discoidin receptor
  • [Other-IDs] NLM/ PMC2360060
  •  go-up   go-down


85. Bemelman WA: Minimally invasive surgery for early lower GI cancer. Best Pract Res Clin Gastroenterol; 2005 Dec;19(6):993-1005
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimally invasive surgery for early lower GI cancer.
  • Two technical developments in colorectal surgery-i.e. transanal endoscopic microsurgery (TEM) and laparoscopic surgery for colorectal disease-are now available for the treatment of early lower GI cancer.
  • Benign lesions and early-stage tumours of the rectosigmoid are amenable for a transanal approach.
  • After installation of a pneumorectum, lesions up to 25 cm from the anal verge, including circumferential lesions, can be removed with a recurrence rate of 0-5% for adenomas, 3% for low-risk T1 carcinomas, and 8% for all carcinomas.
  • Early colonic cancer requires laparoscopic colectomy guided by preoperative colonoscopy or preoperative endoscopic tattooing for localisation of the affected segment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16338654.001).
  • [ISSN] 1521-6918
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 57
  •  go-up   go-down


86. Yuasa Y, Okitsu H, Seike J, Ishikura H, Ichimori T, Ishikawa M, Kimura S, Sakata A: [A case of rectal cancer treated by preoperative chemoradiation]. Gan To Kagaku Ryoho; 2005 Nov;32(12):1973-5
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of rectal cancer treated by preoperative chemoradiation].
  • Fifty-one-year-old male visited our hospital suffering from anal pain and subileus.
  • Further examination revealed that advanced rectal cancer which invaded to presacral space (Ai, N 0, P 0, H 0, M(-), stage IIIa) caused such symptom.
  • We administered neo-adjuvant chemoradiotherapy for fear of non curative resection of the rectum.
  • For example, diarrhea, nausea, and mucosal dysfunction were each less than grade 2, and there was much tolerate for renal, liver, and bone marrow function.
  • This combination chemoradiotherapy is considered to be effective for locally advanced rectal cancer.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16282738.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / UFT(R) drug; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


87. Itoh H, Iwasaki M, Hanaoka T, Sasaki H, Tanaka T, Tsugane S: Urinary bisphenol-A concentration in infertile Japanese women and its association with endometriosis: A cross-sectional study. Environ Health Prev Med; 2007 Nov;12(6):258-64

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The subjects were interviewed and their urine samples were obtained prior to a laparoscopic diagnosis of endometriosis between January 2000 and December 2001.
  • Median urinary BPA concentration in women with stage 0-1 endometriosis (0.74 μg/g creatinine) did not significantly differ from that in those with stage II-IV endometriosis (0.93 μg/g creatinine) (p for difference=0.24).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Shokuhin Eiseigaku Zasshi. 2001 Apr;42(2):71-8 [11486386.001]
  • [Cites] Environ Mol Mutagen. 2006 Oct;47(8):571-8 [16795089.001]
  • [Cites] Chem Res Toxicol. 2002 Oct;15(10):1281-7 [12387626.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Nov 25;780(2):365-70 [12401363.001]
  • [Cites] Environ Health Perspect. 2003 Jan;111(1):101-4 [12515686.001]
  • [Cites] Obstet Gynecol Clin North Am. 2003 Mar;30(1):1-19, vii [12699255.001]
  • [Cites] Environ Health Perspect. 2004 Mar;112(3):331-8 [14998749.001]
  • [Cites] Nihon Eiseigaku Zasshi. 2004 Nov;59(4):403-8 [15626028.001]
  • [Cites] Environ Health Perspect. 2005 Apr;113(4):391-5 [15811827.001]
  • [Cites] Environ Res. 2005 Sep;99(1):118-25 [15927178.001]
  • [Cites] Sci Total Environ. 2006 Apr 15;359(1-3):90-100 [16546516.001]
  • [Cites] Environ Sci. 2006;13(1):15-29 [16685249.001]
  • [Cites] Nihon Koshu Eisei Zasshi. 1991 Aug;38(8):567-74 [1747547.001]
  • [Cites] Fertil Steril. 1985 Mar;43(3):351-2 [3979573.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Dec 12;312(2):441-8 [14637157.001]
  • [Cites] Best Pract Res Clin Obstet Gynaecol. 2004 Apr;18(2):177-200 [15157637.001]
  • [Cites] Fertil Steril. 2004 Dec;82(6):1501-8 [15589850.001]
  • [Cites] Shokuhin Eiseigaku Zasshi. 2004 Dec;45(6):339-43 [15794093.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Jun 5;820(1):49-57 [15866492.001]
  • [Cites] Int J Hyg Environ Health. 2005;208(4):237-45 [16078637.001]
  • [Cites] Anal Chem. 2005 Aug 15;77(16):5407-13 [16097788.001]
  • [Cites] Anal Bioanal Chem. 2005 Oct;383(4):638-44 [16132150.001]
  • [Cites] Ann N Y Acad Sci. 2002 Mar;955:11-22; discussion 34-6, 396-406 [11949940.001]
  • (PMID = 21432072.001).
  • [ISSN] 1342-078X
  • [Journal-full-title] Environmental health and preventive medicine
  • [ISO-abbreviation] Environ Health Prev Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Other-IDs] NLM/ PMC2723486
  • [Keywords] NOTNLM ; HPLC-MS/MS / endocrine disruptor / epidemiology / urine / xenoestrogen
  •  go-up   go-down


88. Hessien MH, El-Sharkawi IM, El-Barbary AA, El-Beltagy DM, Snyder N: Non-invasive index of liver fibrosis induced by alcohol, thioacetamide and Schistosomal infection in mice. BMC Gastroenterol; 2010;10:53
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-invasive index of liver fibrosis induced by alcohol, thioacetamide and Schistosomal infection in mice.
  • BACKGROUND: Non invasive approaches will likely be increasing utilized to assess liver fibrosis.
  • This work provides a new non invasive index to predict liver fibrosis induced in mice.
  • The following methods were employed: (i) The METAVIR system was utilized to grade and stage liver inflammation and fibosis;.
  • (ii) Determination of hepatic hydroxyproline and collagen; and (iii) Derivation of a new hepatic fibrosis index from the induced changes, and its prospective validation in a group of 70 mice.
  • These parameters were highly correlated with both the histological stage and the grade.
  • They were combined in a logarithmic formula, which non-invasively scores the severity of liver fibrosis through a range (0 to 2), starting with healthy liver (corresponding to stage 0) to advanced fibrosis (corresponding stage 3).Receiver operating characteristic curves (ROC) for the accuracy of the index to predict the histological stages demonstrated that the areas under the curve (AUC) were 0.954, 0.979 and 0.99 for index values corresponding to histological stages 1, 2 and 3, respectively.
  • Also, the index was correlated with stage and grade, (0.947 and 0.859, respectively).
  • The AUROC was 0.869 and there was good correlation with the stage of fibrosis and grade of inflammation.
  • CONCLUSION: The index fulfils the basic criteria of non-invasive marker of liver fibrosis since it is liver-specific, easy to implement, reliable, and inexpensive.

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • Hazardous Substances Data Bank. THIOACETAMIDE .
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 1999 Dec;30(6):1529-30 [10610352.001]
  • [Cites] Hepatology. 2009 Jun;49(6):1821-7 [19291784.001]
  • [Cites] N Engl J Med. 2001 Feb 15;344(7):495-500 [11172192.001]
  • [Cites] Lancet. 2001 Apr 7;357(9262):1069-75 [11297957.001]
  • [Cites] Hum Exp Toxicol. 2001 May;20(5):251-4 [11476157.001]
  • [Cites] Hepatology. 2002 Oct;36(4 Pt 1):986-92 [12297848.001]
  • [Cites] Am J Gastroenterol. 2002 Oct;97(10):2614-8 [12385448.001]
  • [Cites] Hepatology. 1997 Dec;26(6):1393-8 [9397976.001]
  • [Cites] Hepatology. 1999 Jan;29(1):14-20 [9862843.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] J Hepatol. 2003 Aug;39(2):222-30 [12873819.001]
  • [Cites] J Hepatol. 2003 Aug;39(2):239-44 [12873821.001]
  • [Cites] Hepatology. 2003 Aug;38(2):518-26 [12883497.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2003 Feb;2(1):69-72 [14607650.001]
  • [Cites] Anal Biochem. 1979 Jun;95(2):351-8 [36810.001]
  • [Cites] Res Exp Med (Berl). 1980;177(3):201-11 [6449727.001]
  • [Cites] Pharmacol Ther. 1985;29(1):129-56 [3914644.001]
  • [Cites] Pharmacol Toxicol. 1987 Mar;60(3):171-4 [3588511.001]
  • [Cites] Exp Pathol. 1988;34(4):229-36 [2853079.001]
  • [Cites] Hepatology. 1996 Aug;24(2):289-93 [8690394.001]
  • [Cites] Arch Biochem Biophys. 1959 May;82(1):70-7 [13650640.001]
  • [Cites] Gastroenterology. 2005 Feb;128(2):343-50 [15685546.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Feb;3(2):167-74 [15704051.001]
  • [Cites] Alcohol Clin Exp Res. 2006 Aug;30(8):1429-35 [16899047.001]
  • [Cites] J Hepatol. 2007 May;46(5):775-82 [17321634.001]
  • [Cites] Clin Chim Acta. 2007 Jun;381(2):119-23 [17442291.001]
  • [Cites] Rinsho Byori. 2007 Aug;55(8):751-7 [17882797.001]
  • [Cites] Hepatology. 2008 Feb;47(2):455-60 [18038452.001]
  • [Cites] Cancer Res. 2008 Mar 15;68(6):2033-42 [18339886.001]
  • [Cites] Chest. 2008 May;133(5):1101-6 [18071010.001]
  • [Cites] Anal Biochem. 2000 Oct 1;285(1):16-20 [10998259.001]
  • (PMID = 20515488.001).
  • [ISSN] 1471-230X
  • [Journal-full-title] BMC gastroenterology
  • [ISO-abbreviation] BMC Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 075T165X8M / Thioacetamide; 3K9958V90M / Ethanol; 9007-34-5 / Collagen; EC 2.3.2.2 / gamma-Glutamyltransferase; GAN16C9B8O / Glutathione; RFM9X3LJ49 / Bilirubin; RMB44WO89X / Hydroxyproline
  • [Other-IDs] NLM/ PMC2894747
  •  go-up   go-down


89. Chan AK, Wong AO, Jenken DA: Preoperative capecitabine and pelvic radiation in locally advanced rectal cancer--is it equivalent to 5-FU infusion plus leucovorin and radiotherapy? Int J Radiat Oncol Biol Phys; 2010 Apr;76(5):1413-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative capecitabine and pelvic radiation in locally advanced rectal cancer--is it equivalent to 5-FU infusion plus leucovorin and radiotherapy?
  • PURPOSE: The aim of this retrospective case-matching study was to compare the treatment outcomes and acute toxicity of preoperative radiotherapy (RT) with capecitabine vs. preoperative RT with intermittent 5-fluorouracil (5-FU) infusion, leucovorin, and mitomycin C in rectal cancer.
  • METHODS AND MATERIALS: We matched 34 patients who were treated with preoperative concurrent capecitabine and 50 Gy of RT by their clinical T stage (T3 or T4) and the tumor location (<or=7 cm or >7 cm from the anal verge) with another 68 patients who were treated with preoperative intermittent 5-FU infusion, leucovorin, mitomycin C, and 50 Gy of RT for a comparison of the pathologic tumor response, local control, distant failure, and survival rates.
  • The acute toxicity profile was comparable, with little Grade 3 and 4 toxicity.
  • CONCLUSIONS: When administered with concurrent preoperative RT, both capecitabine and intermittent 5-FU infusion with leucovorin modulation provided comparable pathologic tumor response, local control, relapse-free survival, and disease-specific survival rates in rectal cancer.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20338475.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 50SG953SK6 / Mitomycin; 6804DJ8Z9U / Capecitabine; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


90. Hwang MR, Park JW, Kim DY, Chang HJ, Hong YS, Kim SY, Choi HS, Jeong SY, Oh JH: Prognostic impact of peritonealisation in rectal cancer treated with preoperative chemoradiotherapy: extraperitoneal versus intraperitoneal rectal cancer. Radiother Oncol; 2010 Mar;94(3):353-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of peritonealisation in rectal cancer treated with preoperative chemoradiotherapy: extraperitoneal versus intraperitoneal rectal cancer.
  • BACKGROUND AND PURPOSE: The oncologic outcomes of extraperitoneal (EP) rectal cancer are known to differ from those of intraperitoneal (IP) rectal cancer; however, these differences have not been studied in rectal patients treated by preoperative chemoradiotherapy (CRT).
  • MATERIALS AND METHODS: This study analyzed the data of 362 patients who received preoperative CRT and underwent curative surgery for locally advanced rectal cancer at 3-9 cm above the anal verge.
  • Multivariate analysis revealed the following independent risk factors for recurrence: the absence of peritonealisation (p=0.023), ypT stage (p=0.015) and ypN stage (p<.0001).
  • CONCLUSIONS: Peritonealisation of rectal cancer may be a prognostic factor of disease-free survival in patients with rectal cancer treated by preoperative CRT and surgery.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20006392.001).
  • [ISSN] 1879-0887
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


91. Barriger RB, Calley C, Cárdenes HR: Treatment of anal carcinoma in immune-compromised patients. Clin Transl Oncol; 2009 Sep;11(9):609-14
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of anal carcinoma in immune-compromised patients.
  • This study was undertaken to evaluate local control (LC), overall survival (OS) and toxicity in immune-compromised patients with anal carcinoma treated with radiotherapy with or without chemotherapy.
  • METHODS: We identified 25 patients with anal carcinoma and human immunodeficiency virus (HIV) infection or history of solid-organ transplant on chronic medical immune-suppression.
  • AJCC T-stages were Tis (4%), T1 (8%), T2 (58%) and T3 (29%).
  • One patient had metastatic disease at diagnosis.
  • All patients had acute grade 2-3 skin toxicity.
  • Acute grade 3-4 gastrointestinal (GI), genitourinary (GU) and haematological toxicity occurred in 8%, 0% and 38%.
  • Late grade 3-4 skin, GI and GU toxicity occurred in 8%, 4% and 0%.
  • T-stage and CD4 level in HIV-positive patients predict for LC.
  • T-stage and TT predict for OS.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma / therapy. Immunocompromised Host

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19776001.001).
  • [ISSN] 1699-3055
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


92. Nock NL, Bock C, Neslund-Dudas C, Beebe-Dimmer J, Rundle A, Tang D, Jankowski M, Rybicki BA: Polymorphisms in glutathione S-transferase genes increase risk of prostate cancer biochemical recurrence differentially by ethnicity and disease severity. Cancer Causes Control; 2009 Dec;20(10):1915-26
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms in glutathione S-transferase genes increase risk of prostate cancer biochemical recurrence differentially by ethnicity and disease severity.
  • Although the GSTM1 null genotype has been shown to increase prostate cancer mortality in Caucasians, potential associations between GST polymorphisms and prostate cancer biochemical recurrence (BCR) have not been well studied, particularly in African-Americans.
  • RESULTS: We found that African-Americans with the GSTT1 null genotype had increased BCR risk compared to those having GSTT1 present (hazard ratio (HR) = 2.30; 95% CI = 1.01–5.18; p = 0.04); and African-Americans with the GSTT1 null genotype and high grade tumors had an even greater risk (HR = 7.82; 95% CI = 2.49–24.50; p < 0.001).
  • In Caucasians, an increased risk was observed in those patients with high grade tumors and the GSTM1 null genotype (HR = 2.88; 95% CI = 1.16–7.14; p = 0.02).
  • Similar associations were observed for advanced stage and more aggressive (high grade or advanced stage) disease.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 2003 Feb;61(2):365-9 [12597949.001]
  • [Cites] J Urol. 2003 Jan;169(1):157-63 [12478126.001]
  • [Cites] Am J Hum Genet. 2003 Jun;72(6):1492-1504 [12817591.001]
  • [Cites] J Urol. 2003 Apr;169(4):1320-4 [12629352.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1996;36:203-32 [8725388.001]
  • [Cites] Biochemistry. 1996 Oct 22;35(42):13664-72 [8885846.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):176-81 [15668493.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2005;45:51-88 [15822171.001]
  • [Cites] Int J Cancer. 2005 Oct 20;117(1):8-13 [15880531.001]
  • [Cites] Prostate. 2006 Feb 1;66(2):146-56 [16173036.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1236-45 [17548691.001]
  • [Cites] Pathology. 2007 Jun;39(3):299-304 [17558856.001]
  • [Cites] J Urol. 2007 Oct;178(4 Pt 1):1271-6 [17698101.001]
  • [Cites] Clin Cancer Res. 2008 Feb 1;14(3):750-7 [18245535.001]
  • [Cites] Urology. 2008 Jan;71(1):161-7 [18242387.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Urol. 2008 Oct;180(4):1336-9; discussion 1340-1 [18707696.001]
  • [Cites] Prostate. 2006 Oct 1;66(14):1535-41 [16921513.001]
  • [Cites] Cancer Detect Prev. 2006;30(5):412-22 [17067754.001]
  • [Cites] In Vivo. 2000 Jan-Feb;14(1):173-82 [10757075.001]
  • [Cites] Cancer. 2000 May 1;88(9):2082-91 [10813720.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 7;93(3):219-25 [11158191.001]
  • [Cites] Cancer. 2002 Dec 1;95(11):2302-7 [12436435.001]
  • [Cites] Anal Biochem. 1996 Apr 5;236(1):184-6 [8619490.001]
  • (PMID = 19568698.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA129162-02; United States / NCI NIH HHS / CA / K07-CA129162; United States / NIEHS NIH HHS / ES / R01-ES011126; United States / NIEHS NIH HHS / ES / R01 ES011126; United States / NCI NIH HHS / CA / K07 CA129162-02; United States / NCI NIH HHS / CA / K07 CA129162
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1
  •  go-up   go-down


93. Christoforidis D, Cho HM, Dixon MR, Mellgren AF, Madoff RD, Finne CO: Transanal endoscopic microsurgery versus conventional transanal excision for patients with early rectal cancer. Ann Surg; 2009 May;249(5):776-82
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transanal endoscopic microsurgery versus conventional transanal excision for patients with early rectal cancer.
  • OBJECTIVE: To compare transanal endoscopic microsurgery (TEMS) with conventional transanal excision (TAE) in terms of the quality of resection, local recurrence, and survival rates in patients with stage I rectal cancer.
  • METHODS: We retrospectively reviewed information on all patients with stage pT1 and pT2 rectal adenocarcinoma who underwent local excision from 1997 through mid-2006.
  • We found no significant differences in patient characteristics, adjuvant therapy, tumor stage, or adverse histopathologic features.
  • In the TAE group, 52 (40%) of tumors were <5 cm from the anal verge (AV); in the TEMS group, only 1 (2%) (P = 0.0001).
  • In our multivariate analysis, the tumor distance from the anal verge, the resection margin status, the T stage, and the use of adjuvant therapy--but not the surgical technique (i.e., TEMS or TAE) itself--were independent predictors of local recurrence and DFS.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal. Female. Humans. Male. Microsurgery. Middle Aged. Patient Selection. Prognosis. Retrospective Studies. Survival Analysis